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Abstract 
Shared decision making is now an integral part of renal practice. Quality of life is 
therefore an important consideration, especially for older patients. This thesis provides 
insight into the influence of dialysis modality on quality of life in older people with 
advanced kidney disease. It also explores the relationship between cognitive 
impairment and dialysis. 
Firstly, quality of life measures were compared between older patients on assisted 
peritoneal dialysis and haemodialysis. Patients on assisted peritoneal dialysis were 
matched to haemodialysis patients by baseline characteristics. Quality of life 
assessments were carried out quarterly for 2 years. Following multivariate analyses, 
there was no consistent difference in quality of life between patients on haemodialysis 
and assisted peritoneal dialysis. 
The second study assesses the influence of dialysis on cognition and patient reported 
outcome measures in patients with advanced kidney disease. Patients on 
haemodialysis, peritoneal dialysis or with chronic kidney disease (eGFR < 30ml/min) 
patients were recruited. Study participants were assessed 4 monthly for up to 2 years. 
Mixed model analysis showed that cognitive function declined faster in dialysis 
patients compared with non-dialysis patients with chronic kidney disease. In the 
dialysis cohort, executive function was better preserved in patients on peritoneal 
dialysis compared with haemodialysis patients. Dialysis did not consistently influence 
trends in patient reported outcome measures during follow up. 
Finally, the relationship between cognition and decision making capacity was explored 
in a small pilot of renal patients. Cognition and decision making capacity were 
assessed by the Montreal Cognitive Assessment and Macarthur Competence 
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Assessment tools respectively. Patients with lower cognitive scores tended to have 
lower capacity assessment scores, albeit without reaching statistical significance. 
In older patients with advanced kidney disease, risk factors other than dialysis 
modality, influence quality of life. Cognitive decline, one such risk factor, may 
accelerate with dialysis depending on modality. It may also affect decision making. 
These findings highlight the need to screen for geriatric syndromes in older patients 
with renal disease. 
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1. INTRODUCTION 
This thesis explores the impact of renal disease on the wellbeing of older people. In 
this chapter, I will review key age related concepts including aging and frailty. I will 
also review the current literature on health-related quality of life (QoL) and key 
determinants in advanced kidney disease.    
Section 1.1 reviews aging trends in the population and introduces the concept of 
accelerated aging and frailty in kidney disease. Section 1.2 provides an overview of 
end stage renal disease (ESRD) in older people including management options and 
survival outcomes. Section 1.3 reviews quality of life (QoL) outcomes for older patients 
with ESRD. In section 1.4, cognitive impairment is discussed as non-renal risk factor 
of QoL in advanced kidney disease and the gaps in current evidence are highlighted. 
The chapter concludes with a review of the thesis aims. 
1.1 Aging and the Frailty Syndrome 
1.1.1 Aging 
1.1.1.1 Population trends and types of aging 
 Over the years, life expectancy in the general population has increased significantly. 
In the UK, the median age of the general population increased from 35.4 years in 1985 
to 39.7 years in 2010. The proportion of people over 65 years of age in the UK, has 
also increased from 15% in 1985 to 17% in 2010. It is projected to reach 23% by 
2035.[1] Similar population trends have been reported in other developed countries. 
For example in 2010, people over 65 years of age accounted for 13% and 21% in the 
United States and Germany respectively.[2]  
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Figure 1.1: Percentage of older people in the UK 1985, 2010, 2035. Source: Office for National 
Statistics, National Records of Scotland, Northern Ireland Statistics and Research Agency. 
Reproduced with permission 
 
 The increase in human life expectancy is thought to be due to a reduction in mortality 
from acute infectious diseases (with the advent of antibiotics and improved hygiene) 
and more recently, from cardiovascular disease. Nonetheless, aging does seem to be 
an inevitable process. However, the onset and the rate of aging varies from individual 
to individual. Physiological aging refers to cellular, organic and systemic changes 
that occur over time. These changes are often influenced by environmental factors, 
and can be expected to occur during the lifespan of healthy individuals. Such changes 
have been described as usual aging.[3] With successful aging, external influences 
exert minimal or no impact on the aging process.[3] Accelerated aging is thought to 
occur as a result of the influence of unhealthy lifestyle behavior and concomitant 
disease processes. These aging trends exist in continuum. It is thus, often difficult to 
distinguish between changes that are expected for age and pathology. This dilemma 
exists with renal disease and will be explored subsequently.   
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  Genetic and environmental factors play a role in the aging process [4] and are likely 
to explain the variability in the rate of aging observed in humans. Some of the 
postulated theories of aging are discussed in the next session. 
1.1.1.2 Theories of Aging 
 There is a lack of consensus on how aging occurs. Several theories have been 
proposed.[5] These are broadly divided into programmed and error based theories. 
These theories rarely exist in isolation and potentially interact. The programmed 
theories postulate that there are intrinsic biological controls for aging while the error 
based theories suggest that aging is the result of cumulative damage from 
environmental influences.  
Error based theories 
Free radical theory 
 This theory suggests that cellular aging is due to cumulative damage from free 
radicals. These free radicals are generated during oxidative metabolism and cause 
damage to DNA, fat and proteins. [6] Supportive evidence for this theory comes from 
invertebrate experiments. For example, the increased expression of superoxide 
dismutase (SOD), an enzyme that exerts antioxidant effects, has been associated with 
increased life span in flies. The validity of this theory in larger organisms is less 
certain.[7]  
Wear and tear theory 
 This theory suggests that cellular and tissue components become worn over time from 
repeated use. This theory however fails to explain some of the discrepancies in 
lifespan seen between similar organisms. These discrepancies may be explained by 
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variations in DNA repair mechanisms, which are not taken into consideration by the 
wear and tear theory. 
Cross linking theory 
This theory suggests that aging results from cellular and tissue damage because of 
crosslinked proteins, DNA or lipids. Crosslinked proteins become attached to other 
structural molecules, rendering them ineffective. These crosslinked proteins are 
resistant to enzymatic degradation and therefore accumulate over time. Advanced 
glycation end products (AGEs) are examples of cross linked proteins. They have been 
implicated in atherosclerosis and consequent increased cardiovascular risk. 
Rate of living theory 
The lifespan of organisms is thought to be determined by their metabolic rate. In other 
words, those with higher energy consumption die earlier. This theory is linked with the 
free radical theory. Free radicals are generated from oxidative metabolism and can 
cause cellular damage, leading to aging. However, this theory does not hold true for 
all organisms. 
Somatic mutation theory 
This theory suggests that DNA mutations accumulate over time in somatic cells, 
leading to aging. This is because they are generated at a rate that outstrips the rate 
repair. The accumulation of random mutations potentially results in the inactivation of 
genes that may be vital for cell function, leading to cell death.[8] 
Programmed theories 
Genetic (programmed senescence) theory 
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This theory proposes that genes control the biological “clock“ that determines the 
lifespan of cells. There is a prespecified limit to the number of times a cell can replicate, 
after which it becomes apoptotic (Hayflick’s limit). Telomeres, which are specialized 
structures with repeat DNA sequences, are linked to this theory. They are found at the 
end of chromosomes and they regulate the life span of cells. Telomere shortening is 
associated with an arrest in cellular replication (senescence). This  may be a 
consequence of  progressive loss in DNA with each cell replication (replicative 
senescence)[9] or in response to DNA damage or oncogenes (stress induced 
senescence). Humans with longer telomeres have been shown to live longer 
compared to those with shorter telomeres.[10] However, it remains unclear whether 
telomere shortening is a cause rather than consequence of aging. It has been 
suggested that stress induced senescence is more compatible with other theories of 
aging, such as the free radical theory.[11] Telomere shortening has also been linked 
with diseases seen with advancing  age. 
Alterations in gene expression are thought to play a role in the different aging 
trajectories seen in humans. This is supported by centenarian studies which have 
shown that siblings of centenarians have an 8 to 17 fold higher risk of surviving to 100 
years of age compared to siblings of non- centenarians.[12]  A genome wide 
association study identified a locus on chromosome 4 which is linked to long life 
span.[13] A genetic marker for the Microsomal Transfer protein (MTP) was 
subsequently identified within this locus. It has been shown  to influence longevity, in 
a cohort of French long living individuals.[14] The forkhead box 03A (FOXO3A) 
transcriptor factor [15] and some alleles of apolipoprotein E (APOE) [16] have been 
implicated in several populations.  
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 Endocrine theory 
System based theories suggest that aging results from a decline in organ  systems 
that are key  to one’s ability to adapt to the environment.[11] In humans, the endocrine 
system is one such vital system. Insulin and insulin like growth factor (IGF-1) pathways 
have been implicated in the regulation of aging.[17] Animal studies suggest that 
reduction in IGF-1 signaling is associated with longevity. These findings have been 
corroborated in humans. Ashkenazi Jewish centenarians have been shown to have 
reduced IGF-1 receptor activity and IGF-1 signaling, compared to younger controls. 
[18, 19]     
Immunological theory     
The immune system becomes less effective with advancing age 
(Immunosenescence).However, rather than being a consequence of aging, the 
immunologic theory suggests that changes in the immune system are linked to 
longevity.[20]  Human studies have found that immune dysregulation and inflammation 
are associated with clinical conditions, commonly seen with advancing age.[21]  
1.1.1.3 Aging and the Kidney  
There are physiological and structural changes that occur within the kidney with age. 
In addition, the prevalence of kidney disease increases with age. Conversely, renal 
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disease has been associated with accelerated aging. In this section, I will review the 
complex interaction between age and the kidney. 
 
The aging kidney 
From the 4th decade of life, the glomerular filtration rate (GFR) declines at a rate of 
about 0.8 ml/min per year.[22] The decline in renal function is a consequence of a fall 
in glomerular capillary plasma flow rate and ultrafiltration coefficient. There is also a 
reduction in afferent arteriolar resistance which is associated with a rise in glomerular 
capillary hydrostatic pressure.[23] In the aging kidney, there is an imbalance between 
vasoconstrictive (mediated by the renin angiotensin system) and vasodilatory 
(potentially mediated by nitric oxide) mechanisms. This disruption in renal 
autoregulation, partly explains the increased susceptibility of older people to kidney 
injury.[23] 
Structurally, there is a reduction in renal mass with advancing age. Biopsy studies in 
healthy living donors have demonstrated an increasing prevalence of 
glomerulosclerosis with advancing age. [24] Arteriosclerosis, arteriolar hyalinosis, 
tubular atrophy and interstitial fibrosis are seen increasingly with age.[25] 
The features described above are also seen in patients with chronic kidney disease 
(CKD). This will now be reviewed with emphasis on older people. 
Chronic Kidney Disease in the Elderly 
Chronic Kidney Disease (CKD) has been defined by the Kidney Disease: Improving 
Global Outcomes (KDIGO) CKD working group as “abnormalities of kidney structure 
or function, present for more than 3 months, with implications for health”.[26] 
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In 2002, CKD was stratified into 5 stages based on estimated Glomerular Filtration 
Rate (eGFR), a measure of excretory function and markers of kidney damage (such 
as proteinuria). Each stage has been associated with increasing risk of adverse 
outcomes. Table 1.1 shows the current approach to the staging of CKD following 
subtle modifications. CKD is an independent risk factor for cardiovascular disease and 
all-cause mortality, [27] and increased healthcare costs,[28] highlighting it as an public 
health concern. The estimated prevalence of CKD in the UK ranges from 6.8 to 
13%.[29-31] Similar figures have been reported in the United States where the 
prevalence is reportedly increasing alongside that of diabetes and hypertension.[32] 
 CKD is increasingly common with age. The reported prevalence of CKD in UK 
individuals aged 85 years or more is 50%.[29] In the US, 39.4% of individuals over 60 
years of age have CKD in comparison to 8.5% of those between 20 and 39 years 
old.[33] The CKD burden in the elderly is partly attributed to the increase in 
cardiovascular risk factors including diabetes and hypertension. [34]  
Declining renal function in the elderly - disease or renal aging? 
Glomerulosclerosis, tubular atrophy and interstitial fibrosis are seen in CKD regardless 
of the underlying aetiology. These features are also seen with advancing age, in 
healthy individuals. Renal function also declines with age, potentially to levels that 
would be considered to represent CKD by current guidelines. GFR potentially falls as 
low as 45ml/min in health individuals over 65 years of age.[25] There are therefore 
concerns that the prevalence of CKD in the elderly is overestimated by the current 
staging .[35]  A threshold of 45 ml/min in the absence of other markers of kidney 
damage has been proposed, for diagnosing CKD in the elderly.[36] It is also worth 
remembering that the estimated GFR adopted by KDIGO, is based on serum 
creatinine. This is a poor marker of renal function, particularly in the elderly. In this 
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cohort, a decline in renal function is offset by reduced urinary creatinine excretion 
following changes in muscle mass. Serum creatinine therefore remains constant 
initially, despite substantial changes in GFR.[23] 
To delineate disease from renal aging in the elderly, it may be helpful to consider the 
risk associated with a particular eGFR. In a study of 1669 patients aged 80 years and 
above, the mortality risk was higher in patients with an eGFR of 45 to 59.9 ml/min 
compared to those with an eGFR > 60 ml/min [adjusted hazard ratio =1.6 (1.3 – 2.1)] 
,even after considering the degree of albuminuria.[37] Conversely, other studies have 
suggested that the mortality risk associated with an estimated GFR of 45 to 59.9ml/min 
in older people, in the absence of other markers of kidney damage, is trivial to non-
existent. [39]  
Comparative meta - analyses have shown that the risk of progression to end stage 
renal disease (ESRD) are higher in older people with an estimated GFR < 60 ml/min 
compared to those with an estimated GFR > 60 ml/min. These findings were 
independent of albuminuria or cardiovascular risk factors [pooled hazard ratio in 
patients without albuminuria = 5.2 (3.3–8.0)]. [38] [39] The authors acknowledge the 
limitations in this study , including the lack of standardization in the measurement of 
serum creatinine and albuminuria. In addition, most older patients with CKD do not 
progress to ESRD due to the competing risk of death. Progression to ESRD, may 
therefore add little to this debate. 
The role of the kidney in accelerated aging 
  CKD has been  associated with accelerated aging.[40] There is some clinical 
evidence to support this association. For example, the mortality risk of a young patient 
with CKD has been shown to be equivalent to that of a non CKD patient 50 years 
older.[41]  In addition, dialysis patients have been shown to have higher age specific 
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senescence rates compared to the general population, using mathematical modelling 
(Figure 1.2). [42] Cognitive impairment [43] and frailty[44], often seen in the older 
general population,  are fairly common in younger dialysis patients.  
 
Table 1.1: Current CKD staging 
CKD stage (according to GFR) Estimated GFR ranges (ml/min/1.73m2) 
G1 (Normal or High) >90 
G2 (Mildly decreased) 60 - 89 
G3a (Mildly to Moderately decreased) 45 - 59 
G3b (Moderately to severely 
decreased) 
30 - 44 
G4 (Severely decreased) 15 - 29 
G5 (Kidney Failure) <15 
  
CKD stage (according to 
albuminuria) 
Albumin Creatinine Ratio (ACR) 
(mg/mmol) 
A1 (Normal to mildly increased) < 3 
A2 (Moderately increased) 3 - 30 
A3 (Severely increased) > 30 
Adapted from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 
2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 
Kidney inter., Suppl. 2013; 3: 1–150 
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The mechanisms by which renal disease contributes to accelerated aging are subject 
to ongoing research. It is thought that CKD and physiological aging share similar 
characteristics.  
             
Figure 1.2: Age-specific senescence rates of dialysis patients (using the 
derivative of the Gompertz equation) when compared with transplant patients 
and the general population)[42] 
 
Older people have been shown have persistent low level inflammation, characterised 
by increased cytokine activity (such as IL-6 and TNF-α) and immune dysfunction.[45] 
Such low grade inflammation has been associated with increased morbidity and 
mortality in the elderly.[46] Patients with moderate to severe CKD have also been 
shown to have increased inflammatory markers when compared to healthy 
controls.[47]   
Oxidative stress has been discussed previously in the context of the free radical theory 
of aging. Markers of oxidative stress increase with advancing CKD[48] and more so 
on dialysis. Indoxyl sulphate , a protein bound uraemic solute, has been associated 
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with accelerated aging by inducing oxidative stress and apoptosis.[49] Advanced 
glycation end products (AGEs) are a heterogeneous group of proteins, lipids and DNA 
that undergo non- enzymatic glycation, in the setting of oxidative stress. They 
accumulate with age and are known to promote senescence.[50] By promoting 
crosslinking of collagen in the vessel wall, AGEs contribute to vascular stiffening and 
endothelial dysfunction. They also promote the oxidation of low density lipoproteins 
(LDL) and consequent atherogenesis.  AGEs accumulate in patients with advanced 
CKD regardless of age and are also generated during the dialytic process. In 
conjunction with systemic inflammation, oxidative stress is therefore associated with 
endothelial dysfunction and the consequent cardiovascular risk seen in CKD patients. 
[51] 
Premature senescence, occurring in the uraemic state, is mediated by several 
mechanisms. Abnormal telomere shortening, associated with senescence, has been 
found in mononuclear cells of predialysis and dialysis patients.[52]  Telomerase (an 
enzyme that preserves telomere length) activity  is also low in HD patients compared 
to healthy controls.[53]  
 Klotho is a transmembrane protein that has been implicated in phosphate metabolism 
and CKD induced mineral bone disorders. It has been shown to be deficient in patients 
with CKD.[54] This protein also has anti senescence activity, mediated potentially by 
suppressing IL-6 and IL-8 activity.[55] Phenotypically, klotho deficiency has been 
linked to premature aging syndromes in mice.[56] Phosphate has also been implicated 
in the aging process, independent of klotho activity. This is thought to be mediated by 
the influence of phosphate on glucose metabolism and oxidative stress. [57] Vitamin 
D, along with parathyroid hormone, plays a vital role in CKD mineral bone disorders. 
It has also been shown to have multi systemic effects, with links to conditions often 
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associated with chronological age. These include osteoporosis, neurodegenerative 
disease and cardiovascular disease. At a cellular level, vitamin D has been shown to 
have anti-senescence effect, as it regulates several proteins involved in the cell cycle. 
Associations have also been found between vitamin D levels and telomere length. 
Another potential mechanism by which vitamin D is associated with aging, is by via its 
influence on klotho activity. [58]  
The mechanisms discussed above support the theory of accelerated aging in patients 
with chronic kidney disease. They do not exist in isolation but often interact with each 
other. They are by no means exhaustive, as the interaction between CKD and aging 
is complex and yet to be fully understood.  
1.1.2 Frailty  
Cognitive dysfunction, falls, immobility and incontinence have been highlighted as 
geriatric giants, affecting older people.[59]  Similar problems are also seen in patients 
with advanced kidney disease, especially as the renal population gets older. 
Dealing with multimorbidity is one of the management challenges faced in older 
patients with CKD. Multimorbidity is generally considered to exist when two or more 
comorbidities are present. Specifically, it has more to do with the impact of two or more 
long term conditions on the affected patient rather than a mere interaction between 
disease processes.[60] Multimorbidity is associated with mortality,[61] poor quality of 
life,[62] polypharmacy[63] . It is associated with frailty. [64] However, frailty and 
multimorbidity are not synonymous. 
Frailty has gained recognition as an important predictor of outcomes in patients with 
kidney disease and will be discussed further in this section. 
1.1.2.1 Frailty – definition and prevalence 
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Frailty is defined as a state of increased vulnerability, characterised by a loss of 
physiologic reserve leading to an impaired response to acute stressors.[65] In the frail 
patient, there is a substantial and disproportionate decline in physical and mental 
health following a minor event (such as infection or new medications). Although frailty 
is associated with aging, it does not exist solely in the elderly. It has been shown to be 
associated with dependence, increased hospitalisation, mortality, poor quality of life 
and the use of long term care facilities.[66, 67]  
  The prevalence of frailty in the general population varies, depending on how it is 
assessed, between 4 and 59.1%.[68] In the UK, it affects up to 14% of community 
dwellers. Frailty becomes more common with age affecting 6.5% of those between 60 
and 69 years of age and 65% of those over 90 years of age. [69] It has also been 
shown to be more  common in women  compared with men, among the elderly in the 
UK [69] as well as among US community dwellers.[66] Ethnicity may also have a role 
to play. Studies from the US have reported a higher prevalence of frailty in African 
Americans compared with Caucasians.[66, 70] A wide variation in reported prevalence 
rates also exist among European nations.[71] 
1.1.2.2 The pathogenesis of Frailty 
 Frailty occurs when there is an acceleration in the aging process, mediated through 
interactions between genetic, epigenetic and environmental factors (figure 1.3). It has 
been postulated that it results from multi systemic cumulative deficits leading to 
reduced physiologic reserve. These systemic changes are shown in table 1.2.  
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Figure 1.3: Pathophysiology of frailty (reproduced with permission)[68] 
1.1.2.3 Models of Frailty 
Frailty was first widely accepted as an operationalized concept in 2001. There are now 
two predominant models for defining the construct of frailty. These are the phenotype 
model and the cumulative deficit model. 
The phenotype model 
This criterion based model identifies frailty based on the five physical variables shown 
in Table 1.3. The presence of three or more is diagnostic of frailty. This model was 
developed by Fried et al, following a secondary analysis of 5210 older community 
dwellers from the Cardiovascular Health Study.[66] The presence of frailty as defined 
using this model, has been associated with a higher risk of hospitalisation, increased 
disability and mortality in the general and renal population.[72] 
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Table 1.2: Systemic changes associated with frailty [11, 73, 74] 
System Aging related changes 
Cardiovascular 
system 
Left ventricular hypertrophy 
Reduced maximum heart rate response 
Reduced responsiveness to catecholamines 
Reduced vascular compliance 
Respiratory  
Reduced arterial partial pressure of oxygen 
Reduced chest wall and lung compliance 
Reduced ciliary function 
Musculoskeletal 
system 
 
Reduced osteoblastic activity 
Osteoporosis 
Sarcopenia – reduced muscle mass and quality 
Nervous system 
Atrophy of grey matter 
Reduction in synaptic transmission of signals 
Reduced sensory responsiveness to stimuli 
Endocrine system  
Reduced androgenic hormones 
Reduction in growth hormone and IGF- 1 
Immune system 
Immunosenescence 
• Thymic involution 
• Reduced naïve T cell population, increased memory T cells 
• Reduced peripheral B cell count and B cell function 
• Increased resistance to apoptosis 
• Impaired innate immunity 
• Low grade inflammation – increased IL-6 and TNF-α 
 
The cumulative deficit model 
 Using this model, frailty is the consequence of individual deficits accumulating over 
time. These deficits include symptoms, physical signs, comorbidities, abnormal 
laboratory tests and recognised disabilities. They exert individual deleterious effects, 
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which in combination result in frailty. The frailty index, based on this model, was 
developed by Rockwood et al, using a cohort of 10263 elderly Canadian participants. 
Being a continuous index, it is thought to be more sensitive to changes in the degree 
of frailty, compared to the phenotype model. Frailty, identified using this model, has 
also been associated with a higher risk of institutionalisation and death. [75] 
Table 1.3: Variables used in the Fried model of frailty[66] 
Physical variables Specific criteria 
Self-reported exhaustion 
 
Self-reported exhaustion, identified by two questions 
from the Center for Epidemiologic Studies Depression 
Scale (CES–D) scale 
Weight loss 
weight loss, unintentional, of ≥10 pounds in prior year 
or, at follow-up, of ≥5% of body weight in prior year (by 
direct measurement of weight) 
Low energy expenditure 
A weighted score of kilocalories expended per week 
based on each participant's report, lowest 20% of the 
population 
Slow gait speed 
 
Slowest 20% of the population as defined at baseline, 
by time to walk 15 feet, adjusted for gender and standing 
height 
Weakness 
Grip strength in the lowest 20% at baseline, adjusted for 
gender and body mass index 
 
1.1.2.4 Frailty assessment tools 
Several measures of frailty have been proposed over the years. These proposed 
assessment tools are associated either with the phenotype or deficit model. It will 
become apparent though that these tools are measuring either the determinants or 
effects of frailty, rather than frailty itself. Construct validity is therefore difficult to 
establish with these tools, highlighting the challenges associated with conceptualising 
frailty. 
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The Fried index is a criterion based score using the phenotype frailty model. Patients 
with three more of the following; weakness, exhaustion, weight loss, slow gait speed 
and low energy expenditure, are considered to by frail. Those with one or two criteria 
are considered to be pre frail, while those without any criteria were considered to be 
robust.[66] The index has been used extensively for research purposes. Although, the 
first three criteria are based on self-report, the others require formal clinical 
assessment. It is debatable as to how easy it is to incorporate into a time constrained 
outpatient clinic visit. Although it is one of the more popular measures of frailty, the 
original authors recognise that this index may not detect subtle depletions in 
physiologic reserve.[66] This is especially as frailty is not measured in continuum, by 
this measure. Although predictive validity has been well demonstrated with the Fried 
index, responsiveness is a concern. Moreover, the Fried index excludes important 
determinants of frailty, such as cognition and mood.[76]  
In patients with advanced kidney disease, it has been associated with mortality and 
hospitalisation.[44] The Fried index has been modified in dialysis patients, by replacing 
measures of grip strength and gait speed with self-reported measures of physical 
function. Frailty, as assessed by this modified version, was still associated with 
mortality.[77]    
The Frailty index was established using data from the Canadian Study for Health and 
Aging. It is defined as the proportion of accumulated deficits out of 70 possible clinical 
variables. These clinical variables include symptoms, signs, abnormal laboratory tests, 
disabilities and comorbidities.[67] These deficits are identified after a detailed clinical 
assessment (e.g. a comprehensive geriatric assessment). The resulting index is a 
continuous score, with higher scores indicating increasing frailty. Its use though, is 
labour intensive, limiting its utility in routine clinical practice.  
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Clinical Frailty Scale is a seven-point scale (Table 1.4) that stratifies patients into 
increasing levels of frailty, from robust health (1) to severe frailty (7). This is based on 
the user’s clinical assessment of comorbidities and dependence for activities of daily 
living. This easy to use scale, although subjective, has construct validity. This is 
because it correlates well with the frailty index (Pearson’s coefficient = 0.81, p <0.01). 
It has been shown to predict death and institutionalisation in the general 
population,[67] as well as in predialysis and dialysis patients.[78, 79] The CFS has 
recently been upgraded to a 9 point scale to include the “very severely frail” and “the 
terminally ill”.[80]  
Timed Up and Go (TUAG) test measures the time taken to stand from a sitting 
position, walk a fixed distance, return to the chair and sit down. This is a measure of 
physical function that is predictive of falls. Yet, it  is also thought to be indicative of 
physical frailty.[81] In a cohort of 1814 Irish older participants, the TUAG correlated 
well with the Fried index, in identifying frailty (AUC = 0.87). It was less effective in 
distinguishing the nonfrail from the prefrail.[82] The TUAG has the advantage of being 
simple to use. As it is a continuous measure, it is possible that the TUAG may be 
responsive to changes in the degree of frailty. This is speculative though, as it has not 
been validated against other frailty measures.  
Although its diagnostic accuracy is yet to be proven, it has been recommended by 
British Geriatric Society as a screening tool for frailty.[83] A duration greater than 10 
seconds is thought to be indicative of frailty. Table 1.5 shows some other available 
frailty assessment tools. 
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Table 1.4: The Clinical Frailty scale 
Score Definition 
1 Very fit – robust, active, energetic, well-motivated and fit 
2 Well – no active disease, but less fit than people in category 1 
3 Well, with treated comorbid disease -  controlled symptoms 
4 Apparently vulnerable – commonly complain of being “slowed up” 
5 Mildly frail –  limited dependence on others for instrumental 
activities of daily living 
6 Moderately frail – help is needed with both instrumental and non-
instrumental activities of daily living 
7 Severely frail – completely dependent on others for the activities 
of daily living, or terminally ill 
 
Table 1.5: Other recognised tools for assessing frailty 
Frailty Assessment Tool Items 
Edmonton Frailty Scale [84] Cognitive screening, time up and go, Health 
status, social support, medications, functional 
dependence. 
Groningen Frailty Indicator [85] 15 items on self-reported functional limitations 
Tilburg Frailty Indicator [86] Self-report questionnaire with physical, 
psychological and social components 
Short Emergency Geriatric 
Assessment (SEGA) [87] 
13 item tool validated in adults admitted to 
emergency department and community dwellers, 
assessing comorbidities, dependence, mobility 
and cognitive function 
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1.1.2.5 Frailty in advanced kidney disease 
Frailty is common in patients with advanced kidney disease and CKD is associated  
with a higher risk of frailty compared to the general population. The overall  
prevalence of frailty in CKD ranges from 2.8 to 24%.[88-90] . The risk of frailty  
however, increases as renal function declines. In the Third National Health and  
Nutrition Evaluation Survey (NHANES) study, the odds ratio for frailty was 2.21, 2.27  
and 5.5 for patients with CKD stage 1 to 2, 3a and 3b to 5 respectively, compared with 
non CKD patients.[88] In patients with ESRD, frailty is even more common with a 
reported prevalence of 35% - 73% [44, 72, 91] and 47.8%[92] in HD and PD 
populations respectively. In a study of 537 US kidney transplant recipients, Mcadams-
Demarco et al reported a prevalence of 19.9%. The variation in the reported 
prevalence of frailty is partly due to differences in the assessment tools. [93] Table 1.6 
shows the studies that have evaluated frailty in CKD. 
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Table 1.6: Studies evaluating frailty in CKD 
Author, year Study design Sample characteristics 
Frailty assessment 
tool 
Risk of Frailty Frailty vs clinical outcomes 
Pugh et al, 2016 [78] 
Prospective cohort  
Single centre (UK) 
283 CKD patients 
median age – 70 (63-81yrs) 
CFS  
Higher CFS associated mortality 
(Exp B=1.35,1.16 -1.57) 
Delgado et al, 2015 [94] 
Retrospective cohort 
(US) 
812 participants in MDRD 
study  
Median Age - 52 (42–61) yrs 
Modified Fried index* 
Lower odds for frailty with higher GFR 
mGFR- OR per 10ml/min = 0.71(0.60-
0.86) 
eGFRcr – OR per 10m/min = 0.80 
(0.67-0.94) 
eGFRcys – OR per 10ml/min = 
0.75(0.62 -0.90) 
Frailty associated with mortality 
(HR = 1.71,1.26 – 2.30) 
Walker et al, 2015[95] 
Baseline analysis from 
longitudinal study 
(Canada) 
217 CKD patients (eGFR<30 
ml/min)  
Mean age - 70.3 (60–79.1) yrs 
SPPB < 10 
56% Frail at baseline 
GFR not associated frailty as defined 
 
Hubbard et al, 2015[96] 
Cross sectional 
(Australia) 
111 CKD patients  
Mean age 65.2 years 
Frailty index 
Fried index 
19.1% Frail by fried index 
Frailty index (p =0.04) and Fried index 
(0.018) associated with KD stage but 
not after considering age and gender 
 
Lee et al, 2015 [97] 
Cross sectional (South 
Korea) 
168 CKD patients Modified Fried index* 37.5% Frailty prevalence 
Frailty associated with lower Short 
Form 36 PCS (B = -0.57, p 
<0.001) and MCS (B = -0.49, 
p<0.001) 
Mansur et al, 2014 [98] Cross sectional (Brazil) 
61 CKD patients in a 
predialysis clinic 
Mean age- 60.5 ± 11.5 yrs 
Modified Fried index* 42.6% Frailty prevalence 
Frailty associated with lower Short 
Form 36 PCS (B = -1.12, p 
<0.001) and MCS (B = -0.75, 
p<0.001) 
Reese et al, 2013 [99] Cross sectional (US) 
1111 participants from the 
CRIC study 
Median age - 65 (57-71) yrs 
Fried index 
Compared with eGFR >60 ml/min, 
eGFR 30-59 (odds ratio, OR 1.45; p = 
0.024), eGFR 15-29 (OR 2.02; p = 
0.002) and eGFR <15 (OR 4.83; p < 
0.001) associated with worse frailty 
status  
 
Mansur et al, 2012 [92] Cross sectional (Brazil) 
146 patients (86 CC, 37 HD 
and 23 PD) 
Mean age -57.7±13.1yrs 
Modified Fried index* 
Frailty prevalence - 36% of patients on 
CC, 37.8% In HD and 47.8% in PD 
patients. 
 
Roshanravan et al, 
2012 [100]  
Cross sectional (US) 
336 CKD 1 to 4 patients 
compared with community 
dwelling older adults 
Mean age - 59 years 
Fried index 
Frailty prevalence 14% (CKD) vs 7% 
(non-CKD). 
Compared with eGFRcys > 60, 2.8 
(1.3-6.3) and 2.1 (1.0-4.7) fold greater 
prevalence of frailty with eGFRcys 
categories < 30 and 30 – 44 ml/min 
respectively  
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Ng et al, 2016 [101] 
Cross sectional 
(Chinese)  
193 PD patients 
Mean age - 60.6 ± 12.1 yrs 
Chinese frailty 
questionnaire 
69.4% frailty prevalence 
Frailty associated with higher risk 
of hospitalisation and longer 
hospital stay but not with survival 
Mcadams-Demarco et 
al, 2016 [102] 
Prospective cohort (US) 233 patients with ESRD Fried index  
Frailty associated with Fair/Poor 
HRQOL at follow-up (OR: 2.79, 
95% CI: 1.32-5.90) and worsening 
HRQOL at follow-up (RR: 2.91, 
95%CI: 1.08-7.80) 
Van Munster et al, 2016 
[103] 
Cross sectional (Dutch) 
95 participants with ESRD 
65.2 years ±12.0 yrs 
Frailty index as gold 
standard 
GFI 
ISAR-HP 
VMS 
 
37% frailty prevalence using frailty 
index 
44% prevalence > 65 years 
28% prevalence < 65years 
Compared with frailty index GFI – 
89% sensitive and 57% specific, 
ISAR-HP 83% sensitive and 77% 
specific,  
VMS 77% sensitive and 67% 
specific 
Drost et al, 2016 [104] Cross sectional (Dutch) 
95 participants with ESRD 
Mean age - 65.2 ± 12.0yrs 
Frailty index 
Fried index 
37% frailty prevalence using Frailty 
index. 
62.5% agreement between Frailty 
index and Fried index 
 
Johansen et al, 2016 Prospective cohort(US) 
762 HD patients 
Mean age - 57.1±14.2 yrs 
Fried index 
Modified Fried index* 
31% frailty prevalence by Fried index 
52% frailty prevalence by modified 
Fried index 
Higher mortality risk reported by 
either measure 
Fried index – HR = 2.16(1.41 to 
3.29); Modified Fried index- (1.24 
to 3.00) 
Mcadams-Demarco et , 
2015 [105] 
Prospective cohort (US) 
324 incident HD patients 
Mean age - 54.8 ± 13.3yrs 
Fried index 37% frailty prevalence 
Frailty associated with worse 
cognitive function 
Delgado et al, 2015 
[106] 
Prospective cohort (US) 
1646 incident HD patients 
Median age - 63 (52-73) yrs 
Self-report of poor 
physical function, 
activity and exhaustion 
(2 of 3) 
77% frailty prevalence 
Frailty associated with higher risk 
of falls and fractures (HR= 1.60, 
1.16–2.20). 
Meulendijks et al, 2015 
[107] 
Prospective cohort 
(Dutch) 
65 predialysis patients 
Median age -75 (66–92) yrs 
GFI 32% frailty prevalence 
Higher prevalence of death (30% 
vs 9%, p =0.04) and 
hospitalisation (90% vs 53%, p = 
0.005) in frail vs fit patients 
Salter et al, 2015[108] Cross sectional (US) 
146 HD patients 
Median age - 61 (53- 70) yrs 
Fried index 
Perceived frailty by 
patient and healthcare 
professionals 
 
Poor agreement between fried 
index and perceived frailty 
(nephrologist, Nurse, and patient: 
64.1%, 67.0%, and 55.5% 
Alfaadhel et al, 2015 
[79] 
Prospective cohort (US) 
390 HD patients 
Mean age - 63 ±15 yrs  
CFS  
Higher risk of death with rising 
CFS score [HR =1.22 (1.04 - 1.43; 
P=0.02). 
Chao et al, 2015 [109] 
Prospective cohort 
(Taiwan) 
Dialysis patients 
Mean age - 67.3 ± 11.9 yrs 
 
 
GFI, TFI, simple 
FRAIL scale, EFS, G8, 
Strawbridge 
questionnaire 
Frailty prevalence  
G8-82.6%, SF - 69.6%, GFI -54.3%, 
EFS- 43.5%, TFI- 30.4% The simple 
FRAIL scale -19.6%. 
Correlation between frailty 
assessment tools except G8 
Johansen et al,2014[77] Cross sectional (US) 
731 Dialysis patients 
Mean age - 67.3 ± 11.9yrs 
 
Fried Index 
Modified Fried Index* 
Frailty prevalence 
Fried index – 23% 
Modified Fried index- 53% 
Compared with Fried Index- 
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Modified Fried Index 
with validated cut off 
for SF36 PF 
  Modified Fried index- 90% 
sensitivity, 64% specificity, 72.5% 
accuracy 
With validated SF36 PF cut off - 
84%; (95% CI=79%-89%) and 
superior specificity (88% 
Kutner et al, 2014 [110] Cross sectional (US) 
745 Dialysis patients 
Mean age 57.1±14.1 yrs 
Fried index Frailty prevalence – 13.8%  
Mcadams –DeMarco et 
al,2013 [111] 
Prospective cohort (US) 
97 HD patients 
Mean age 60.5 ± 12.6 yrs 
Fried index  
Frailty associated with a higher 
risk of falls (HR=3.09,1.38-6.90, 
P=0.006) 
Mcadams –DeMarco et 
a, 2013 [72] 
Prospective cohort (US) 
146 HD patients 
Mean age - 60.6 ± 13.6 yrs 
Fried index  
Frailty associated with a higher 
mortality risk (HR-2.6,1.04-6.49, p 
=0.04) and more hospitalisation 
(Coefficient – 1.4,1.00-2.03, P = 
.049) 
Bao et al, 2012 [91] Prospective cohort (US) 
1576 Dialysis patients 
1411 on HD; 165 on PD 
Mean age 59.6 ± 14.2 yrs 
Modified Fried index 
(weight loss excluded) 
Frailty prevalence -73% 
Frailty associated with mortality 
[HR= 1.57, 1.25-1.97; P < .001) 
and time to first hospitalization 
(HR, 1.26, 1.09-1.45]; P < .001). 
Johansen et al, 2007 
[44] 
Prospective cohort (US) 
2393 Dialysis patients 
Mean age 58.2 ± 15.5 yrs 
Modified fried index Frailty prevalence -66% 
Frailty associated with higher 
mortality risk (adjusted HR 2.24; 
1.60 to 3.15) and risk of 
hospitalization (adjusted HR 1.56; 
95% CI 1.36 to 1.79). 
CC – conservative care,CFS=Clinical Frailty Scale, CRIC -Chronic Renal Insufficiency Cohort,  eGFRCr-estimated glomerular filtration rate creatinine, eGFRcys- estimated glomerular filtration rate 
cystatin, GFI – Groningen Frailty Indicator ,HD- Haemodialysis, HR- hazard ratio, ISAR-HP-  the Identification of Seniors at Risk-Hospitalized Patients MCS – mental component summary, MDRD – 
Modification of Diet in renal Disease, PCS – physical component summary, SPPB – Short  Physical Performance Battery, VMS – Veiligheidsmanagementsysteem; *  -  performance based  
components of Fried index replaced with self – report measures
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The interaction between frailty and uraemia is complex. Uraemia has previously been 
discussed in association with accelerated aging. Frailty on the other hand, is 
considered to be a manifestation of accelerated aging.[112] Fatigue, weakness and 
weight loss which are included in the diagnostic criteria for frailty, are often seen in the 
uraemic state. The question therefore arises as to whether frailty is overestimated in 
patients with advanced kidney disease, by the existing assessment tools. Validation 
studies for the these tools, are limited, in the renal population.[103]  A 
counterargument is that uraemic symptoms potentially improve with dialysis and 
transplantation. Yet, frailty and the associated consequences continue to be reported 
in prevalent dialysis and transplant patients. 
 Some risk factors have been associated with frailty in patients with advanced kidney 
disease. Frailty is evidently seen in older people. Yet, it is not restricted to older 
patients with kidney disease. Mcadams-Demarco et al found that frailty affected 35.4% 
of dialysis patients less than 65 years old [72].  In a larger observational study of 2275 
dialysis patients, frailty was present in 44% of those less than 40 years and more than 
50% of those between 40 and 50 years of age.[44] Female gender, presence of 
diabetes, previous stroke and low serum albumin were also linked to frailty in that 
study. Black ethnicity, peripheral vascular disease and cardiac co morbidities were 
reportedly linked with a higher risk of frailty in a cohort study of 745 dialysis 
patients.[110] 
 As in the general population, frailty has been associated with hospitalisation and 
mortality in dialysis [44, 72] and transplant [113, 114] patients, independent of other 
risk factors. It has also been associated with higher GFR at the initiation of dialysis 
[91] , poor QoL[102]  and delayed graft function in transplant patients.[115]  
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1.1.3 Conclusion 
  This section provides an overview of aging and frailty. It highlights the aging trend of 
the general and renal population. There is recognition that people age at different rates 
due to genetic and environmental influences (usual aging). This is distinct from 
“accelerated aging”, which is associated with disease processes. The modern theories 
of aging are also briefly discussed. CKD, a public health concern, is increasingly 
common with age. It is recognised however that the current CKD classification may 
overestimate its prevalence in older patients. There are functional and structural 
changes that occur in the kidney with advancing age. These changes may not be 
easily distinguished from renal pathology (i.e. CKD) in the elderly. Studies evaluating 
clinical outcomes in older patients with eGFR of 45 to 60 ml/min report conflicting 
results. A threshold of < 45ml/min has been suggested for CKD in the elderly.  
Conversely, the relationship between CKD and accelerated aging is highlighted, 
buttressed by clinical studies that report equivalence in cardiovascular risk in young 
dialysis patients and much older people from the general population. 
  The concept of frailty, as a phenotype of accelerated aging, is also introduced in this 
section. Two models of frailty are recognised. The Fried model predominantly 
assesses physical dimensions of frailty while the cumulative deficit model is better at 
measuring frailty as a continuum, providing a better fit for the aging process. Various 
tools for assessing frailty are described, recognising that few have been validated in 
the renal population. The challenge of incorporating most of them into busy clinical 
practice, is also highlighted. Nevertheless, frailty is common in patients with advanced 
kidney disease regardless of chronological age. It is predictive of poor outcomes in the 
HD, PD and transplant population. 
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 The management of the older person with advanced kidney disease is therefore, not 
without challenges. Treatment modalities have the potential to add considerable 
burden to CKD patients. This will be discussed further subsequently. 
1.2 End-stage renal disease in elderly 
 This section provides an overview of ESRD in the elderly. I will discuss the prevalence 
of ESRD in the older population as well as the treatment options currently available. It 
concludes with a review of survival outcomes for older people with ESRD with focus 
on the impact of treatment modalities. 
1.2.1 Epidemiology of end-stage renal disease in the elderly 
 ESRD, the severe end of the CKD spectrum, occurs when there is an irreversible 
decline in renal function such that renal replacement therapy (RRT) is required for 
survival. Although CKD stage 5 (eGFR < 15mls/min/1.73m2) is thought to represent 
established kidney failure, the commencement of RRT is often subjective, guided by 
clinical symptoms and signs. In the UK, the average eGFR for initiating RRT is about 
8ml/min/1.73m2. [116] 
 The older population account for the largest cohort of incident and prevalent patients 
with end stage renal disease. According to UK renal registry data, the annual 
prevalence of patients receiving RRT increased by 4% between 2010 and 2011, to 
842 per million population (pmp). The prevalence was highest over 75 years of age 
for male patients (2007 pmp) and over 65 years of age for female patients (1460 pmp). 
[117] Similar patterns have been reported from registry data in other high income 
countries. By 2008, the prevalence of ESRD in the United States had increased by 
25%  in patients over 65 years old  and 31% in those over 75 years , over the preceding 
8 years. [118]  It has been suggested that the current observed trends will persist for 
years to come.[119] 
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1.2.2 Management options for older patients with ESRD 
  The presence of frailty and multimorbidity adds to the challenge of managing ESRD 
in older people. The current dialytic and non-dialytic therapies that are available to 
such patients, are discussed below. 
1.2.2.1 Haemodialysis is a form of RRT whereby uraemic toxins are removed by a 
process of diffusion (haemodialysis) and/or convection (haemofiltration) across a 
semipermeable dialyser membrane. Vascular access to the circulation is required 
which takes the form of an arteriovenous fistula, graft or a dialysis catheter. Blood is 
delivered by the patient’s vascular access through an extracorporeal circuit, (figure 
1.3) in counter current flow to the dialysate, generating a concentration gradient across 
the membrane. In addition, a negative pressure gradient may be generated to enable 
fluid removal (ultrafiltration). HD is predominantly provided at a dialysis centre (hospital 
or satellite unit), conventionally for about 4 hours, three times a week. 
 In the older population, hospital based HD is the predominant dialysis modality, 
accounting for 64% [120] of prevalent patients on RRT over 65 years old in the UK.  In 
incident patients on RRT, this figure approaches 83%.[116]  
Hospital based HD is not always tolerated by older patients. Advancing age has been 
associated with prolonged fatigue post dialysis.[121] They also encounter HD related 
complications including cardiovascular instability and access related hospitalisation. 
As frailty and dependence are common in this age group, hospital provided transport 
is often required. There are often transportation delays which add to the difficulties 
faced by older people on HD. Hospital based dialysis is conventionally provided in 
thrice weekly visits. This means that older patients on HD potentially spend a 
considerable amount of time in hospital. 
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 Conversely, patients often value the regular social interaction with other patients and 
staff, during dialysis. There is also the assurance that health problems can be 
addressed fairly quickly, because of regular contact with medical staff. 
Home HD has emerged as a home-based alternative to conventional HD, in patients 
with ESRD. It offers the flexibility that is not always feasible with hospital based HD. 
However, in comparison to the other RRT options, the uptake of home HD is relatively 
low. In 2014, patients receiving home HD accounted for 4.3% of all dialysis patients in 
the UK.[122] There are challenges involved in delivering home HD, especially in the 
frail elderly. It is however possible with care giver assistance.[123]
 
Figure 1.4: Schematic diagram of Haemodialysis Circuit. Reproduced with 
permission from https://commons.wikimedia.org/wiki/File:Hemodialysis-
en.svg, author – Yassine Mrabet 
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1.2.2.2 Peritoneal Dialysis 
 This home-based form of RRT involves the removal of uraemic toxins by diffusion 
across the peritoneal membrane. Dialysate is passed into the peritoneal cavity through 
a catheter, where it dwells for a variable amount of time. This allows for the movement 
of solute across a concentration gradient, before the peritoneal fluid is drained out.  
This process may be performed manually, when dialysis fluid is drained in and out of 
the peritoneal cavity (exchanges) up to 4 times a day (continuous ambulatory 
peritoneal dialysis –CAPD) or with assistance of a programmed cycler machine 
(automated peritoneal PD). 
 PD enables dialysis at home and promotes independence. PD does exert some 
haemodynamic effects. In contrast to HD,  these effects do not appear to be 
hypotensive in nature.[124] As a result, PD is potentially better tolerated by older 
patients. Conventional PD though, requires the patient to carry out exchanges 
independently. Geriatric syndromes, have traditionally been perceived to be a barrier 
to the use of PD in older patients.[125] It has however been shown that with 
appropriate support, 60% of eligible patients chose PD as preferred therapy with up to 
40% initiating RRT on PD.[125] 
Assisted PD is an emerging alternative for frail older patients with ESRD (incapable of 
using self-care PD), enabling them to dialyse at home.[126] PD is provided with the 
assistance of a paid healthcare worker or a family member. This mode of dialysis 
delivery is increasingly utilised in developed as well as emerging economies [125, 127, 
128] . France has the largest experience, where PD is the prevalent dialysis modality 
for older patients. [129, 130]   
The delivery of assisted PD varies from country to country. In the UK, assisted PD is 
predominantly delivered as assisted APD. The paid healthcare worker visits once daily 
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to set up and programme the cycler machine. The patient and /or a family member 
remains responsible for connections to and from the machine. Assisted CAPD has 
been utilised in other countries, including France. In this model of care, the paid 
healthcare worker visits several times during the day, to perform manual exchanges 
for the patient. [129, 131]   
 
 
Figure 1.5: Schematic diagram for peritoneal dialysis. Reproduced from 
“Treatment methods for kidney failure: peritoneal dialysis” (National Institutes 
of Diabetes and Digestive and Kidney Diseases 2006b). 
  
The cost implications of providing assistance for PD, have not been extensively 
evaluated. However, a UK pilot study in 2006 suggested that costs for assisted PD are 
equivalent to HD, when hospital transport costs are considered.[132]  Assisted PD has 
been reported to be a cost effective therapy for the frail elderly, in a recent Dutch cost 
analysis.[133]   Peritonitis and technique survival rates comparable to self-care PD 
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have also been reported in several series.[127-129] But there are no studies 
comparing outcomes between assisted PD and HD in older people. 
1.2.2.3 Conservative kidney management  
 This is a planned holistic but non - dialytic approach to the management of patients 
with ESRD.  The components of conservative kidney management (CKM) have been 
defined recently, as shown in table 1.7.[134] 
Table 1.7: Components of Conservative Kidney Management 
Defining conservative kidney management 
Interventions to delay progression of kidney disease and reduce complications  
         -  Use of diuretics and ACE inhibitors 
         - Correction of metabolic acidosis 
         - Anaemia management 
Shared decision making  
Active symptom management  
Detailed communication including advance care planning  
Psychological support  
Social and family support  
Cultural and spiritual domains of care 
 
This approach is valid for patients who are unlikely to thrive on dialysis and is often 
delivered by a multidisciplinary team with links to palliative care. CKM practices vary 
widely from centre to centre,[135] in scope and structure. In addition, it is thought there 
are an unknown proportion of individuals with undiagnosed advanced CKD. It is 
therefore difficult to ascertain the current trends of CKM in ESRD. In 2010, a survey 
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from the UK renal registry estimated that about 20% of patients with stage 5 CKD over 
75 years of age were receiving conservative care.[136]  
1.2.3 Survival outcomes for older people with ESRD 
Mortality rates are high in older patients with advanced kidney disease. The median 
survival after commencing dialysis in patients over 75 years of age, is 2 years 
according UK registry data.[137]. Mortality rates increase with advancing age in older 
patients on dialysis. The mortality rate at one year  approaches 20% in patients 
between 70 and 74 years of age, 31% between 75 and 79 years and 46% over 90 
years of age.[138] 
The influence of dialysis modality on survival in the elderly is less certain. Due to the 
ethical difficulties associated with conducting randomised controlled trials in this 
domain, current studies have been mostly observational. These studies are thus 
hampered by selection bias and residual confounding. Koreevaar et al[139] 
successfully randomised 38 patients to PD and HD.They found that survival outcomes 
where better with PD after 5 years [adjusted HR (HD vs PD) = 3.6 (0.8 to 15.4)] . Other 
studies have however shown no difference in survival outcomes for older patients on 
HD and PD.[140, 141]  More recently, a large meta - analysis of observational studies 
has reported a higher risk of death in PD patients.[142] However, there was significant 
heterogeneity among the included observational studies. There are no comparative 
studies specifically between assisted PD and HD. However, the French PD registry 
(majority of patients  on assisted PD) reported a median survival of 27.1 months, in 
patients who were 75 years and older.[130] This is similar to outcomes reported by the 
UK registry (mostly on HD). 
 Some studies have reported a modest survival benefit of dialysis over conservative 
care in older patients. There is no difference in survival however, after adjusting for 
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multiple co morbidities.[143] One UK prospective cohort study involving 170 patients,  
reported a 13 month deficit in median survival in patients opting for conservative care 
compared to those on haemodialysis.10 of those months represented  time in hospital 
whilst on dialysis. In essence, the net hospital free survival was only 3 months in the 
dialysis cohort compared to those on CKM.  [144]  Patients receiving CKM also spend 
fewer days in hospital and are more likely to die at home or a hospice compared to 
dialysis patients. [145] 
 Patients though, are willing to forego months of survival for quality of life. Morton et al 
evaluated patient preferences in an observational study of 105 patients. Patients were 
willing to forgo 7 months of life expectancy to reduce the number of required visits to 
hospital and 15 months of life expectancy to increase their ability to travel. The impact 
of dialysis on quality of life was shown to be influential when making decisions about 
renal replacement therapy.[146] As there is no clear survival benefit of one modality 
over the other in this high risk group, quality of life is at least as important an outcome 
as survival. 
1.2.4 Conclusion 
 In this section, ESRD is recognised as the severe end of the CKD spectrum, when 
renal replacement therapy becomes necessary. The ESRD population now 
predominantly consists of older people. Due to frailty and multimorbidity, the 
management of these patients can be challenging. 
 HD, PD (self-caring and assisted) and CKM are discussed as available treatment 
options for older people with ESRD.HD is the predominant modality in the UK for 
patients over 65 year of age. This is partly because of frailty and dependence which 
are seen with advancing age. These problems are perceived to preclude the use of 
self-care PD. With the emergence of assisted PD, such patients are able to dialyse at 
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home without the haemodynamic instability often experienced with HD. Comparative 
outcomes between assisted PD and HD are however lacking. 
Lastly, I reviewed survival outcomes in older people with ESRD. Survival is poor and 
deteriorates with advancing age.  It is not clear that one treatment modality provides 
a significant survival advantage over the others. Most of the comparative studies are 
observational and flawed by selection bias. Finally, the concept of quality of life is 
introduced as an equally valid outcome, to be assessed in older patients with ESRD. 
This will be discussed in the next section. 
1.3 Quality of life and advanced kidney disease 
 This section reviews quality of life (QoL) in the context of advanced kidney disease. 
It discusses QoL outcomes in advanced kidney disease with focus on the influence of 
dialysis modality. Then, physical function, depression and protein energy wasting are 
reviewed as non-dialytic risk factors.  
1.3.1 Defining quality of life  
Quality of life (QoL)  has been defined as “a broad multidimensional concept that 
usually includes subjective evaluations of both positive and negative aspects of 
life.”[147] There are several domains of QoL including social, cultural and financial 
domains. In this thesis, QoL refers specifically to health-related quality of life. In the 
NHS, the value of assessing health related quality of life (HRQOL) through patient 
reported outcome measures (PROMs) is now recognised.[148] These PROMs are 
questionnaire based surveys that subjectively evaluate a patient’s assessment of his 
or her own health. A variety of measures have been developed over the years which 
are either as generic, preference based or disease specific.  
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1.3.2 Assessing quality of life in advanced kidney disease 
 Disease specific PROMS have been developed for use in renal disease and are 
increasingly used by renal units. [149]  Key considerations in choosing an optimal 
PROM, are its characteristics in terms of validity, reliability.[150] These concepts are 
briefly discussed below.   
Validity 
A test is said to be valid, if it measures what it claims to measure. There are however 
different facets to the concept of validity. 
Predictive validity is a measure of how well an assessment tool predicts outcomes of 
interest, while concurrent validity is a measure of how well an assessment tool 
correlates with an accepted standard. Both are often considered to represent different 
aspects of criterion based validity. Content validity is a measure of the extent to which 
as assessment tool contains the relevant domains for a particular construct. Face 
validity refers to the extent to which an assessment tool appears to measure what it 
claims to measures. By inference, face validity is subjective and is often considered to 
be the least scientific. However, it is relevant  in terms of the practicalities of using a 
test.[151] Construct validity evaluates the extent to which a test operationalises a 
theoretical construct. Construct validity is often difficult to assess as it tends to be 
measured indirectly.[151] Convergent and discriminant validity are two subtypes of 
construct validity. Convergent validity tests whether a true relationship exists between 
constructs that are perceived to be related. In contrast, an assessment tool is said to 
have discriminant validity, if it distinguishes between constructs that are not related.  
The optimal PROM also needs to possess internal and external validity. Internal 
validity is tested by ascertaining whether a true relationship exists between the 
assessment tool and outcomes. It is however just as important for it to be externally 
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validated. This ensures that the measure performs consistently in different settings 
and populations. 
Reliability  
Reliability refers to the repeatability of a measure.[152]. In the context of PROMs, it is 
considered to be interchangeable with precision. Reliability is important, as a PROM 
cannot be valid if it is not reliable. 
Feasibility should also be considered, when choosing a PROM. Shorter and reliable 
measures potentially increase response rates.[153] Thus far, the majority of such 
measures have been associated with significant completion burden. Three of these 
measures are described below.  
Short Form -36 (SF36) 
 This generic PROM contains 36 items which assess health status in 8 domains. 
These include bodily pain (BP), general health perceptions (GH), mental health  
(MH), physical functioning (PF), role limitations due to emotional health problems 
(RE), role limitations due to physical health problems (RP), social functioning (SF), 
and vitality (VT).[154] It is scored using a weighted algorithm which generates two 
summary scores; the physical component summary score (PCS) and the mental 
component summary score (MCS). Each score ranges from 0 to 100, with higher 
scores indicating better QoL. It has been shown to have good internal consistency 
and validity in patients with renal disease.[155, 156]  The SF 36 has been shown to 
have ceiling and floor effects in some domains.[157] In the elderly population, the SF 
36 performs well as a valid measure, albeit with the assistance of an 
interviewer.[158] As a self-administered questionnaire, response rates are poor in 
the elderly.[159] Abbreviated versions of the SF 36 have also been developed. The 
SF-12, a 12 item scale, has over 90% agreement with the SF-36.[160] The 
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completion burden is thus reduced, especially in older patients. It has been shown to 
reliable in the older population.[161] In dialysis patients, the SF12 possesses 
predictive validity, that is comparable to the SF36.[162] 
EuroQol 5D (EQ5D) 
This is a preference based PROM that assesses 5 domains including mobility, self- 
care, usual activities, pain and anxiety/depression. It includes a health index,  
calculated using population specific weighted algorithms and a visual analogue  
(thermometer) score. The thermometer measures perception of health with scores  
ranging from 0 to 100. Each domain had 3 categorical responses (EQ5D 3L) in the  
original version. This has been expanded to 5 responses per domain (EQ5D 5L). The  
EQ5D exhibited similar properties of validity when compared to the SF6D (derived  
from SF36 items),  in a study older dialysis patients.[163] Response rates were higher  
with EQ5D.  The EQ5D 5L has recently been shown to be more sensitive to changes  
in health outcomes compared to other preference based measures.[164] 
Kidney Disease Quality of Life (KDQOL) 
Developed by the Kidney Disease Quality of Life Working Group, the KDQOL- long 
form (KDQOL-LF) is a 134-item questionnaire that incorporates measures from the SF 
36 as well as well as disease specific domains including symptoms, cognitive function, 
sleep and impact of kidney disease. Four summary measures are generated, including 
- Physical Functioning (PCS), Mental Health (MCP), Kidney specific and Patient 
satisfaction (KDCS).[165] The KDQOL short form (KDQOL-SF) is the 80 item shorter 
version of the KDQOL-LF. Both versions have been shown to have good internal 
consistency and validity.[165, 166]. In the prospective cohort study of 469 Dutch 
dialysis patients, the KDQOL- SF was shown to have construct validity, as the generic 
and disease specific domains correlated well with health status, as judged by the 
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EQ5D. Longitudinal changes in the KDQOL-SF, also correlated significantly with 
longitudinal changes in residual function and serum albumin.[167] These PROMs do 
however have significant completion burden. In the aforementioned study, 20% of 
enrolled participants were unwilling or unable to complete the questionnaires. 
Nonetheless, a systematic review by the Oxford Patient Reported Outcome Measures 
group suggests that QoL be assessed by the KDQOL in conjunction with the EQ5D, 
in patients with kidney disease. [168]  
1.3.3 Quality of life outcomes in advanced kidney disease 
Quality of life starts to decline early in a patient’s journey with CKD and continues to 
do so as renal function deteriorates.[169] It deteriorates further with the initiation of 
dialysis,[170] regardless of modality.[171] Da Silva-Gane et al assessed QoL in a 
study of 170 patients with advanced kidney disease. They found that life satisfaction 
was better preserved in patients receiving conservative kidney management over a 
follow up period of up to 3 years, compared to those on dialysis. All comers were 
invited to participate in the study and the CKM group were significantly older than 
those on dialysis.[144]  
 The outcomes are not different in the few studies that have evaluated QoL exclusively   
in older patients. The North Thames Dialysis study used the SF-36 and KDQOL to 
assess QoL in 174 patients aged 70 years at baseline. Although the PD group had 
higher KDQOL at baseline compared to HD patients, there were no differences in QoL 
measures at 6 and 12 months.[140]  In the Broadening Options for Long Term Dialysis 
in the Elderly (BOLDE study), PD patients had significantly lower illness intrusion 
compared to HD patients. There were no significant differences in other QoL 
measures. [172] The PD patients in these studies, were on self - caring PD. They did 
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not include patients on assisted PD, who are likely to be frail and dependent with 
potentially different outcomes.  
 Small cross sectional studies suggest that there is no difference in quality of life 
between older patients on dialysis and those on conservative kidney 
management.[173, 174]  A more recent prospective observational study of 101 older 
patients receiving CKM reported no difference in the trajectory of physical and mental 
component summary scores of the KDQOL-SF, between those who were 
subsequently started on dialysis and those who remained on CKM. However, scores 
relating to the impact of kidney disease on QoL deteriorated in the dialysis group 
compared to the CKM group.[175] There are no other longitudinal studies evaluating 
the trajectory of QoL in this age group. Based on these studies, it would seem that 
there are risk factors other than RRT modality that influence QoL, especially in older 
patients. 
1.3.4 Non-renal risk factors associated with QoL in advanced kidney disease 
The interaction between chronic disease and quality of life (QoL) is multifaceted. A 
conceptual model was proposed by Wilson and Cleary, which suggests that 
“physiologic” variables have an impact on quality of life through symptoms and 
functional limitations (Fig 1.6). 
 
Figure 1.6: Wilson and Cleary's Model of HRQOL.[176] 
Adapted from Adapted from Wilson, I.B., & Cleary, P.D (1995). Linking Clinical Variables with 
Health-Related Quality of Life: A Conceptual Model of Patient Outcomes. JAMA. 273, 59–65 
Physiologic 
variables
Symptom 
status
Functional 
Health
General 
Health 
perception
Overall QoL
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Current nephrology practice provides the setting to identify and intervene on the 
physiologic variables and disease specific risk factors in patients with advanced kidney 
disease. These are listed in table 1.7 as “renal” risk factors. Cognition, depression and 
functional decline are common but under recognised in advanced kidney disease. 
They are also risk factors for poor QoL but are not necessarily specific to renal patients 
(“non-renal”). 
Table 1.8: Risk factors for quality of life in advanced kidney disease 
Risk factors 
Renal 
Anaemia                         
GFR  
Comorbidities  
Medications                 
Dialysis 
Non-Renal  
Cognition                       
Depression  
Symptom Burden         
Illness intrusiveness      
Nutrition 
Physical function 
Frailty 
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1.3.4.1 Physical function and Advanced Kidney Disease 
The WHO model of functional decline recognises the complex interaction between a 
health condition, the environment and personal factors, with deleterious effects on, 
body structure and function, activities of daily living and social participation.[177] 
Physical function can therefore be assessed in several domains, ranging from physical 
activity, exercise capacity to measures of disability.  
Older Patients with CKD have a higher risk of functional decline when compared with 
age matched patients from the general population. A UK cross sectional study of 
13309 community subjects over the age of 75 years showed that the risk of functional 
impairment increased with declining renal function. The odds ratio for partial 
dependence for activities of daily living was 2.2 and 1.6 for an eGFR of >30ml/min and 
>45ml/min respectively, when compared eGFR >60 ml/min.[178] This association 
between functional decline and declining renal function has also been demonstrated 
in other studies.[179, 180] CKD is also associated with longitudinal changes in 
physical function. In a study of  1221 participants over 60 years of age, gait speed 
declined faster in patients with eGFR < 60 ml/min versus those with eGFR > 60ml /min 
(β = 0.07 [SE 0.02], p = 0.022).[181] The relationship between CKD and physical 
function is also reciprocal, as increased physical activity has been associated with a 
reduced rate of decline in renal function.[182]  A sharp decline in functional status has 
been demonstrated in the last month of life in patients with advanced kidney disease 
who are receiving conservative care.[183] This contrasts with the trajectory noticed in 
other chronic illnesses. Outcomes on dialysis are no better, however. Functional 
decline is common in dialysis patients [184] with evidence to suggest a substantial 
deterioration in physical function after  initiating dialysis.[185] 
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Patients with renal disease have reduced skeletal muscle mass and function 
(Sarcopenia). This leads to impaired muscular performance and consequent 
functional impairment. In a study of 13770 community dwelling NHANES participants, 
class 1 sarcopenia was defined as a skeletal mass index 1-2 standard deviations 
below young adult values and class II as > 2 standard deviations below young adult 
values. An increasing prevalence of sarcopenia was reported, with declining GFR [(> 
or = 90 ml/min/1.73 m2, 22.8% class I, 3.8% class II; 60-89 ml/min/1.73 m2, 33.6% 
class I, 5.3% class II, and < 60 ml/min/1.73 m2, 50.7% class I, 9.4% class II (p < 
0.0001)]. After adjusting for age and comorbidity however, the association was no 
longer significant.[186]  
 The muscular changes seen in CKD patients have also been associated with poor 
nutritional status and inflammation.[187]  25-hydroxyvitamin D deficiency has been 
linked with muscle weakness and a consequent increased risk of falls.[188] Clinical 
correlates of functional decline on HD include male sex, low serum albumin, 
comorbidity and dialysis vintage [189] while fluid overload has been shown to correlate 
strongly with reduced exercise capacity in PD patients.[190] 
Functional decline is an independent risk factor for mortality in the general [191] and 
renal populations.[185] It is also associated with poor QoL[192] as well as increased 
healthcare use, carer burden[184] and nursing home admissions.[193] 
1.3.4.2 Depression and advanced kidney disease 
 Depression in renal disease is often underdiagnosed and under treated.[194] The 
lifetime prevalence of depression in the general population is reported to be 
approximately 7%. The prevalence of depression in patients with renal disease varies 
depending on how it is assessed. Depression as judged by symptom scales tend to 
report higher prevalence compared to physician based diagnosis. This is because 
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there is an overlap between depressive symptoms and those of uraemia. 
Nevertheless, a recent meta-analysis estimates the prevalence to be approximately 
25% in the CKD population. In the dialysis population, depression is the commonest 
mental health problem with a prevalence approaching 39 %. 25% of renal patients are 
depressed after renal transplantation. [195] 
 In the Dialysis Outcomes and Practice Patterns (DOPPS) study, younger age, white 
race, female sex, increasing co-morbidities and longer dialysis vintage were 
associated with a greater prevalence of physician-diagnosed depression. [196] Few 
studies have evaluated the influence of renal replacement choices on the presence 
and severity of depression. In a three year prospective study of 170 patients, the 
depression scores were similar between those who had opted for dialysis and those 
who received conservative kidney management.[144] The outcomes for patients on 
PD and HD are less certain.  Griva et al recently reported higher mean levels of 
depressive symptoms  in the PD population compared to the community based HD 
group in a cross sectional study of 433 patients.[197] Conversely, the Broadening 
Options for Long-term Dialysis in the Elderly (BOLDE) study, a UK based cross 
sectional study of 140 patients over 65 years old, reported a higher prevalence of 
possible depression in patients receiving hospital haemodialysis compared to those 
on PD (HD= 26%, PD = 10%, p = 0.015).[172] 
 Cerebrovascular disease is thought to have a role in the pathogenesis of depression 
in advanced kidney disease. This hypothesis is supported by the presence of white 
matter changes on brain MRI imaging, seen in late onset depression.[198] These 
changes are also common in patients with ESRD.[199] 
Depression is an independent risk factor for mortality in CKD.[200] It is considered to 
be a surrogate for cardiovascular disease, which is itself linked with survival.[201] 
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Other proposed mechanisms for this association in renal disease include malnutrition, 
poor adherence to treatment and immune dysfunction mediated by activation of the 
hypothalamic pituitary adrenal axis.[202-204] Depression has also been associated 
with poor QoL,[205]increased hospitalisation, [206] increased peritonitis rates in PD 
patients,[207] progression to ESRD,[208] and dialysis withdrawal.[209] 
1.3.4.3 Protein Energy Wasting and Advanced Kidney Disease 
Protein and energy wasting (PEW) is a term devised by the International Society of 
Renal Nutrition and Metabolism (ISRNM) that refers to  a “state of decreased body 
stores of protein and energy fuels (body protein and fat masses)”.[210] It is common 
in CKD.[211] The prevalence of PEW in early to moderate CKD is ≥20-25% and 
increases as CKD progresses.[212] It affects up to 75% of the dialysis population.[213] 
A secondary analysis from the BOLDE study reports that there was no difference in 
the energy and protein intake and nutritional status between older people on HD and 
PD.[214] 
PEW in renal disease is multifactorial in origin, with influences ranging from metabolic 
changes such as hypercatabolism and growth hormone resistance to psychosocial 
factors (Table 1.8). Poor nutrition is an independent risk factor for mortality and has 
also been linked to increased hospitalisation and poor quality of life.[211, 215] 
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Table 1.9: Risk factors for Protein Energy wasting in Advanced Kidney disease 
Dialysis related factors 
• Hypercatabolism from nutrient loss in dialysate (HD and PD) 
• Abdominal fullness from PD fluid 
• Delayed gastric emptying during peritoneal dialysis 
• Proinflammatory effects 
Inflammation 
Metabolic derangements 
• Metabolic acidosis 
• Hyperparathyroidism 
• Hypogonadism 
• Growth hormone resistance 
Comorbidities 
• Insulin resistance 
• Cardiovascular disease 
• Diabetes 
Reduced Dietary intake  
• Poor appetite 
• Dietary restrictions 
Physical Inactivity 
 Psychosocial factors 
• Depression 
• Social support 
• Socioeconomic status 
Uraemia 
 
1.3.5 Conclusion 
 QoL has been explored as a relevant outcome in older patients with advanced kidney 
disease. The role of PROMs in evaluating QoL is discussed with emphasis on validity 
and reliability. The SF36, EQ5D and KDQOL have been utilised in patients with 
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advanced kidney disease. These measures have been shown to possess some 
degree of validity and reliability in patients with advanced kidney disease. However, 
most of these measures are associated with significant completion burden, especially 
in older people.  
QoL outcomes in advanced kidney disease were subsequently reviewed. The 
evidence suggests that QoL deteriorates as renal function declines, and more so with 
the initiation of dialysis. It is however not clear that one RRT modality is superior to the 
other, at least in terms of QoL. Similar findings have been reported in studies that have 
exclusively assessed QoL in older people with ESRD. But, there is a dearth of 
evidence on QoL in frail older patients on assisted PD. This thesis will provide some 
insight on the impact of assisted PD on QoL.  
 As dialysis modality may exert little or no influence on QoL, functional decline, 
depression and PEW were briefly discussed as “non- renal “risk factors. Each of them 
become increasingly common as renal function declines and are associated with 
adverse outcomes. Cognitive impairment, another risk factor for poor QoL is discussed 
in the next section. 
1.4 Cognitive impairment and decision making capacity  
Patients with advanced kidney disease are often required to make life altering 
decisions about dialysis. These patients will need to process a significant amount of 
information, so as to make informed decisions. Cognitive impairment is an under 
recognised phenomenon in advanced kidney disease, which potentially impacts on 
the ability to make such decisions. Section 1.4.1 reviews the prevalence and 
pathogenesis cognitive impairment in advanced kidney disease. Section 1.4.2 
explores the concept of decision making capacity, highlighting the paucity of evidence 
in renal patients.   
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1.4.1 Cognitive impairment and advanced kidney disease 
1.4.1.1 Defining cognitive impairment  
Cognition is defined as “the mental processes involved in gaining knowledge and 
comprehension”. These mental processes or domains include memory, language, 
executive function, intellect, emotion, attention, visuospatial abilities and processing 
speed.  
Global cognitive function is preserved with age. However, there are subtle changes in 
some cognitive domains which do not impact on daily living. As with other aspects of 
the aging process, the rate of change varies between individuals and cognitive 
domains. Clinical studies suggest that there is a decline in processing speed with 
age.[216] A decline in working memory, as well as some attention and executive 
abilities have also been reported with age.[217] Other cognitive abilities are 
preserved.[218] The aforementioned changes are distinct from pathological cognitive 
aging seen with mild cognitive impairment and dementia.  
Mild cognitive impairment ensues when cognitive function declines beyond what is 
expected for chronological age. Dementia is the severe end of the spectrum. It is 
defined as a clinical syndrome that encompasses difficulties in memory, language, and 
behaviour that leads to impairments in activities of daily living.[43, 219] (Figure 1.7) 
MCI is broadly classified into amnestic MCI (where the memory is affected) and non –
amnestic MCI which involves other cognitive domains, especially executive function. 
MCI does not invariably progress to dementia. However, patients with MCI have a 
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higher risk of dementia compared with healthy controls.[220]  
 
Figure 1.7: Spectrum of cognitive decline 
Alzheimer’s dementia is the commonest subtype of dementia in the general 
population. [219]  In contrast, the affected cognitive domains (particularly executive 
function) in patients with CKD are similar to that on vascular dementia, due to burden 
of cerebrovascular disease. A population cohort study of 7839 participants over 65 
years, reported an association between declining renal function and a higher risk of 
dementia with a vascular component.[221] 
1.4.1.2 Prevalence of Cognitive impairment in Advanced Kidney Disease 
CKD is associated with a high risk of cognitive impairment. The REasons for 
Geographic and Racial Differences in Stroke (REGARDS) Study, reported an 11% 
increase in the risk of cognitive impairment for every 10ml decrease in eGFR below 
60ml/min/1.73m2[222] with a 20% prevalence in those with eGFR < 20ml/min/1.73m2. 
The same prevalence rate was reported in a UK single centre cohort of predialysis 
patients.[223] 
  In the haemodialysis population, the prevalence of cognitive impairment approached 
70% in one cross sectional study. However, only 2.9% of the studied population had 
a clinical diagnosis.[224] This may be because patients with kidney disease first 
Cognitive Aging
Mild Cognitive 
Impairment 
(MCI)
Dementia
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develop executive dysfunction before global cognitive impairment becomes apparent 
[225]. Similar prevalence rates have been reported in in patients on peritoneal dialysis. 
[226]  
The reported prevalence of cognitive impairment in renal patients is dependent on the 
cognitive tool used. For example, in a cross-sectional study of 383 HD patients, 16% 
were judged to have cognitive impairment based on a modified MMSE (3MS) score < 
80. However, 29% had executive dysfunction based on a Trail making test B score > 
300. [227]  Moreover, the majority of cognitive tests have not been validated in the 
CKD population. The KDQoL cognitive subscale which is a component of the KDQOL 
questionnaire has been shown to be poorly sensitive to cognitive performance in HD 
patients.[228] Conversely, the Montreal cognitive assessment (MoCA) test correlated 
well (sensitivity-76.7%, specificity -78.6%) with a neuropsychological battery in a small 
study of 43 HD patients. A cut off value of less than 24 out of 30 was suggested as 
indicative of cognitive impairment in this study.[229] The external validity of this 
criterion is yet to be confirmed. 
1.4.1.3 Pathogenesis of Cognitive impairment in Kidney Disease 
The causes of cognitive impairment in advanced kidney disease has changed over 
time. Dialysis dementia related to aluminium toxicity in dialysis patients, is no longer 
common.[230] This has been replaced by an insidious cognitive decline often 
undiagnosed in clinical practice.  The underlying aetio-pathogenesis for cognitive 
impairment in advanced kidney disease remains unclear. It is thought to be due to a 
complex interaction between vascular, nephrogenic and dialysis related factors.[43]  
 Cerebrovascular disease is thought to underpin the pathogenesis of cognitive 
impairment in patients with advanced kidney disease. This is supported by the 
similarities in affected cognitive domains in patients with vascular dementia and those 
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with renal impairment.[43] As vascular changes tend to occur in the frontal regions of 
the brain, executive function is the most affected cognitive domain. Dialysis patients 
have been shown to have a higher burden of silent cerebral infarcts, micro bleeds, 
cerebral atrophy and sub clinical ischaemic white matter changes on magnetic 
resonance imaging, compared to the healthy controls.[199, 231-233] These findings 
have also been reported in patients with moderate to severe CKD, not on dialysis.[234] 
 Transient changes in cognition occur during the haemodialysis session [233] and 
improvements in cognitive deficits have been reported in dialysis patients after 
transplantation.[235, 236] This would suggest that the dialytic process has a role to 
play in cognitive impairment. Intuitively, this might be thought to be due to 
haemodynamic fluctuations during dialysis. Indeed, cerebral blood flow is reduced 
especially to the frontal regions, during haemodialysis.[237]. However, there is no 
proven association between cognitive impairment and blood pressure during dialysis 
.[238] The influence of intradialytic hypotension on cognitive impairment is also yet to 
be established.[227, 238, 239] The presence of similar ischaemic changes in patients 
on PD where haemodynamic instability is less likely, would suggest that other 
mechanisms are involved. Cerebral blood flow is also reduced in PD patients without 
a significant influence on cognitive performance.[240, 241] In the non-dialysis CKD 
cohort, studies evaluating cerebral blood flow have been inconsistent. An association 
between lower eGFR and higher as well as lower cerebral blood flow, has been 
reported. [242] Oxidative stress, one other purported mechanism for cognitive 
impairment, is increased in CKD as well as during dialysis.[48, 243] Its role in 
atherosclerosis has been well established. However, no relationship has been found 
between markers of oxidative stress and cerebrovascular disease in dialysis 
patients.[244] 
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Figure 1.8: Pathogenetic mechanisms of cognitive impairment in CKD 
(reproduced with permission)[43] 
Uraemic toxins such as indoxyl sulphate and p-cresyl sulphate, are thought to be 
associated with cognitive impairment in advanced kidney disease. The exact 
mechanisms by which they exert their effects are unknown. Direct neuronal damage 
as well as vascular dysfunction may be involved.[245] However, the adequacy and 
frequency of dialysis, which removes some of these toxins, have not been associated 
with cognitive impairment.[246, 247]  
 The influence of dialysis modality is not any clearer. PD patients also have similar 
ischaemic white matter changes and small vessel disease on MRI as reported in HD 
patients.[248] Small cross sectional studies have reported similar cognitive 
performances in HD and PD patients.[249] In contrast, a recent large retrospective 
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study of 121623 patients found that PD patients had a  lower 5 year cumulative risk of 
dementia compared to HD patients.[250] It is worth noting that baseline cognitive 
function was not considered, due to the retrospective nature of the study. The 
presence of cognitive impairment at baseline may have been an indication for starting 
HD instead of PD. The diagnosis of dementia was obtained from a database rather 
than formal clinical assessment. Variable reporting may therefore have influenced the 
outcome of the study. 
 Several studies have identified albuminuria as a risk factor for cognitive impairment 
in CKD. This association is independent of GFR in the early stages of CKD but does 
not extend to the latter stages of CKD, where GFR becomes more influential. [251]  
Other risk factors  recently associated with cognitive impairment include low 25 
hydroxy vitamin D [252] and  high FGF-23 levels.[253] 
1.4.1.4 Cognitive impairment and Outcomes 
Cognitive impairment is associated with increased mortality in renal patients. In a UK 
prospective cohort study, the 7 year survival rate was 49% for dialysis patients with 
cognitive impairment compared to 83% in those with normal cognition.[254] In a recent 
US study of 292 maintenance  HD patients, impaired memory and executive function 
were associated with higher mortality.[255]  
 Cognitive impairment  has also been associated with sleep disorders, increased 
length of hospital stay, poor nutrition, dialysis withdrawal and impaired physical 
function.[43]  Cognitive impairment may also influence the renal patient’s ability to 
make decisions.[43]. Decision making capacity (DMC) is discussed in the next section.  
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1.4.2 Decision making capacity and advanced kidney disease 
1.4.2.1 Domains of decision making capacity 
The doctor – patient relationship has evolved over time from a paternalistic approach 
to that of shared decision making.[256] Shared decision making however, presumes 
that the patient is capable of making autonomous decisions. Mental competence and 
capacity are two concepts that are linked to this ability. These terms are similar but not 
interchangeable. Competence is a legal term referring to the possession of sufficient 
functional abilities such that the power to make decisions can be exercised. It has 
connotations outside health. In contrast, mental capacity is often a clinical term that is 
time and situation specific with variable thresholds. 
  In the UK, a person is presumed to have mental capacity unless proven otherwise. 
Grisso et al [257] have defined four pre requisite abilities for defining decision making 
capacity. These include (1) The ability to express a choice about treatment; (2) the 
ability to understand information relevant to the treatment decision; (3) the ability to 
appreciate the significance of that treatment information for one’s own situation; and 
(4) the ability to reason with relevant information so as to engage in a logical process 
of weighing treatment options. These abilities overlap with the domains stated in the 
mental capacity act.  
 The assumption of capacity, as dictated by the capacity acts of England and Wales 
(2005) as well as Scotland (2000) may not always be sufficient in ensuring truly 
informed consent. Also, there is often a discrepancy in capacity assessment among 
clinicians. Physicians often tend to overestimate capacity in medical patients when 
compared with expert opinion. [258]  
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1.4.2.2 Prevalence of impaired decision making capacity 
The prevalence of impaired decision making capacity (DMC) varies depending on the 
patient group, assessor, assessment tool and the decision in question. In medical 
inpatients, prevalence rates between 20 and 74% have been reported in several small 
studies. [259-264] For older inpatients, prevalence rates between 15 and 59% have 
been reported.[265, 266] The prevalence of impaired decision making capacity in renal 
patients is unknown. 
1.4.2.3 Cognitive impairment as a risk factor for impaired decision making capacity  
Several studies have found cognitive function to be associated with impaired DMC in 
patients with known cognitive impairment [267-269] and acute medical patients without 
known cognitive impairment.[262, 264, 270-279]  DMC is also associated with the 
degree of cognitive impairment. Patients with mild cognitive impairment (MCI) have 
been shown to perform better in capacity assessments, compared with those with 
dementia.[280] However, this has not been consistently reported in all studies.[261, 
281] Impairments in executive function, [267, 282, 283] memory, [269, 283-287] and 
language domains have been associated with DMC.[269, 287]  In spite of the above, 
cognitive impairment is not synonymous with impaired DMC. Up to 50% of patients 
with moderate dementia have been shown to be capable of making decisions 
regarding treatment.[288] Increasing age is the only demographic variable that has 
been consistently associated with impaired DMC.[264, 272, 275]  Cognitive 
impairment may be confounding the association between age and DMC, as it often 
affects older people. 
1.4.2.4 Assessing capacity in medical patients 
 The clinical assessment of DMC varies depending on the level of expertise. 
Mackenzie et al reported good inter-rater agreement (72%) with a kappa of 0.44 
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following capacity assessments from two neuropsychologists, in 34 stroke patients. 
Agreement varied significantly when compared to the assessments of multi-
disciplinary professionals.[281] In contrast, Marson et al [289] found that  agreement 
was poor  among physicians using standardised consent capacity interview to 
evaluate DMC in patients with Alzheimer’s disease (k- 0.14, agreement – 56%).  
 A few studies have attempted to evaluate capacity using cognitive tests. Whilst there 
is evidence to suggest that cognitive function influences DMC, they are not 
interchangeable constructs. It is thus not surprising that these tests have poor 
agreement with assessments from experts.[290, 291] 
 Several assessment tools have been developed to assist with the assessment of 
DMC. These predominantly take the form of semi structured interviews. The Macarthur 
Competency Assessment Tool is one such assessment tool and is discussed below. 
 Macarthur Competency Assessment Tool- Treatment (MACCAT-t) 
 MACCAT-t is considered to be the gold standard for capacity assessment [292] and 
was used in this thesis. It is a semi structured interview that evaluates the capacity to 
consent to treatment under the domains of understanding the medical problem and 
treatment options, reasoning, appreciation and expression of choice. It has been used 
to assess capacity in medical patients with good inter-rater reliability.[264, 274]  The 
MACCAT-t has demonstrated moderate agreement with formal clinical assessment in 
dementia patients, general medical and psychiatric inpatients. [293, 294] In addition, 
precursors to the MACCAT-t which evaluated one of the four required abilities were 
used in early validation studies to evaluate DMC in medical patients. [270, 295, 296]. 
Grisso et al [295] reported an inter-rater agreement of >85% when using the 
Understanding Treatment Disclosure (UTD) tool in pilot study of 102 medical and 
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psychiatric patients. Pruchno et al found that UTD had good internal consistency 
(Cronbach alpha of 0.71) in long term care patients.[297]  
 1.4.2.5 Decision making capacity in advanced kidney disease 
 There is ongoing extensive research into the shared decision making process in 
patients with advanced kidney disease. Little, however is known about the decision-
making capacity in these patients.  
 To date, only 1 published study has assessed DMC in advanced kidney disease. 
Terawaki et al, in a pilot study of 26 patients with CKD 5, evaluated capacity to consent 
to treatment and cognitive function using the Macarthur competence assessment tool 
(MACCAT-T) and MMSE respectively. They reported poor performances in the 
domains of understanding, reasoning and appreciation. These were attributed to 
attentional deficits found in the MMSE. As the MMSE does not assess executive 
function, the predominant domain affected in renal patients, there are limitations in the 
validity of the study. [277]  
1.4.3 Conclusions 
 The risk of cognitive impairment increases as renal function deteriorates, with a 
prevalence approaching 70% in dialysis patients. Cerebrovascular disease is thought 
to play a major role in the pathogenesis of cognitive impairment in renal patients. 
Although dialysis affects cognition, it is unclear how dialysis modality affects the risk 
of cognitive impairment. This may be because most of the studies evaluating cognitive 
impairment are cross sectional in nature. Cognitive impairment is associated with 
adverse outcomes including an impaired ability to make decisions. 
 The 4 domains of DMC include understanding, reasoning, appreciation and 
expression of choice. There is often poor agreement among health professionals when 
DMC is formally assessed. Several tools have been devised to help assess DMC, with 
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MACCAT-t recognised as the gold standard. Cognitive impairment is highlighted as a 
risk factor for impaired DMC. However, not all patients with cognitive impairment lack 
DMC. It is recognised that there is a dearth in evidence with regards to impaired DMC 
in renal patients.  
1.5 Thesis aims    
 Most of the studies evaluating QoL and determinants in advanced kidney disease are 
cross sectional, providing a snapshot of potential associations with little or no 
prospective data. Longitudinal studies are needed to evaluate the influence of dialysis 
modality on the trajectory of these outcomes. In addition, there are no comparative 
studies evaluating QoL between older patients on assisted PD and those on HD. 
Objectives 
1. To compare quality of life outcomes in the frail elderly receiving assisted PD 
and HD, using the Frail and Elderly Patient Outcomes on dialysis (FEPOD) 
study. 
2. To determine the rate of decline in patient reported outcomes and cognitive 
function in patients with end stage renal disease (ESRD) and the associated 
risk factors. 
3. To evaluate the impact of cognitive impairment decision making capacity in 
patients with advanced kidney disease. 
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Hypotheses 
1. Dialysis is associated with a rapid decline in cognitive function and patient 
reported outcomes. The rate of decline varies depending on the dialytic 
modality. 
2. Frail older patients on assisted peritoneal dialysis have a better quality of life 
than those on haemodialysis 
3. Cognitive dysfunction is associated with impaired decision making in patients 
with advanced kidney disease.  
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2. FRAIL ELDERLY PATIENT OUTCOMES ON DIALYSIS (FEPOD) – 
A COMPARISON OF ASSISTED PERITONEAL DIALYSIS WITH  
IN- CENTRE HAEMODIALYSIS 
2.1 Introduction 
This study compares measures of QoL and physical function between older patients 
on assisted PD and those on HD, hypothesizing that outcomes are better preserved 
in the former. In chapter 1, QoL was shown to be poor in patients with advanced kidney 
disease. In the elderly, the North Thames Dialysis and BOLDE studies, health related 
QoL were shown to be similar between HD and PD patients. The BOLDE study though, 
did report less illness intrusion in the PD cohort. 
 The emergence of assisted PD in the early 2000s [132] has changed the landscape 
for the management of ESRD in frail older patients. Such patients can now be dialysed 
at home, promoting independence which is a key determinant of wellbeing in the older 
person. Therefore, one may postulate that QoL is better preserved in older patients on 
assisted PD compared to those on HD. Yet the majority of older patients with ESRD 
receive HD in the UK.  
 The FEPOD study, therefore aims to compare measures of QoL and physical function 
in older patients on assisted PD and HD. This study commenced in June 2012.I 
became involved with the study from May 2013 during the extended recruitment phase 
of the study. I have since been involved in study coordination, study assessments and 
the analysis, interpretation and presentation of study data. 
2.2 Study design 
The FEPOD study is a multicentre observational study consisting of two subsets. 
FEPOD 1 was a cross sectional study comparing QoL outcomes at a single time point. 
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The study was then expanded to include a second subset. FEPOD 2 was a prospective 
cohort study with 2 year follow up, comparing trends in QoL between modalities. 
2.3 Location of the sample 
Patients were recruited from 22 renal centres in the UK. FEPOD 1 recruited from renal 
units in London and Northern Ireland, while FEPOD 2 recruited from renal units from 
the rest of England and Northern Ireland (Table 2.1). The study was approved by the 
London – Fulham research ethics committee (REC Approval: 11/LO/ 1428 for FEPOD 
part 1, 11/LO/1886 for FEPOD part 2).  
2.4 Patient selection 
Patient over 60 years of age, who had been on dialysis for at least 3 months and free 
of hospital admission for at least 30 days, were eligible for the study. Hospitalisation 
and the initiation of dialysis have been associated with poor outcomes. These factors 
may therefore have influenced the outcomes of the study. Patients who were deemed 
to have a life expectancy of less than 6 months by the managing clinician, were 
excluded from the study. Patients with dementia as well as those unable to understand 
English, were also excluded. 
Assisted PD patients were defined as those unable to perform PD without the 
assistance of paid healthcare worker or family member. To be eligible for inclusion, 
the HD patients required hospital provided transport to receive dialysis in centre. 
Hospital transport is predominantly provided for multimorbid and dependent patients 
in the UK. This was to ensure that the HD and PD cohorts were similar in terms of 
level of dependence.  
There was no sample size calculation in this study. The sample size was restricted by 
the number of eligible patients on assisted PD. The uptake of assisted PD varied from 
unit to unit (Reported estimated prevalence = 5 to 30% of all PD patients) as well as 
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during the recruitment period. There were 180 eligible patients on assisted PD during 
the recruitment phase. Consenting participants were recruited from this cohort first. To 
limit the influence of baseline participant characteristics, the assisted PD recruits 
where matched to HD patients at each centre, according to age (within 2 years), 
gender, time on dialysis (within 1 year) diabetes status, and  ethnicity and socio 
economic status as defined by the index of deprivation (2007).[298] Suitable HD 
matches were approached in order, according to the number of matched 
characteristics. Where there were two or more suitable matches, the participant with 
the best match by index of deprivation was approached first. 
Recruitment took place between June 2011 and September 2013 for the FEPOD1 
cohort and September 2011 and December 2013 for the FEPOD 2 cohort. 
2.5 Study assessment 
2.5.1 Setting 
Table 2.1 shows the renal units that participated in this study. The FEPOD 1 cohort 
had a single baseline study visit. For the London centres, this was carried out by a 
team of researchers from Imperial College Healthcare NHS trust. For the FEPOD 2 
cohort, the baseline visit was conducted at individual centres, by local research team. 
Follow up study assessments were carried out every 3 months, in the form of postal 
surveys. These were returned directly to the Imperial College healthcare NHS trust. 
2.5.2 The study visit 
Eligible patients were approached with a patient information sheet at least 24 hours 
prior to the study visit. Those willing to participate provided written consent during the 
baseline visit. For the HD matches, study assessments were conducted before dialysis 
or on a non-dialysis day. The following demographic and clinical information were 
collected during the interview and from medical records.  
 
83 
 
Table 2.1: Participating FEPOD centres 
Number RENAL UNIT STUDY COHORT 
1 Belfast HSC Trust FEPOD 1 AND 2 
2 Bradford Teaching Hospitals, Bradford FEPOD 2 
3 
Central Manchester University Hospitals, 
Manchester 
FEPOD 2 
4 Derby City General Hospital, Derby FEPOD 2 
5 Hull Royal Infirmary, Hull FEPOD 2 
6 Imperial College Healthcare NHS Trust FEPOD 1 and 2 
7 Kent & Canterbury Hospital, Canterbury, Kent FEPOD 1 and 2 
8 Kings College Hospital, London FEPOD 1 and 2 
9 Leicester General Hospital, Leicester FEPOD 2 
10 Lister Hospital, Stevenage FEPOD 1 
11 Newcastle Hospitals, Newcastle FEPOD 2 
12 Northern General Hospital, Sheffield FEPOD 2 
13 Northern HSC Trust, Northern Ireland FEPOD 1 and 2 
14 Royal Free Hospital, London FEPOD 1 AND 2 
15 Royal London Hospital, London FEPOD 1 
16 Salford Royal Hospital, Manchester FEPOD 2 
17 Southern HSC Trust, Northern Ireland FEPOD 1 AND 2 
18 St George’s Hospital, London FEPOD 1 
19 St Helier’s Hospital, London FEPOD 1 AND 2 
20 St. James University Hospital, Leeds FEPOD 2 
21 Western HSC Trust, Northern Ireland FEPOD 1 AND 2 
22 
University Hospitals of North Staffordshire, 
Stoke on Trent 
FEPOD 2 
 
Demographic data   
Age 
Gender  
Ethnicity 
Dialysis modality 
Time on dialysis (in months) 
Post code 
Clinical data  
Cause of ESRD 
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Most recent blood tests-  Serum Hb, Adjusted calcium, phosphate, Bicarbonate, 
Alkaline phosphatase, C - reactive protein, measures of dialysis adequacy ( Kt/v, Urea 
Reduction Ratio, weekly creatinine clearance) 
Comorbidities were assessed using the Stoke –Davies comorbidity score. This 
prognostic score evaluates the burden of comorbidities under seven domains – 
Ischaemic heart disease, Peripheral Vascular disease, Left Ventricular Dysfunction, 
Diabetes, Malignancy, Systemic Collagenous vascular disorders and other conditions 
that affect survival. Scores range from 1 to 7, with higher scores indicating higher 
disease burden. The Stoke-Davies score has been shown to be predictive of survival 
[299] and is superior to the Charlson Comorbidity index as a predictor of 
hospitalisation, in PD patients. 
2.5.3 Study questionnaires 
The study assessments were carried out in a standard order as shown in table 2.2. 
The baseline study visit was identical for the FEPOD1 and FEPOD 2 cohorts, except 
for the cognitive and Timed Up and Go tests. These were only assessed in the FEPOD 
1 cohort. In the follow up phase of the study (FEPOD 2), the participants were 
assessed every 3 months by postal survey, according to the grid shown in table 2.3. 
The questionnaires will now be reviewed individually. 
2.5.3.1 Outcomes 
Short Form-12 (SF-12) version 2:  The SF-12 is a self- assessment of physical and 
mental HRQOL. Using patient responses, two summary scores are calculated: the 
Physical Component Summary scale (PCS) and the Mental Component Summary 
scale (MCS). Higher scores are indicative of better HRQOL. As previously discussed 
in section 1.3.2, the SF12 has over 90% agreement with the widely used SF36. It has 
also been shown to be a valid and reliable measure of HRQOL in older people.[161] 
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This measure was adopted for this study due to the lower completion burden, 
anticipating better response rates. 
Hospital Anxiety and Depression Scale (HADS): This questionnaire screens for 
depression or anxiety with scores ranging from 0 to 21.  A depression score of 8 and 
above is suggestive of possible depression. [300] .  
Table 2.2: Study Assessments in order of delivery 
Questionnaires (in order of delivery) Domain assessed 
Timed Up and Go*  Physical Function 
Trail Making Test-B*   Cognitive Function 
Mini Mental State Examination * Cognitive Function 
Illness Intrusiveness Rating Scale  Quality of Life 
SF-12   Quality of Life 
Hospital Anxiety and Depression Scale  Mood 
Palliative Outcome Symptom Scale  Symptom burden 
Dialysis Recovery Time Quality of Life 
Falls Questionnaire Fall frequency and impact 
Renal Treatment Satisfaction 
Questionnaire 
Satisfaction with Treatment 
Social Support Questionnaire Social Support 
Healthcare Use Proforma Hospital admissions,  
Outpatient visits 
Barthel Index Dependence 
Clinical Frailty Scale Frailty 
Demographics and clinical information Demographic and clinical data 
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Due to the overlap between depressive and uraemic symptoms, most depression 
scales may overestimate the presence of depression when compared to clinical 
diagnosis.[301] The HADS scale does not assess somatic symptoms of depression. It 
has been shown to be comparable to other self -report scales in dialysis patients.[302] 
Good internal consistency has been reported with the HADS depression scale in older 
people,[303] but other psychometric measures are relatively poorer.  
Table 2.3: FEPOD Assessment Grid 
Follow up time 
points 
Month 
3 
Month 
6 
Month 
9 
Month 
12 
Month 
15 
Month 
18 
Month 
21 
Month 
24 
Frailty scoring 
(nurse) 
 X  X  X  X 
SF12 (patient) X X X X X X X X 
HADS (patient) X X X X X X X X 
Illness 
intrusiveness 
rating (patient) 
X X X X X X X X 
Barthel score 
(nurse) 
X X X X X X X X 
Symptoms 
(patient) 
X X X X X X X X 
Dialysis 
recovery time 
(patient) 
X X X X X X X X 
Falls (patient)  X  X  X  X 
Satisfaction 
with treatment 
(patient) 
 X  X  X  X 
Social support 
(patient) 
 X  X  X  X 
Healthcare 
resource 
(hospital) 
(nurse) 
X X X X X X X X 
Participant 
dropout 
record(hospital) 
(nurse) 
Once only after each participant dropout 
 
Illness Intrusiveness Ratings Scale (IIRS):  This self-reporting tool assesses the 
extent to which the illness and/or treatment interferes with a patient’s life. The rating 
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scale evaluates intrusiveness in 13 life domains.  It has been validated in patients with 
end-stage kidney disease.[304] IIRS has been shown to correlate with uraemic 
symptoms, intercurrent non-renal illnesses, fatigue, and difficulties in daily activities. 
Scores range from 13 to 91, with higher scores indicating more illness intrusion.   
Symptoms were measured using the Palliative Care Outcome Scale- Symptoms 
(POS-S) renal scale.  This is an adaptation of the Palliative Care Outcome Scale 
(POS), which was originally developed for oncology patients to evaluate their palliative 
care needs. For non-dialysis patients with advanced kidney disease, it has been 
modified to include renal-specific symptoms.[305] Scores range from 0 to 80 with 
higher scores indicating increasing symptom burden. The POS-S renal score has also 
been shown to be predictive of mortality in HD patients.[306] The POS-S Renal score 
addresses more symptoms when compared to the other scales, such as the Edmonton 
symptom scale. Symptom scales such as the Dialysis Symptom index have only been 
validated in the HD population.   
Satisfaction with treatment was assessed using the Renal Treatment Satisfaction 
Questionnaire (RTSQ).[307] This 11 item tool has been validated in HD, PD and 
transplant patients. It assesses various aspects of treatment satisfaction, including 
convenience, flexibility and freedom afforded by treatment and impact on lifestyle. 
Scores range from 0 to 66 with higher scores suggesting more treatment satisfaction. 
While other treatment satisfaction survey tools exist, the RTSQ provides a brief but 
valid and reliable measure of patient satisfaction. This is relevant in this study, due to 
the number of outcome measures adopted. 
Barthel Index. This questionnaire evaluates performance in 10 activities of daily living. 
[308] Scores range from 0 to 100, with lower scores suggesting increased disability. 
Rather than being a direct measure of physical function, the Barthel index measures 
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dependence, a consequence of functional impairment. It is however sensitive to 
change over time. In this study, the follow up assessments were by postal survey. 
“Field” tests of physical function could therefore not be employed in this fashion.  
Timed up and go test (TUG) This “field” test of physical function measures the time 
taken for the patient to stand up from an armchair, walk 3 metres, turn around, walking 
back to the chair and sit down.[81] Completion time ≥ 14 seconds is associated with 
an increased risk of falls. In patients with advanced CKD, the TUG has been shown to 
have predictive validity in terms of fracture risk [309] and mortality. [310] 
2.5.3.2 Other clinical assessments 
The Canadian Study of Health and Aging (CSHA) Clinical Frailty scale was used 
to measure frailty. Scores range from 1 to 7, with higher scores corresponding to 
increasing level of frailty. It evaluates dependence for activities of daily living and has 
been shown to be predictive of death or the need to be institutionalized, similar to other 
established measures of frailty. [67]  
Mini Mental State Examination (MMSE):  This cognitive test is routinely used in 
clinical practice,[311]  with available normative data stratified by age groups and 
education levels.[312]  Scores range from 1-30, with a score < 24 suggesting cognitive 
impairment.  It is sensitive to changes to global cognitive function but does not assess 
executive function.  
Trail Making Test-B (TMT-B):  This test measures the time taken to follow a trail of 
alternating numbers and alphabets.[313] A completion time of more than 5 minutes is 
suggestive of executive dysfunction. This test was included recognising the limitation 
of the MMSE, in terms of assessing executive function. In addition, a proforma was 
designed to collect data on social networks, falls and healthcare use. The social 
network proforma has been used previously in the BOLDE study.[172] 
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2.6 Baseline analysis 
2.6.1 Statistical methods 
 As the study assessments were almost identical, the FEPOD 1 and 2 cohorts were 
combined and analysed as one sample at baseline. This was to increase the sample 
size and power of the study. 
2.6.1.1 Unadjusted analysis 
All analyses were carried out using the SAS program (version 9.3). Continuous 
variables were expressed as median and interquartile ranges, as they did not follow a 
normal distribution. Categorical variables were compared between the HD and PD 
cohorts using Fisher’s exact tests. Continuous variables were compared at baseline, 
using the Mann-Whitney test. However, baseline demographic characteristics were 
not compared between the HD and assisted PD groups. This is because these groups 
had been matched by demographic characteristics and did not constitute random 
samples. 
2.6.1.2 Regression analysis 
To determine the association between participant characteristics and study outcomes, 
regression analysis was employed. For each study outcome, a generalised linear 
model with gamma distribution was fitted adjusting for age, gender, time on dialysis, 
stoke comorbidity score, frailty score as well as dialysis modality. This method was 
used because the outcome variables followed a skewed distribution, after data 
exploration. Attempts to transform the data to fit a normal distribution, were 
unsuccessful. Univariate and Multivariate analysis were carried out, the latter showing 
the influence of each risk factor on the study outcome after adjusting for the other 
covariates. Risk factors associated with possible depression were determined using 
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logistic regression analysis. The HADS score was analysed as a categorical outcome 
variable with a score ≥ 8, suggesting possible depression. 
2.6.1.3 Adjusting p values for multiple significance testing 
Due to the high number of outcome measures and significance tests performed, there 
was the potential for false positive associations. To protect against this, all p values 
were adjusted for multiple comparisons. In this analysis, the false-discovery rate 
adjustment of Benjamini & Hochberg was used.[314] This method is said to be more 
conservative in comparison to other methods of multiple adjustments (such as the 
Bonferroni method). It is therefore possible that true associations were no longer 
significant because of the adjustment. This trade-off was considered to be acceptable, 
due to the observational nature of the study.  In addition, it has been recommended 
for use in health studies in a recent review.[315]. Unadjusted as well as adjusted p 
values will be presented. However, only adjusted p values ≤ 0.05 were considered to 
be significant. 
2.6.1.4 Retrospective power calculation 
As mentioned earlier, the sample size was restricted by the number of eligible patients 
on assisted PD. There was therefore no a priori sample size calculation. However, a 
retrospective power calculation was carried out during statistical analysis. The power 
calculation suggests that the study sample size would have 80% power to detect 
associations, which give a small increase in multiple correlation (0.028), in a model 
that has low overall multiple correlation (r = 0.100). The values suggest that the 
hypothetical effect estimates are small. In other words, this study possessed 80% to 
detect significant relationship between predictor variable and the outcome, even when 
the strength of the association is relatively small. Multiple regression sample size 
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calculations are based on many assumptions and this retrospective power calculation 
should be regarded as approximate.  
2.6.2 Results 
251 patients (129 assisted PD recruits and 122 HD matches) were recruited at 
baseline. An estimated 72% of eligible participants on assisted PD were recruited.  
The 7 unmatched PD patients were included in the analysis. 
2.6.2.1 Demographic characteristics  
The assisted PD and HD cohorts were well matched for age, gender, time on dialysis, 
diabetes status and ethnicity (Table 2.4). In comparison to the UK renal population, 
the study cohort was older but with a higher prevalence of diabetes. As this is not a 
like for like comparison, these differences are to be expected. The study cohort was 
predominantly of white European ethnicity, consistent with the UK renal population 
(Table 2.5). Diabetes was also the most common cause of ESRD in the study cohort. 
88.4% lived in their own home while 43% required paid help for activities of living, at 
least once a week. 
2.6.2.2 Clinical characteristics 
Table 2.6 shows the clinical characteristics for the cohort. 48% met the criteria for 
frailty (frailty scores ≥ 5) (51.9% PD, 42.6% HD, p = 0.32). The groups did not differ in 
terms of comorbidity burden.  46 % of the study group had been admitted to hospital 
in the previous 3 months and 33% sustained 1 or more falls in the preceding 6 months. 
Of those who fell, 14.4% sustained fracture after the fall (4.8% of the study cohort). 
Cognitive function was assessed in the FEPOD 1 subset (n = 106 patients). Only 4 
patients (4.8%) had abnormal MMSE scores. In contrast, 41% had executive 
dysfunction (Trail Making Test B time > 300 seconds) with no significant difference in 
prevalence between assisted PD and HD patients.  
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Table 2.4: Demographics according to matching criteria 
Matching Criterion^ Assisted PD 
(n = 129) 
HD (n = 122) UK PD 
cohort* 
UK HD 
cohort* 
Age (years)  76 (70 – 81) 75 (69 – 80) 63.4 66.4 
Male Gender (%) 58.9 59.8   
Dialysis vintage 
(months) 
22 (11 – 35) 27.5 (15.5– 39.5) 20.4 40.8 
Diabetes (%) 49.5 50.5 22.3 22.7 
Ethnicity (% of n) 
White European 
Afro-Caribbean 
Asian  
Other  
 
86.0 
4.7 
8.5 
0.8 
 
86.8 
7.4 
5.0 
0.8 
 
79.3% 
7.3% 
11.7% 
1.7% 
Index of Deprivation 16.3 (10.1 – 33.1) 20.4 (12.8 – 32.3) - - 
 * Data were obtained from the 16th UK renal registry report.; ^ median (IQR) unless otherwise stated  
Table 2.5: Other Demographic characteristics 
Other demographic characteristics Assisted PD (n=129) HD (n = 122) 
Cause of Kidney Disease (% of n) 
Diabetes 
Glomerulonephritis 
Pylon/Tubulointerstitial nephritis 
Hypertension 
Renovascular disease 
Other 
Unknown 
 
26.6 
11.3 
16.1 
8.9 
11.3 
16.9 
8.9 
 
21.0 
10.1 
6.8 
5.9 
21.0 
18.5 
16.8 
Social support (% of n) 
Residence 
   Own Home  
  Warden controlled  
   Nursing home 
Living alone 
Help from family for daily activities 
Paid help for daily activities  
 
 
92.9 
6.3 
0.8 
23.3 
54.3 
49.6 
 
 
84.5 
13.9 
1.6 
27.9 
63.9 
36.1 
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Table 2.6: Clinical characteristics  
Clinical characteristics aPD      
n = 129 
HD        
n = 122 
Unadjusted 
p values 
Adjusted 
p values 
Median Frailty score (IQR) 
Score >5 (%) 
5 (4 - 5) 
51.9 
4 (3 - 5) 
42.6 
0.05 
0.14 
0.17 
0.32 
Comorbidities (% of n) 
Malignancy 
Ischaemic Heart Disease 
Peripheral Vascular disease 
Left ventricular dysfunction 
Systemic collagenous vascular disorders 
Previous Stroke 
Visual impairment 
Arthritis 
 
10.9 
26.6 
54.2 
23.4 
5.5 
14.0 
5.7 
17.1 
 
21.3 
38.5 
45.8 
18.0 
6.6 
8.2 
3.1 
17.2 
 
0.18 
0.04 
0.59 
0.29 
0.91 
0.15 
0.31 
0.97 
 
1.00 
0.15 
0.79 
0.54 
1.00 
0.53 
0.72 
1.00 
Median Stoke Davies Comorbidity 
Score(IQR) 
2 (1 - 3) 2 (1 - 3) 0.43 0.66 
Cognitive function (% of n)* 
TMT-B time >300 sec (HD = 47, PD =48)* 
MMSE <24 (HD = 43, PD = 40)* 
 
54.2 
2.3 
 
27.7 
7.5 
 
0.01 
0.35 
 
 
0.37 
0.62 
Hospital admissions in last 3 months 
Patients admitted (% of n) 
Dialysis related (% of all admissions) 
 
49.2 
55.5 
 
42.9 
23.1 
 
0.31 
0.01 
 
1.00 
0.14 
Falls in the preceding 6 months 
Patients affected (% of n) 
Fracture (% of patients who fell) 
 
34.1 
6.2 
 
32.0 
3.3 
 
0.72 
0.38 
 
1.00 
0.79 
 
2.6.2.3 Study outcomes 
 In this section, I will report the results from the baseline analysis of study outcomes. 
Unadjusted outcomes were compared between assisted PD and HD using the Mann-
Whitney and Fisher’s exact tests. The influence of dialysis modality on these outcomes 
was then evaluated after adjusting for baseline participant characteristics.  
i. Unadjusted Study outcomes 
 Table 2.7 shows the unadjusted outcomes for assisted PD and HD patients. The 
assisted PD group had higher HADS depression scores [median (IQR) PD = 6 (3 – 
7.75), HD =5 (3 – 8.75); p = 0.05], and a higher prevalence of possible depression 
(38.8% vs 23.8%, p = 0.05). Conversely, the RTSQ score was higher in assisted PD 
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patients [median (IQR) 55 (48 – 59.75) vs 51(44 -57), p < 0.01]. The other outcome 
measures did not differ between modalities. 
 
Table 2.7: Unadjusted study outcomes at Baseline 
Outcome Variable Assisted PD HD Unadjusted 
p value 
Adjusted p 
value 
SF12 PCS,* median 
(IQR) 
33 (26.6 -40.3) 31.7 (25.2- 38.2) 0.33 0.57 
SF12 MCS,* 
median(IQR) 
49.3 (38.4 – 
54.2) 
50.8 (40.3 -59.6) 0.17 0.35 
Illness Intrusiveness 
Rating Scale, median 
(IQR) 
33 (21 -  43.75) 33 (23 - 43) 0.77 0.86 
HADS depression, 
 median (IQR) 
6 (3 – 8.75) 5 (3 – 7.75) 0.01 0.05 
HADS depression > 8 
(%) 
38.8 23.8 0.01 0.05 
RTSQ score,  
median (IQR) 
55 (48 – 59.75) 51 (44 - 57) <0.01 0.01 
Symptom count,  
median (IQR) 
8 (6 - 10) 9 (7 - 11) 0.04 0.14 
Symptom score,  
median (IQR) 
14 (9 - 20) 16 (11 - 22) 0.19 0.39 
Barthel’s score, 
median (IQR) 
90 (75 - 100) 90 (78.3 -100) 0.72 0.82 
Timed up and go >14 
secs (%) (HD = 46, PD 
= 49) 
80.4 79.6 0.59 0.99 
*A higher score indicates better quality of life.   
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ii. Multivariate analysis of QoL outcomes 
Multivariate analysis was performed using generalised linear modelling. The intention 
was to assess whether there was an association between of dialysis modality and 
each outcome, after adjusting for patient characteristics. The SF12, Barthel index, 
HADS score, IIRS and RTSQ were the dependent variables of interest. Generalised 
linear models were generated for each of the aforementioned dependent variables. A 
sequential modelling approach was not used, as the intention was not generate 
predictive models. Such models are designed predict the absolute value of the 
outcome measure based on the value to the predictor variables. This study was 
deemed too small to build such models. Instead age, gender, dialysis vintage, co-
morbidity score and the frailty score were chosen, a priori, as potential confounders 
by the research team. These variables were included, along with dialysis modality (the 
variable of interest) in each of the models. The results from univariate and multivariate 
analysis are shown in tables 2.8 and 2.9 respectively.  
After multivariate analysis, HD was associated with lower RTSQ scores (Exp B = 0.93, 
95% CI = 0.89 – 0.98; p = 0.04) compared to assisted PD. There were no significant 
differences in other outcomes between HD and assisted PD. An increase in the frailty 
score was associated with worse SF12 MCS, SF12 PCS, Barthel, symptom, illness 
intrusion and HADS scores (p < 0.01), while age was associated with lower illness 
intrusion (p < 0.01). 
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Table 2.8: Univariate effects of predictor variables on outcomes 
Outcome Predictors Effect 
Estimate 
95% CI Unadjusted 
p value 
Adjusted p 
value 
SF12 PCS Age 
Gender 
Time on Dialysis  
Comorbidity Score 
Frailty Score 
1.00 
0.89 
0.99 
0.95 
0.91 
0.99 – 1.01 
0.83 – 0.97 
0.98 – 1.01 
0.98 – 1.00 
0.88 – 0.94 
0.72 
< 0.01 
0.24 
0.16 
<0.01 
0.84 
0.02 
0.49 
0.35 
<0.01 
SF12 MCS Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
1.00 
0.98 
1.00 
0.99 
0.93 
1.00 – 1.01. 
0.91 – 1.05 
0.99 – 1.01 
0.96 – 1.01 
0.90 – 0.96 
0.28 
0.10 
0.60 
0.07 
<0.01 
0.53 
0.26 
0.79 
0.22 
<0.01 
IIRS Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
0.98 
0.97 
1.00 
1.04 
1.15 
0.98 – 0.99 
0.86 – 1.09 
0.99 – 1.00 
0.99 – 1.09 
1.10 – 1.22  
<0.01 
0.60 
0.36 
0.10 
<0.01 
<0.01 
0.79 
0.58 
0.25 
<0.01 
Barthel 
index 
Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
1.00 
0.95 
1.00 
0.96 
0.88 
0.99 – 1.01 
0.89 – 1.00 
0.99 – 1.00 
0.93 – 0.98 
0.86 – 0.89 
0.32 
0.29 
0.91 
0.01 
<0.01 
0.57 
0.54 
0.94 
0.06 
<0.01 
Symptom 
score 
Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
0.99 
1.04 
1.00 
1.03 
1.21 
0.98 – 1.00 
0.89 – 1.21 
0.99 – 1.00 
0.97 – 1.10 
1.13 – 1.29 
0.15 
0.69 
0.72 
0.32 
<0.01 
0.43 
0.74 
0.98 
0.91 
< 0.01 
RTSQ Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
1.00 
1.00 
1.00 
0.99 
0.98 
0.99 – 1.00 
0.95 – 1.04 
1.00 – 1.01 
0.97 – 1.01 
  0.96 – 1.00 
0.95 
0.92 
0.13 
0.36 
0.06 
0.97 
0.96 
0.38 
0.63 
0.22 
HADS Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
0.99 
1.09 
1.00 
1.04 
1.20 
0.98 – 0.99 
0.93 – 1.23 
0.99 – 1.00 
0.97 – 1.11 
1.13 – 1.29   
0.05 
0.16 
0.67 
0.13 
<0.01 
0.15 
0.35 
0.82 
0.31 
<0.01 
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Table 2.9: Effect estimates from multivariate analysis using generalised linear 
models* 
Outcome Predictors Effect 
Estimate 
95% CI Unadjusted 
p value 
Adjusted 
P value 
SF12 MCS Age 
Gender 
Time on Dialysis  
Comorbidity Score 
Frailty Score 
HD vs PD 
1.00 
1.03 
1.00 
0.98 
0.94 
0.98 
1.00 – 1.01 
0.96 - 1.11 
1.00 – 1.00 
0.95 - 1.02 
0.91 - 0.97 
0.92 – 1.06 
0.70 
0.36 
0.53 
0.33 
<0.01 
0.66 
0.91 
0.63 
0.83 
0.63 
< 0.01 
0.87 
SF12 PCS Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
HD vs PD 
1.00 
1.10 
1.00 
0.99 
0.88 
1.03 
0.99 – 1.00 
1.00 – 1.22 
1.00 – 1.00 
0.95 – 1.04 
0.84 – 0.91 
0.93 – 1.13 
0.57 
0.06 
0.43 
0.76 
<0.01 
0.56 
0.85 
0.23 
0.70 
0.91 
<0.01 
0.85 
IIRS 
 
Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
HD vs PD 
0.98 
1.08 
1.00 
0.99 
1.14 
1.07 
0.98 - 0.99 
0.98 – 1.21 
1.00 – 1.00 
0.94 – 1.03 
1.09 - 1. 20 
0.96 – 1.19 
<0.01 
0.14 
0.59 
0.60 
<0.01 
0.21 
<0.01 
0.40 
0.85 
0.85 
<0.01 
0.51 
Barthel 
index 
Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
HD vs PD 
1.00 
1.02 
1.00 
0.98 
0.89 
0.98 
0.99 – 1.01 
0.93 – 1.12 
1.00 – 1.00 
0.94 – 1.02 
0.86 – 0.93 
0.89 – 1.08 
0.78 
0.72 
0.92 
0.26 
<0.01 
0.66 
0.91 
0.89 
0.96 
0.57 
<0.01 
0.87 
Symptom 
score 
Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
HD vs PD 
0.99 
1.07 
1.00 
0.99 
1.23 
1.00 
0.98 - 1.00 
0.89 – 1.30 
1.00 – 1.00 
0.91 – 1.07 
1.13 – 1.34 
0.83 – 1.20 
0.16 
0.46 
0.96 
0.76 
<0.01 
0.97 
0.43 
0.74 
0.98 
0.91 
< 0.01 
0.98 
RTSQ Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
HD vs PD 
1.00 
1.00 
1.00 
1.00 
0.98 
0.94 
1.00 – 1.00 
0.95 – 1.05 
1.00 – 1.00 
0.98 – 1.02 
0.96 – 1.00 
0.89 – 0.98 
0.84 
0.93 
0.08 
0.85 
0.03 
<0.01 
0.93 
0.96 
0.29 
0.93 
0.14 
0.04 
HADS Age 
Gender 
Time on Dialysis 
Comorbidity Score 
Frailty Score 
HD vs PD 
0.99 
0.97 
1.00 
1.02 
1.21 
0.97 
0.97 – 1.00 
0.80 – 1.17 
1.00 – 1.00 
0.94 – 1.10 
1.11 – 1.31 
0.81 – 1.17 
0.04 
0.72 
0.61 
0.67 
<0.01 
0.76 
0.19 
0.89 
0.86 
0.87 
<0.01 
0.91 
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2.7 Longitudinal analysis 
2.7.1 Statistical methods 
The FEPOD 2 cohort (n= 206) were involved in this analysis. Longitudinal trends in 
each outcome measure were analysed over 2 years, using a mixed model approach 
(SPSS version 22). 
2.7.1.1 Missing data 
  81 out of the 206 patients (39.4%) completed the study. There were 59 deaths 
(28.6%), 61 study withdrawals (29.6%) and 5 transplants (2.5%) during follow up. 
Figure 2.1 shows the missing data distribution at each time point. Figure 2.2 shows 
the same, according to dialysis modality. The reasons for study withdrawal are shown 
in table 2.10.   
 
 
Figure 2.1: Missing data pattern during FEPOD follow up 
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Figure 2.2: Patient numbers for HD and PD at each time point 
 
Table 2.10: Reasons for study withdrawal 
 
 
 
 
 
2.7.1.2 Mixed Modelling Approach  
A linear mixed model approach was used to evaluate the changes over time for each 
outcome measure. This method was chosen because, unlike traditional regression 
methods, it considers the correlation between measures within the same subject. This 
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18 (29.5%) 
3 (4.9%) 
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is crucial to obtaining valid statistical inference. In contrast to other methods of 
repeated measure analysis, this method also does not exclude patients with missing 
data.  
The baseline outcome measure was included in each model as a covariate. The other 
explanatory variables considered for each model are Gender, Age at baseline, Time, 
Ethnicity, Time on dialysis (at baseline), Stoke Comorbidity score at baseline, Frailty 
score at baseline and Time to dialysis recovery. The aforementioned variables were 
chosen a priori as potential predictors. Dialysis modality was also included in each 
model, as the variable of primary interest. 
The missing data in this study could not be assumed to be missing at random. 
Therefore, the missing mechanism was incorporated at the modelling stage. As 
reported in the previous section, drop outs due to death or study withdrawal 
contributed significantly to the missing data profile. Therefore, the follow up status (i.e. 
died, withdrew from study or completed follow up) was included as an explanatory 
variable. For each outcome measure, several models consisting of different 
combinations of the explanatory variables were fitted. The model with the best fit was 
chosen as the final model. Those effects with p values < 0.05 were considered to be 
significant. As there were several outcome measures, adjusting for multiple testing 
was considered. However, this would require the final models to consist of the same 
explanatory variables, for each of the outcome measures. This was not the case, as 
the models were different. In addition, the pattern of missing data varied across the 
outcome measures. The trade off in this study analysis was therefore between finding 
the best model for each outcome measure or adjusting for multiple comparisons.  
Associations with very small p values would likely still be significant even after 
adjustment. 
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2.7.1.3 Modality change during follow up 
10 of the 206 patients changed modality during follow up. 9 PD patients converted to 
HD from PD and 1 HD patient converted to PD. Most of these modality changes 
occurred early during follow up (4 at 3 months, 1 at 6 months, 2 at 9 months, 1 at 12 
months and 1 at 24 months). However in the longitudinal analysis, these crossovers 
were not considered. Instead, the dialysis modality at baseline was used.  
2.7.2 Results 
2.7.2.1 Demographic and clinical characteristics 
The baseline characteristics for the follow up cohort are shown in Table 2.11. The HD 
patients had a higher dialysis vintage and a higher prevalence of malignancy, 
compared to PD. Otherwise, there were no differences between the groups. 
2.7.2.2 Mixed Model Analysis 
The results of the mixed model analyses are presented as tables showing the effect 
estimates of the explanatory variables within each model. To adjust for the effects of 
follow up status at various time points, it was necessary to analyse the variable “time 
point” as a discrete variable. It was also deemed necessary to consider the interactions 
between the variables – timepoint, dialysis modality and follow up status. 
Consequently, the effect estimate tables were cumbersome and difficult to follow. For 
this reason, that I have presented the main effects of the explanatory variables within 
each model, as well the interactions that are relevant to the analysis objectives. The 
full model tables are available in the appendix section. 
 Pairwise comparisons between HD and PD at each follow up time point, are also 
shown as tables. Finally, the longitudinal trend for each outcome measure is depicted 
as a profile plot. The mean predicted values generated from the mixed models have 
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been plotted against time. These were used instead of measured values because they 
account for missing data and have been adjusted for other covariates. 
Table 2.11: Baseline characteristics for follow up cohort 
 
 
 
 
Characteristics HD PD P value 
Age in years, Median (IQR) 75 (69 – 80) 76 (69 – 81) 0.73 
Months on dialysis, Median (IQR) 29 (17 – 41) 24 (12 – 35) 0.05 
Female Gender 42.5% 39% 0.61 
Ethnicity 
White European 
Afro Caribbean 
Asian 
Other 
 
89.0% 
6.0% 
4.0% 
1.0% 
 
90.6% 
0.9% 
8.5% 
0.0% 
 
0.09 
Stoke Comorbidity score, Median 
(IQR) 
2 (1 – 3) 2 (1 - 3) 0.61 
Diabetes Mellitus 
Ischaemic Heart Disease 
LV Dysfunction 
Peripheral Vascular disease 
Malignancy  
Systemic Collagen Vascular disorder 
46.8% 
57.7% 
20.0% 
23.0% 
23.0% 
5.0% 
53.2% 
42.3% 
21.7% 
27.6% 
12.3% 
3.8% 
0.66 
0.06 
0.76 
0.45 
0.04 
0.67 
Frailty score, Median (IQR) 4 (3 – 5) 4 (4 – 5) 0.06 
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Barthel Index 
Table 2.12 shows the effect estimates from the mixed model, with the Barthel index 
as the outcome variable. It adjusted for the Barthel index at baseline, dialysis modality, 
follow up status and time. The Barthel index at baseline was associated with the 
Barthel index during follow up [effect estimate = 0.83 (0.70 -0.96), p <0.01]. The follow 
up status was associated with the Barthel score during follow up. Dialysis modality 
was not associated with the Barthel index during follow up [PD vs HD Effect estimate 
= 4.18 (11.99 to -3.64), p = 0.29] or indeed with the change in Barthel index over time. 
 
Table 2.12: Effect Estimates of from Mixed Model (Barthel index) 
Parameter Estimate 
Upper 
Bound 
Lower 
Bound 
P value 
Intercept 9.43 21.71 -2.85 0.13 
PD  
HD (reference) 
4.18 
- 
11.99 
- 
-3.64 
- 
0.29 
- 
Follow up status 
DD 
SW 
CS (reference) 
 
-30.22 
6.73 
- 
 
-16.19 
35.26 
- 
 
-44.25 
-21.80 
- 
 
<0.01 
0.64 
- 
Time point 
6 months  
12 months  
18 months 
24 months (reference) 
 
4.65 
5.84 
5.54 
- 
 
11.02 
12.31 
12.35 
- 
 
-1.71 
-0.62 
-1.26 
- 
 
0.15 
0.08 
0.11 
- 
Barthel score at baseline 0.83 0.96 0.70 <0.01 
Dialysis Modality* Time point 
PD vs HD* 6 months  
PD vs HD* 12 months  
PD vs HD* 18 months  
PD vs HD* 24 months (reference) 
 
-5.57 
-3.80 
-4.03 
- 
 
3.80 
5.63 
5.69 
- 
 
-14.93 
-13.24 
-13.75 
- 
 
0.24 
0.43 
0.41 
- 
Full model on page 212. DD- died during follow up, SW- withdrew from study, CS – completed study.  
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Table 2.13 shows the estimated mean difference between HD and PD at 6 monthly 
time point, stratified by the follow up status. The only significant difference was in the 
cohort that died during follow up, where the PD cohort had relatively higher Barthel 
scores at 18 months compared to the HD cohort (top panel, figure 2.3).  
Table 2.13: Pairwise comparisons between HD and PD (Barthel index) 
Visit Follow up 
status 
Mean difference         
(HD – PD) 
     95% CI P value 
6 months Death 
Withdrawal 
Study end 
-1.45 
2.58 
1.51 
-11.43 to 8.53 
-6.95 to 12.11 
-5.57 to 8.58 
0.78 
0.59 
0.68 
12 months Death 
Withdrawal 
Study end 
-8.19 
-0.33 
-0.54 
-20.92 to 4.55 
-11.10 to 10.44 
-7.62 to 6.53 
0.21 
0.95 
0.88 
18 months Death 
Withdrawal 
Study end 
-38.56 
11.01 
-0.60 
-54.95 to -22.16 
-7.30 to 29.30 
-8.15 to 6.96 
<0.01 
0.24 
0.88 
24 months Death 
Withdrawal 
Study end 
- 
- 
-4.48 
- 
- 
-12.29 to 3.34 
- 
- 
0.26 
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Figure 2.3: Trends in estimated Barthel score during follow up. Error bars represent 95% CI 
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Renal Treatment Satisfaction Questionnaire (RTSQ) 
Table 2.14 shows the effect estimates from the mixed model with RTSQ as the 
outcome variable. Significant predictors were Ethnicity, Dialysis recovery, RTSQ at 
baseline [Effect estimate = 0.68 (0.54 – 0.82), p < 0.01] and Age at baseline [Effect 
estimate = - 0.17(-0.33 to -0.017), p =0.03].  
Pairwise comparisons according to dialysis recovery time showed that patients with 
shorter dialysis recovery time had higher estimated RTSQ scores compared to those 
who recovered after 12 hours (Figure 2.4). Similar analysis according to ethnicity 
showed that Asians and white Europeans had higher RTSQ scores compared to Afro 
Caribbean participants. [Asian, mean difference = 24.9 (13.26 to 36.62), p <0.01, white 
European, mean difference = 23.1 (12.16 to 34.04), p < 0.01]. There was no significant 
difference in RTSQ scores between HD and PD (figure 2.5). 
 
Figure 2.4: Estimated difference in RTSQ scores according to dialysis recovery 
time 
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Table 2.14: Estimate of Fixed Effects from Mixed Model (RTSQ) 
Parameter Estimate 
95% CI 
Lower 
95% CI 
Upper 
 
p value 
Intercept -9.37 -28.46 9.73 0.33 
 PD  
 HD (reference) 
-1.24 
- 
-3.53 
- 
1.04 
- 
0.28 
- 
Follow up status 
DD  
SW  
CS (reference) 
 
0.37 
0.78 
- 
 
-4.79 
-3.75 
- 
 
5.53 
5.30 
- 
 
0.89 
0.74 
- 
Time point (months) 
6 
12 
18  
24 (reference) 
 
0.63 
3.96 
1.40 
- 
 
-2.76 
0.37 
-2.38 
- 
 
4.01 
7.54 
5.17 
- 
 
0.72 
0.03 
0.47 
- 
Ethnicity 
Asian vs  
White European  
Afro Caribbean (reference) 
 
24.94 
23.10 
- 
 
13.26 
12.16 
- 
 
36.62 
34.04 
- 
 
<0.01 
<0.01 
- 
Time to dialysis recovery 
< 2 hours  
2 to 6 hours  
6 to 12 hours 
>12 hours (reference) 
 
15.09 
15.75 
12.60 
- 
 
3.39 
3.82 
0.47 
- 
 
26.79 
27.68 
24.72 
- 
 
0.01 
0.01 
0.04 
- 
RTSQ at baseline 0.68 0.54 0.82 <0.01 
Age at baseline (years) -0.17 -0.33 -0.017 0.03 
Full model on page 214. DD- died during follow up, SW- withdrew from study, CS – completed study 
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Figure 2.5: Trends in estimated RTSQ during follow up. Error bars represent 95% CI 
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HADS depression score 
 Table 2.15 shows the effect estimates from the mixed model, with the HADS 
depression score as the outcome variable. It adjusted for the HADS depression score 
at baseline, the baseline frailty score, dialysis modality, timepoint and follow up status.  
The baseline frailty score [Effect estimate = 0.55(0.41 – 0.68, p<0.001) and the HADS 
depression score at baseline [Effect estimate = 0.43 (0.02 to 0.84), p =0.042] were 
associated with higher HADS depression scores during follow up. 
Table 2.16 shows the pairwise comparisons between HD and PD stratified by follow 
up status. Among participants who withdrew from the study, the HADS depression 
score was higher in the HD group at 6 months, but did not differ significantly at other 
time points.  At 15 and 18 months, the score was lower in the HD group among 
patients who died during follow up (Table 2.16). The predicted HADS depression 
scores have been plotted against time in figure 2.6. 
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Table 2.15: Effect estimates of Fixed Effects (HADS depression score) 
Parameter Estimate 
95% CI  
Lower 
95%CI 
Upper 
 
P value 
Intercept 1.67 -0.20 3.53 0.08 
PD 
HD (reference) 
- 0.09 
- 
-1.83 
- 
1.65 
- 
0.92 
- 
HADS Depression score at 
baseline 
0.55 0.41 0.68 <0.01 
Frailty Score at baseline 0.43 0.02 0.84 0.04 
Follow up status 
DD  
 SW  
 CS (reference) 
 
8.28 
2.10 
- 
 
3.54 
-4.55 
- 
 
13.03 
8.74 
- 
 
<0.01 
0.54 
- 
Time point 
3 months 
6 months 
9 months  
 12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
      -0.40 
0.21 
-0.60 
-0.06 
-0.20 
0.22 
0.11 
- 
 
-1.59 
-1.02 
-1.85 
-1.27 
-1.40 
-0.97 
-1.03 
- 
 
0.79 
1.44 
0.65 
1.16 
1.00 
1.41 
1.24 
- 
 
0.51 
0.74 
0.35 
0.93 
0.75 
0.72 
0.85 
- 
Dialysis * Timepoint 
PD vs HD * 3 months 
PD vs HD * 6 months  
PD vs HD * 9 months 
PD vs HD * 12 months 
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months 
PD vs HD * 24 months  
 
0.51 
- 0.09 
0.72 
-0.02 
0.93 
- 0.63 
0.03 
- 
 
-1.24 
-1.87 
-1.13 
-1.81 
-0.88 
-2.40 
-1.67 
- 
 
2.27 
1.70 
2.57 
1.77 
2.74 
1.14 
1.73 
- 
 
0.57 
0.92 
0.45 
0.98 
0.31 
0.49 
0.97 
- 
Full model shown on page 216. DD- died during follow up, SW- withdrew from study, CS – completed study 
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Table 2.16: Pairwise comparisons between HD and PD (HADS Depression score) 
Time point Follow up 
status 
HD- PD   
(mean difference)  
95% CI P value 
3 months Death 
Withdrawal 
Study end 
0.40 
0.01 
-0.42 
-1.82 to 2.62 
-2.42 to 2.43 
-2.0 to 1.22 
0.72 
0.99 
0.61 
6 months Death 
Withdrawal 
Study end 
-1.66 
3.00 
0.18 
-4.23 to 0.96 
 0.16 to 5.83 
-1.49 to 1.85 
0.21 
0.04 
0.83 
9 months Death 
Withdrawal 
Study end 
-1.39 
-1.51 
-0.63 
-4.22 to 1.44 
-4.73 to 1.71 
-2.39 to 1.13 
0.33 
0.36 
0.48 
12 months Death 
Withdrawal 
Study end 
1.06 
1.99 
0.11 
-1.79 to 3.90 
-3.32 to 7.28 
-1.62 to 1.84 
0.47 
0.46 
0.90 
15 months Death 
Withdrawal 
Study end 
-5.07 
1.89 
-0.84 
-9.18 to -0.96 
-3.28 to 7.07 
-2.56 to 0.88 
0.02 
0.47 
0.34 
18 months Death 
Withdrawal 
Study end 
-4.76 
- 
0.72 
-9.06 to -0.46 
- 
-0.98 to 2.42 
0.03 
- 
0.41 
21 months Death 
Withdrawal 
Study end 
3.89 
- 
0.06 
-2.57 to 10.35 
- 
1.59 to 1.71 
0.24 
- 
0.94 
24 months Death 
Withdrawal 
Study end 
- 
- 
0.09 
- 
- 
-1.65 to 1.83 
- 
- 
0.92 
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            Figure 2.6: Trends in mean predicted HADS Depression score  
          during follow up. 
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Illness intrusiveness rating scale (IIRS) 
Table 2.17 shows the effect estimates from the mixed model, with IIRS as the outcome 
variable. It adjusted for the IIRS at baseline, dialysis modality, timepoint and gender.   
Table 2.17: Effect estimates of fixed Effects in Mixed Model (IIRS) 
DD- died during follow up, SW- withdrew from study, CS – completed study. This is the final model, there were 
no other interaction terms in this model 
 
The baseline IIRS score, age at baseline [Effect estimate = - 0.60( -1.01 to -0.19), 
p<0.01] and female gender [Effect estimate = - 64.15 ( -111.99 to -16.32), p=0.01] 
were significantly associated with the IIRS scores during follow up. There was also a 
Parameter Estimate 
95% CI 
Lower 
95% CI 
Upper 
P value 
Intercept 65.69 32.87 98.51 < 0.01 
PD  
HD (reference) 
0.25 
- 
-4.06 
- 
4.56 
- 
0.91 
- 
Follow up status 
DD  
SW  
CS (reference) 
 
2.92 
3.74 
- 
 
-2.53 
-1.86 
- 
 
8.38 
9.34 
- 
 
0.29 
0.19 
- 
Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
0.40 
-0.78 
-0.04 
0.67 
1.05 
4.42 
3.19 
- 
 
-3.70 
-4.96 
-4.45 
-3.64 
-3.38 
0.03 
-1.13 
- 
 
4.51 
3.40 
4.36 
4.99 
5.48 
8.80 
7.51 
- 
 
0.85 
0.71 
0.98 
0.76 
0.64 
0.05 
0.15 
- 
Female sex -64.15 -111.99 -16.32 0.01 
IlRS at baseline 0.59 0.42 0.75 <0.01 
Age at baseline (years) -0.60 -1.01 -0.19 <0.01 
Female sex * Age at 
baseline 
0.80 0.16 1.43 0.01 
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significant interaction between gender and age at baseline (Table 2.17). For female 
patients, illness intrusiveness increased as age at baseline increased.  
With pairwise comparisons, there was a trend towards higher mean IIRS score in the 
HD group at 24 months, among those who died during follow up (p=0.05) (Table 
2.18, Figure 2.7). 
Table 2.18: Pairwise comparisons between HD and PD (IIRS) 
Time point Follow up 
status 
HD – PD 
Mean 
difference 
95%CI P value 
6 months Death 
Withdrawal 
Study end 
-1.40 
2.98 
1.49 
-11.25 to 8.45 
- 7.01 to 12.98 
-8.22 to 5.24 
0.78 
0.56 
0.66 
12 months Death 
Withdrawal 
Study end 
-1.86 
3.91 
1.15 
-10.51 to 14.24 
-10.31 to 18.12 
-6.04 to 8.35 
0.77 
0.59 
0.75 
18 months Death 
Withdrawal 
Study end 
12.68 
- 1.26 
- 2.16 
-7.42 to 32.78 
-28.01 to 25.49 
-9.18 to 4.85 
0.22 
0.93 
0.54 
24 months Death 
Withdrawal 
Study end 
30.52 
- 
- 4.01 
-0.56 to 61.59 
- 
-0.86 to 12.85 
0.05 
- 
0.26 
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Figure 2.7: Mean predicted IIRS score over time. Error bars represent 95% CI 
 
20
30
40
50
60
70
80
6 12 18 24
DIED DURING FOLLOW UP
PD HD
18
23
28
33
38
43
48
53
6 12 18 24
WITHDREW FROM STUDY
PD HD
25
30
35
40
45
6 12 18 24
COMPLETED FOLLOW UP
PD HD
 
116 
 
Symptom score  
Table 2.19 shows the effect estimates of predictor variables in a model that adjusted 
for symptom score at baseline, dialysis modality, frailty score at baseline in addition to 
time points and follow up status. The baseline symptom score was significantly 
associated with higher symptom scores during follow up [Effect estimate – 0.74 (95% 
CI – 0.51 to 0.97), p < 0.01]. The symptom burden was also higher at the end of follow 
up (24 months) when compared with earlier time points. (Table 2.19) The symptom 
scores during follow up were generally lower in the PD cohort compared with those on 
HD [Effect estimate = -7.83 (-15.07 to -0.58), p =0.03] 
Table 2.20 shows the pairwise comparisons of the estimated symptom score between 
modalities at each time point. The only significant difference was at 24 months. Among 
patients who completed the study, the HD group had higher symptom scores 
compared to those on PD. There were no statistically significant differences at the 
preceding time points. Figure 2.8 shows the trends in the estimated symptom score 
for the HD and PD cohorts, stratified by the follow up status. There are gaps in the plot 
in the participants who died or withdrew during follow up, especially at latter time 
points. This is because there were insufficient data at these time points to estimate the 
symptom score. 
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Table 2.19: Effect estimates for fixed effects – symptom score 
Parameter Estimate 
95% CI 
Lower 
95%CI 
Upper P value 
Intercept 5.03 -2.36 12.41 0.18 
 PD  
 HD (reference) 
-7.83 
- 
-15.07 
- 
-0.58 
- 
0.03 
- 
Follow up status 
DD  
SW  
CS (reference) 
 
5.94 
2.99 
- 
 
-5.04 
-15.01 
- 
 
16.91 
20.99 
- 
 
0.29 
0.74 
- 
Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
-4.12 
-3.51 
-5.08 
-2.53 
-3.90 
-4.07 
-2.05 
- 
 
-7.72 
-7.04 
-8.56 
-6.11 
-8.16 
-8.40 
-5.68 
- 
 
-0.52 
0.03 
-1.59 
1.04 
0.37 
0.26 
1.59 
- 
 
0.03 
0.05 
<0.01 
0.16 
0.07 
0.07 
0.27 
- 
Symptom score at baseline 0.74 0.51 0.97 <0.01 
Frailty Score at baseline 1.67 -0.06 3.40 0.06 
Dialysis modality * Time point 
PD vs HD * 3 months  
PD vs HD * 6 months  
PD vs HD * 9 months  
PD vs HD * 12 months  
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months  
PD vs HD * 24 months 
 
5.14 
1.42 
4.49 
1.83 
5.66 
3.57 
2.03 
- 
 
-1.72 
-5.51 
-2.41 
-4.86 
-2.46 
-3.39 
-4.46 
- 
 
11.99 
8.34 
11.40 
8.52 
13.77 
10.53 
8.52 
- 
 
0.14 
0.69 
0.20 
0.59 
0.17 
0.31 
0.54 
- 
Full model shown on page 218; DD- died during follow up, SW- withdrew from study, CS – completed study 
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Table 2.20: Pairwise comparison between HD and PD - Symptom score 
Time point Follow up 
status 
HD – PD 
Mean 
difference 
95%CI P value 
3 months Death 
Withdrawal 
Study end 
4.68 
3.18 
2.69 
-3.78 to 13.15 
-6.92 to 13.28 
-4.31 to 9.69 
0.28 
0.53 
0.45 
6 months Death 
Withdrawal 
Study end 
-4.90 
-2.68 
6.41 
-13.8 to 4.00 
-13.8 to 8.46 
-0.38 to 13.20 
0.28 
0.64 
0.06 
9 months Death 
Withdrawal 
Study end 
-10.32 
-  6.71 
3.34 
-21.10 to 0.47 
-18.32 to 4.90 
-3.65 to 10.32 
0.06 
0.26 
0.35 
12 months Death 
Withdrawal 
Study end 
3.89 
8.87 
6.00 
-7.01 to 14.79 
-5.40 to 23.14 
-0.86 to 12.85 
0.48 
0.21 
0.09 
15 months Death 
Withdrawal 
Study end 
 
3.59 
2.17 
 
-11.88 to 19.06 
-6.02 to 10.37 
 
0.65 
0.60 
18 months Death 
Withdrawal 
Study end 
-4.37 
 
4.26 
-19.47 to 10.73 
 
-2.86 to 11.39 
0.57 
 
0.24 
21 months Death 
Withdrawal 
Study end 
- 
- 
5.80 
- 
- 
-0.94 to 12.54 
 
 
0.09 
24 months Death 
Withdrawal 
Study end 
 
 
7.83 
 
 
0.58 to 15.07 
 
 
0.03 
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Figure 2.8: Mean predicted symptom score over time  
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SF12 PCS 
Table 2.21 shows the effect estimates of the mixed model with the SF12 PCS as the 
outcome variable. It adjusts for gender, SF12 PCS at baseline, age in addition to 
dialysis modality, time point and follow up status.  
Table 2.21: Effect estimates of fixed effects from mixed model -SF12 PCS 
Parameter Estimate 
95% CI 
Lower 
95% CI 
Upper 
 
P value 
Intercept 23.58 10.26 36.89 <0.01 
PD vs HD -1.27 -4.82 2.28 0.48 
 Follow up status  
 DD  
 SW  
 CS (reference) 
 
-7.17 
-4.40 
- 
 
-17.05 
-18.12 
- 
 
2.71 
9.33 
- 
 
0.15 
0.53 
- 
 Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
1.06 
0.33 
1.85 
1.85 
1.52 
-0.25 
0.78 
- 
 
-1.53 
-2.33 
-0.81 
-0.85 
-1.14 
-2.83 
-1.71 
- 
 
3.65 
2.99 
4.51 
4.55 
4.19 
2.33 
3.26 
- 
 
0.42 
0.81 
0.17 
0.18 
0.26 
0.85 
0.54 
- 
Female Gender 28.92 7.99 49.85 0.01 
SF12PCS at baseline 0.37 0.25 0.49 <0.01 
Age at baseline 0.13 -0.04 0.30 0.13 
Female * Age at baseline -0.37 -0.65 -0.10 0.01 
Dialysis modality * Time point 
PD vs HD * 3 months  
PD vs HD * 6 months  
PD vs HD * 9 months  
PD vs HD * 12 months  
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months  
PD vs HD * 24 months (reference) 
 
1.20 
-.062 
-0.60 
-0.66 
-1.12 
1.52 
0.32 
- 
 
-2.58 
-4.47 
-4.56 
-4.56 
-5.02 
-2.30 
-3.33 
- 
 
4.98 
3.22 
3.35 
3.25 
2.78 
5.35 
3.98 
- 
 
0.53 
0.75 
0.76 
0.74 
0.57 
0.43 
0.86 
- 
Full model shown on page 223; DD- died during follow up, SW- withdrew from study, CS – completed study 
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The SF12 PCS at baseline [Effect estimate = 0.37(0.25 to 0.49), p<0.01] and female 
gender [Effect estimate = 28.92(7.99 to 49.85), p = 0.01] was associated with higher 
SF12 PCS during follow up. There was also a significant interaction between gender 
and age at baseline. For female participants, the SF12PCS decreased with increasing 
age. Dialysis modality was not associated with the SF12 PCS during follow up [Effect 
estimate PD vs HD = -1.27, (-4.82 to 2.28), p = 0.48]. 
Pairwise comparisons at 6 monthly intervals, did not show any significant difference in 
the SF12 PCS between HD and PD (Table 2.22). 
Table 2.22: Pairwise comparisons between HD and PD -SF12 PCS 
Time point Follow up 
status 
HD – PD (Mean 
difference) 
95% CI P value 
6 months Death 
Withdrawal 
Study end 
1.46 
-2.14 
0.62 
-2.39 to 5.30 
-6.40 to 2.12 
-2.18 to 3.43 
0.46 
0.32 
0.66 
12 months Death 
Withdrawal 
Study end 
2.04 
-0.61 
2.31 
-2.54 to 6.51 
-6.24 to 5.01 
0.61 to 5.22 
0.38 
0.83 
0.12 
18 months Death 
Withdrawal 
Study end 
-0.77 
-3.81 
0.64 
-7.24 to 5.71 
-12.96 to 5.34 
-2.24 to 3.51 
0.82 
0.41 
0.66 
24 months Death 
Withdrawal 
Study end 
12.35 
- 
1.39 
-2.24 to 3.51 
- 
-0.24 to 24.94 
0.05 
- 
0.34 
 
 
 
 
 
 
122 
 
 
 
 
 
 
Figure 2.9: Mean predicted SF12 PCS over time  
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SF12 MCS 
Table 2.23 shows the effect estimates from the mixed model with the SF12 MCS as 
the outcome variable. The mixed model adjusted for the SF12 MCS at baseline, frailty 
score, in addition to dialysis modality, time point and follow up status. Being on PD 
was associated with higher SF12 MCS during follow up compared to HD. 
Table 2.23: Effect estimates of Fixed Effects (SF12 MCS) 
Parameter Estimate 
95% CI 
Lower  
95% CI 
Upper  
p 
value 
Intercept 27.91 21.75 34.07 <0.01 
PD vs HD 8.44 0.76 16.11 0.03 
Follow up status 
DD  
SW  
CS (reference) 
 
-7.65 
-17.88 
- 
 
-20.22 
-35.36 
- 
 
4.92 
-0.39 
- 
 
0.23 
0.05 
- 
Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months   
24 months (reference) 
 
-1.66 
-1.38 
-0.86 
-1.10 
-1.76 
-0.13 
-0.39 
- 
 
-5.05 
-4.86 
-4.35 
-4.56 
-5.24 
-3.51 
-3.66 
- 
 
1.73 
2.11 
2.62 
2.36 
1.73 
3.25 
2.88 
- 
 
0.34 
0.44 
0.63 
0.53 
0.32 
0.94 
0.81 
- 
SF12MCS at baseline 0.19 0.06 0.32 <0.01 
Frailty Score at baseline -0.05 -1.10 1.00 0.92 
PD * Frailty Score at baseline -1.74 -3.32 -0.15 0.03 
Dialysis modality * Time point 
PD vs HD * 3 months  
PD vs HD * 6 months  
PD vs HD * 9 months  
PD vs HD * 12 months  
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months  
PD vs HD * 24 months 
 
-1.01 
-0.22 
1.15 
0.83 
0.05 
-0.10 
-0.58 
- 
 
-5.95 
-5.23 
-4.03 
-4.22 
-5.04 
-5.11 
-5.39 
- 
 
3.93 
4.80 
6.32 
5.89 
5.15 
4.92 
4.24 
- 
 
0.69 
0.93 
0.66 
0.75 
0.98 
0.97 
0.81 
- 
Full model shown on page 223; DD- died during follow up, SW- withdrew from study, CS – completed study 
There was also a significant interaction between dialysis modality and the frailty score 
at baseline. In the PD group, the SF12 MCS decreased with an increase in the frailty 
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score at baseline [Effect estimate = -1.74 (-3.32 to-0.15), p =0.03]. Pairwise 
comparisons showed that the estimated mean SF12 MCS was significantly lower in 
the HD group at 9 and 15 months follow up, among the study withdrawals. 
Table 2.24: Pairwise comparisons between HD and PD (SF12 MCS) 
Time point Follow up 
status 
HD-PD (Mean 
Difference) 
95% CI P value 
3 months Death 
Withdrawal 
Study end 
-1.36 
 1.83 
-0.32 
-6.39 to 3.66 
-3.74 to 7.40 
-4.17 to 3.53 
0.59 
0.52 
0.87 
6 months Death 
Withdrawal 
Study end 
-0.19 
-3.17 
-1.11 
-6.37 to 5.99 
-9.80 to 3.45 
-5.04 to 2.81 
0.95 
0.35 
0.58 
9 months Death 
Withdrawal 
Study end 
-2.36 
-11.5 
-2.48 
-9.17 to 4.46 
-19.50 to -3.46 
-6.64 to 1.69 
0.50 
0.01 
0.24 
12 months Death 
Withdrawal 
Study end 
-6.42 
-8.72 
-2.16 
-13.65 to 0.80 
-22.84 to 5.40 
- 6.25 to 1.93 
0.08 
0.23 
0.30 
15 months Death 
Withdrawal 
Study end 
 12.85 
-19.21 
-1.38 
-0.91 to 26.61 
-32.17 to -6.25 
-5.46 to 2.69 
0.07 
0.01 
0.50 
18 months Death 
Withdrawal 
Study end 
2.14 
- 
-1.23 
-8.24 to 12.52 
- 
-5.26 to 2.79 
0.69 
 
0.55 
21 months Death 
Withdrawal 
Study end 
-11.99 
- 
-0.76 
-29.19 to 5.22 
- 
-4.59 to 3.08 
0.17 
- 
0.70 
24 months Death 
Withdrawal 
Study end 
- 
- 
-1.33 
- 
- 
-5.52 to 2.86 
- 
- 
0.53 
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Figure 2.10: Mean predicted SF12 MCS over time  
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2.8 Conclusions 
The objective of this study was to compare measures of QoL between older patients 
on assisted PD and similarly matched patients receiving in centre HD. The outcome 
measures were the SF12, Barthel index, IIRS, HADS depression score, Symptom 
score and RTSQ score. Multivariate analysis at baseline adjusted for age, gender, 
ethnicity, dialysis vintage, stoke comorbidity score and the frailty score. After 
considering these variables, dialysis modality was not associated with any of the 
outcome measures, except for the RTSQ score. PD was associated with higher 
treatment satisfaction scores compared with HD [Effect estimate = 0.94 (0.89 – 0.98), 
p = 0.04]. In addition, the frailty score was significantly associated with all outcome 
measures, except for the treatment satisfaction score. Whilst these findings are 
noteworthy, they only provide a snapshot of the potential relationship between patient 
characteristics, dialysis modality and patient reported outcome measures. An analysis 
of longitudinal trends would provide further insight, as the cohort consisted of prevalent 
dialysis patients. 
Mixed model analysis evaluated longitudinal trends in the aforementioned outcomes 
during the 2 year follow up. Effect estimates from the final models suggest that dialysis 
modality was not associated with any of the outcome measures during follow up, 
except for the symptoms score and the SF 12 MCS. Symptom scores during follow up 
were lower in the PD cohort compared with those on HD. The SF12 MCS during follow 
up increased as the frailty score at baseline decreased, in the PD cohort. The 
interaction between dialysis modality and time was not statistically significant. This 
suggests that there were no significant differences in the trajectories of the outcome 
measures between PD and HD. 
 
127 
 
Pairwise comparisons at each time point, provided further insight into the differences 
in outcome measures between HD and PD during follow up. These were also stratified 
by follow up status, because of missing data. There were no significant differences in 
the QoL measures between HD and PD among those who completed follow up, except 
for the symptom score. This was higher in the HD group compared to those on PD, at 
24 months. As there were no differences at earlier time points, the influence of dialysis 
modality in this cohort is not conclusive. In the cohort that died during follow up, the 
HD patients had lower estimated HADS depression scores at 15 and 18 months, as 
well as lower Barthel scores at 15 months. Otherwise QoL measures did not differ 
during follow up. Among those who withdrew from the study, the estimated SF12 MCS 
was significantly lower in HD patients compared to those on PD, at 9 and 15 months 
follow up. HD patients also had higher estimated HADS depression scores at 6 months 
but not at other time points. The profile plots show the estimated mean values 
generated from each of the mixed models plotted against the over time. In conjunction 
with the pairwise comparisons, they suggest that there were no consistent differences 
in longitudinal trends between HD and PD. 
The approach to statistical analyses differed at baseline and during follow up. The 
baseline regression models were adjusted for the same baseline characteristics 
regardless of the outcome measure. Other significant confounders may have been 
omitted from the linear models. The p values were also adjusted against false positive 
errors by a relatively conservative approach, with the potential risk of rendering true 
associations insignificant. Dialysis modality was however not associated with the QoL 
measures, even when unadjusted p values were considered. The mixed models 
included interaction terms between dialysis modality, time and follow up status. It was 
of interest to include the interaction between dialysis modality and time to assess as 
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the change in outcome measures during follow up, according to dialysis modality. The 
trajectory of each outcome measure may have varied depending on whether 
participants died, withdrew from the study or completed follow up. Hence the need to 
include interaction terms related to the follow up status. In contrast to the baseline 
analysis, the p values for the longitudinal analysis (mixed models) were not adjusted 
for multiple comparison. This was not determined to be required at the time of analysis 
because the models for each outcome measure were not the same. Retrospectively, 
as dialysis modality did not influence trends (i.e. change over time), multiple 
adjustment would not have altered the primary conclusions from this analysis. 
As the study cohort consisted of older people, some of whom were frail, it is not 
surprising that there were dropouts during follow up. While mixed model analysis is 
capable of handling missing data, it was still necessary to stratify some of the analyses 
by for follow up status (data were not missing at random). Thus, the trends in outcome 
measures were evaluated depending on whether patients died, withdrew or completed 
the study. The trends for those who completed the study, provides the most reliable 
information. Whilst symptoms scores   were persistently higher in the HD cohort 
compared to those in PD (figure 2.8), they did not change over time, as with the other 
outcome measures. Based on the effect estimates, pairwise comparisons and profile 
plots, QoL trends appear to be influenced by risk factors other than dialysis modality. 
The implications of these findings will be reviewed in the discussion.  
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3. COGNITIVE FUNCTION, PATIENT REPORTED OUTCOME 
MEASURES AND DIALYSIS 
3.1 Introduction 
 In this chapter, cognitive function and patient reported outcome measures are 
compared between patients on dialysis and those with advanced CKD, not on 
dialysis.  In section 1.4, cognitive impairment was reviewed as a potential risk factor 
for poor QoL in advanced kidney disease. It has been shown to be highly prevalent 
in the renal population and associated with adverse outcomes, including death and 
hospitalisation. Cerebrovascular disease is thought to play a major role in the 
pathogenesis of cognitive decline in CKD. Other than vascular risk factors, 
nephrogenic and dialytic risk factors may also be implicated. 
 There have been contrasting reports on the influence of dialysis modality on 
cognitive function. While PD patients have been shown have a lower cumulative risk 
of dementia compared to those on HD, other cross sectional studies have reported 
no difference in cognitive performance between modalities.  Longitudinal studies 
which evaluate changes in cognition over time are lacking. 
I hypothesize that cognitive function and patient reported outcomes deteriorate when 
on dialysis and more so on HD compared to PD.  Therefore, this study aims to 
compare trends in cognitive function and patient reported outcomes between HD, PD 
and CKD patients.   
3.2 Study design  
  This is a single centre prospective cohort study of 2 years’ duration. To increase the 
sample size, eligible participants have been recruited throughout the study with 
follow up of up to 2 years. This study was approved by the West of Scotland 
research ethics committee (REC approval number 13/WS/ 0241). 
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3.3 Location of the sample 
 Patients were recruited from 3 outpatient clinics at Imperial College Healthcare NHS 
trust, in London. The HD clinic was located at Charing Cross hospital, while the PD 
and low clearance clinics were located at Hammersmith hospital. 
3.4 Patient selection 
I obtained a list of potential participants from the clinical team. Eligible patients were 
over 55 years of age, on dialysis for at least 3 months and free from hospital admission 
for at least 30 days. This was to minimise the influence of recent hospitalisation and 
dialysis initiation on the studied outcomes. The eligible CKD patient also had an 
estimated GFR ≤ 30ml/min (severe renal insufficiency by KDIGO definition). Patients 
deemed by the clinical team to have a life expectancy of less than 6 months were 
excluded from the study, as were those with known dementia and those unable to 
understand English. 
I approached eligible participants during a routine clinic visit, with a patient information 
sheet. Those willing to take part gave consent at their subsequent clinic visit, during 
which baseline assessments were completed. Patients were recruited between 
November 2013 and October 2015 
3.5 Study assessment 
3.5.1 Setting 
 I carried out the study assessments for all participants in this study. These 
assessments were performed at routine clinic visits in the outpatient department, 
usually after their clinical assessment. For the HD patient, these clinic visits coincided 
with their mid-week dialysis sessions. For convenience, their assessments were 
carried out in the dialysis unit, prior to starting dialysis. Follow up assessments were 
carried out at subsequent clinic visits, every 4 months. 
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3.5.2 The study visit 
During the study visit, several domains were assessed using questionnaires, in a 
standard order (Table 3.1). These are discussed below. 
Table 3.1: Study Assessments 
Domains Study Assessments 
Demographic and clinical 
information 
Designed proforma 
Depression Patient Health Questionnaire – 9 (PHQ-9) 
Health related QoL EuroQol 5D (3 level) (EQ5D) 
Symptom Burden 
Palliative Outcomes Symptom –Scale (Renal) (POS-
S Renal) 
Cognitive Function Montreal Cognitive Assessment (MoCA) 
Physical Function Timed Up and Go test (TUAG) 
Nutritional status Subjective Global Assessment (SGA) 
 
Demographic data were collected using a designed proforma. These include 
- Age 
- Gender 
- Ethnicity 
- Dialysis modality 
- Time on dialysis (in months) 
- Level of education 
Clinical data  
- Cause of ESRD 
- Clinic blood pressure 
- Average pre and post dialysis blood pressure (for HD patients) 
- Interdialytic weight gain (for HD patients) 
- Most recent blood tests-  Serum Haemoglobin, Adjusted calcium, 
phosphate, Bicarbonate, Alkaline phosphatase, C –reactive protein, 
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measures of dialysis adequacy (Kt/v, Urea Reduction Ratio, weekly 
creatinine clearance (PD)) 
- Comorbidity burden was assessed using the Stoke –Davies comorbidity 
score.  
The Patient Health Questionnaire -9 (PHQ-9) is a 9-item questionnaire that screens 
for depression. It evaluates symptoms of depression over the preceding two weeks. 
Scores range from 0 to 27 with higher scores indicative of more severe 
depression.[316] A score above 5, 10 and 15 are indicative of mild, moderate and 
severe depression respectively. The PHQ-9 was used in this study because the 
completion burden is relatively low compared to other screening tools for depression. 
The trade-off however, is that it evaluates somatic symptoms of depression and may 
thus require higher cut offs for possible depression in CKD patients. 
The EuroQol -5D (EQ5D) was used to assess health related QoL in this study. It has 
been described previously in section 1.3.2. It is a utility based measure of QoL but is 
associated with lower completion burden compared to renal specific or generic 
measures. 
The Palliative Outcomes Scale - Symptoms (renal) (POS-S renal) was used to 
assess the symptom burden in the study cohort. It has been discussed previously in 
section 5.5.3.1. 
Montreal Cognitive Assessment (MoCA) assesses cognitive function in 7 domains 
with scores ranging from 0 to 30. It has advantages over the Mini Mental State 
Examination (MMSE) which is widely used. This is because it assesses executive 
function, a domain that is commonly affected in patients with CKD. It has been shown 
to be sensitive to changes in cognition in patients on dialysis. A score less than 26 is 
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suggestive of cognitive impairment, although a cut off of 24 has been suggested for 
HD patients.[229] 
Timed Up and Go Test (TUAG) was used to assess physical function and has been 
discussed previously in section 2.5.3. 
Subjective Global Assessment (SGA) is a nutritional assessment tool. The 7-point 
scale was used in this study. Higher scores indicate a better nutritional state. It has 
been shown to be valid in detecting protein energy wasting in dialysis patients.[317] 
3.6 Statistical methods 
All analyses were carried out using the SPSS program (version 22). Continuous 
variables were expressed as mean and standard errors if normally distributed or 
median and interquartile ranges, if they were not. Categorical variables were 
expressed as percentages and compared between the HD, PD and CKD cohorts using 
the Fisher’s exact tests. Continuous variables were compared at baseline, using the 
ANOVA or Kruskal Wallis test, depending on whether they were parametric or non-
parametric variables. 
Longitudinal trends in the MoCA, EQ5D, POS-S Renal and TUAG scores were 
evaluated using mixed model analysis. Generalised linear mixed models were used 
because the outcome measures were not normally distributed, despite using several 
transformation methods. Predictor variables that were significantly associated with 
each outcome measure in univariate analysis were included in the multivariate model. 
Cognitive trajectories between the CKD and dialysis patients were compared by 
adding interaction terms CKD* time and Dialysis * Time to the multivariate model. To 
evaluate the influence of dialysis modality, this analysis was repeated in the dialysis 
cohort. In this instance, interaction terms HD*time and PD * time were included in the 
model. 
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 3.7 Results 
198 patients were eligible for the study at baseline. 39 patients refused consent 
(19.6%), 16 moved out of area (8.1%), 9 patients were transplanted (4.5%) while 11 
patients died prior to enrolment (5.6%). 1 patient was discharged from clinic (0.5%). 
20 patients could not be approached due to lack of regular clinic attendance.102 (41 
HD; 25 PD; 36 CKD) patients were therefore recruited during the study period. Patients 
were recruited during the entire study period. This means that the follow up period 
varied between patients. There were also dropouts during follow up [Withdrawals – 3 
(2.9%), Died – 9 (8.8%), Transplanted – 4 (3.9%), moved out of centre – 13 (12.7%)]. 
The patient numbers therefore diminished with subsequent time points (Figure 3.1). 
 
Figure 3.1: Patient numbers during follow up 
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3.7.1. Baseline demographic characteristics 
 Table 3.2 shows the baseline characteristics for the study cohort. The case mix was 
similar between study participants and non- participants, in terms of age, gender or 
ethnicity. The HD cohort had significantly longer dialysis vintage compared to the PD 
cohort (p < 0.01). There was also a trend towards a lower mean age in the HD cohort 
(p = 0.068). The study cohort was predominantly male (70%) and of white European 
(45 %) and Asian (44%) ethnicity. 72.5% of the study cohort had been educated at 
least to secondary school level (> 12 years). There were no significant differences in 
gender, ethnicity or level of education between HD, CKD and PD participants. 
3.7.2 Baseline clinical characteristics 
 The prevalence of diabetes and ischaemic heart disease in the study cohort was 53% 
and 46 % respectively. Diabetic nephropathy was the most common cause of renal 
failure (57%). The comorbidity burden did not differ significantly between HD, PD and 
CKD cohorts. The PD group had significantly lower serum haemoglobin (Hb) and 
albumin levels compared to the other groups, while the HD group had lower serum 
bicarbonate and parathyroid hormone levels. 19.6% met the criteria for depression 
(PHQ-9 ≤ 9) with no significant difference in PHQ-9 scores between treatment 
modalities. (Table 3.3) 
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Table 3.2: Demographic details for study cohort 
Demographic 
characteristics 
HD 
(n = 41) 
PD 
(n = 25) 
CKD 
(n = 36) 
P 
value* 
Not 
consented 
(n = 96) 
Mean Age in 
years (± SE)§  
68.9 ± 1.3 72.8 ± 1.6 72.5 ± 1.5 0.07 69.6 ± 0.9 
Age 
range(years)^ 
55 – 64 
65 – 74 
75 – 84 
>85 
 
 
34.1% 
36.6% 
29.3% 
0.0% 
 
 
16.0% 
44.0% 
28.0% 
12.0% 
 
 
16.7% 
44.4% 
27.8% 
11.1% 
0.21 
 
 
25.0% 
46.9% 
22.9% 
5.2% 
Male Sex ^ 70.7% 76.0% 63.9% 0.59 62.5% 
Ethnicity ^ 
White European 
Afro Caribbean 
South Asian 
Other 
 
39% 
14.6% 
43.9% 
2.4% 
 
64% 
8% 
24% 
4% 
 
33.3% 
13.9% 
52.8% 
0.0% 
 
0.22 
 
51.0% 
15.6% 
28.2% 
5.2% 
Years of 
Education^ 
0 – 6 
6 – 12 
> 12 
 
5.6% 
33.3% 
61.1% 
 
0.0% 
0.0% 
100.0% 
 
5.0% 
30.0% 
65.5% 
 
0.22 
- 
Months on 
Dialysis+ (IQR) 
35 (15.5 - 60) 8 (5 -32) 0 < 0.01 - 
* compares HD, PD and CKD cohorts, § ANOVA, ^ Fisher’s exact test, + Kruskal Wallis test 
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Table 3.3: Clinical characteristics 
Clinical Characteristics HD PD CKD P value 
Cause of Renal Failure^ 
Diabetic Nephropathy 
Glomerulonephritis 
ADPKD 
RVD 
Tubulointerstitial disease 
Unknown 
 
24.4% 
26.8% 
7.3% 
2.4% 
7.3% 
22.0% 
 
40.0% 
20.0% 
4.0% 
12.0% 
8.0% 
16.0% 
 
63.9% 
5.6% 
2.8% 
5.6% 
2.8% 
13.9% 
 
0.20 
Comorbidities^ 
Diabetes 
IHD 
PVD 
LV Dysfunction 
Malignancy 
Collagen Vascular disorder 
 
46.3% 
46.3% 
17.1% 
9.8% 
7.3% 
19.5% 
 
44% 
40% 
32.0% 
16.0% 
8.0% 
4.0% 
 
66.7% 
50% 
22.2% 
13.9% 
2.8% 
8.3% 
 
0.12 
0.74 
0.37 
0.74 
0.61 
0.12 
Comorbidity score (IQR)+ 2 (1-3) 1 (1-2) 2 (1-2) 0.40 
Previous transplant^ 7.3% 4.0% 0.0% 0.26 
Pathology∞  
Hb (g/dl) § 
Na (mmol/l) § 
Albumin (IQR) (g/dl) + 
Bicarbonate (mmol/l) § 
CRP (IQR) (mmol/l) + 
Calcium (mmol/l) § 
Phosphate (mmol/l) § 
PTH (IQR) (µmol/l) + 
eGFR (ml/min) 
 
11.7± 0.2 
136.8 ± 0.5 
32 (30 – 35) 
20.6 ± 0.4 
7.8 (4.3-26.2) 
2.36 ± 0.02 
1.49 ± 0.08 
21 (10 – 32.5) 
- 
 
10.8 ± 0.3 
136.6 ± 0.6 
29 (25 – 32) 
23.4 ± 0.7 
6.1 (1.9- 29.9) 
2.43 ± 0.04 
1.44 ± 0.07 
34 (26 – 53.5) 
- 
 
11.3 ± 0.2 
139.2 ± 0.2 
34 (32 – 37) 
22.9 ± 0.5 
3.7 (1.4 – 7.9) 
2.40 ± 0.02 
1.24 ± 0.04 
33 (16.5- 36.5) 
16.9 ± 0.9 
 
0.02 
< 0.01 
< 0.01 
< 0.01 
0.02 
0.21 
0.02 
0.03 
- 
PHQ-9 (IQR) + 
PHQ-9 < 10 (%) ^ 
5.5 (3 – 9) 
21.1% 
7 (3 – 10) 
30.4% 
8 (2 – 10) 
11.1% 
0.28 
0.18 
SGA (IQR) + 6 (5 – 6) 6 (5 – 7) 6 (5 – 7) 0.80 
HD Parameters∞ 
Hours/ session (IQR) 
Ultrafiltration rate (ml/ hr) (IQR) 
Mean KT/v  
 
4.5 (4 – 4.5) 
378 (250- 538) 
1.9 ± 0.1 
 
- 
 
- 
 
- 
PD Parameters∞   
CAPD (n) 
APD (n) 
Weekly Residual CrCl  
Weekly Total CrCl  
 
13 
12 
43.4 ± 5.2 
71.2 ± 6.2 
- - - 
* compares HD, PD and CKD cohorts; § ANOVA; ^ Fisher’s exact test; + Kruskal Wallis test; SE- standard error; 
∞ expressed as mean ± SE unless otherwise stated. Hb – Haemoglobin, Na- sodium, CRP- C reactive protein, 
PTH – Parathyroid hormone 
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3.7.3 Baseline outcome measures and treatment modality 
Table 3.4 shows the baseline outcome measures for the HD, PD and CKD cohorts. 
60.5 % of the study cohort had a MoCA score < 26 (suggestive of cognitive 
impairment). There were no significant differences in cognitive function or patient 
reported outcomes measures between modalities at baseline. 
Table 3.4: Baseline Outcome Measures 
Outcome Measures HD PD CKD 
p 
value 
MoCA Score (IQR)+ 
MoCA < 26^ 
23 (20 – 27) 
63.6% 
24 (23 – 27) 
64.3% 
25 (23 -27) 
53.8% 
0.77 
0.83 
MoCA Subscales (IQR) + 
Executive Function 
Naming 
Memory 
Orientation 
Attention 
Language 
 
4 (3 – 4) 
3 (2-3) 
3 (1 – 3) 
6 
5 (4 – 6) 
3 (2-3) 
 
3 (3 – 4) 
3 (2-3) 
2 (1-3) 
6 
6 (5 – 6) 
3 (2 – 3) 
 
4 (2 – 4) 
3 (2-3) 
3 (2-3) 
6 
6 (5- 6) 
3 (3 – 3) 
 
0.90 
0.84 
0.91 
0.65 
0.40 
0.10 
EQ5D Index (IQR)+ 
0.69 (0.22-
0.83) 
0.69 (0.62-
0.80) 
0.66 (0.24 - 
0.85) 
0.59 
EQ5D VAS (IQR)+ 50 (45 – 78) 65 (50 -75) 50 (45 – 80) 0.29 
TUAG (Mean ± SE)§ 10.9 ± 1.6 13.2 ± 2.2 14.0 ± 1.6 0.89 
POS –S RENAL (IQR)+ 11 (9 – 16) 10 (6 – 15) 10 (7 – 17) 0.71 
§ ANOVA, ^ Fisher’s exact test, + Kruskal Wallis test 
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3.7.4 Dialysis and longitudinal cognitive trends 
Generalized linear mixed model (GLMM) analysis was used to compare the change in 
MoCA score over time, first between dialysis and CKD patients and subsequently 
between HD and PD patients. As the MoCA score distribution was skewed, a gamma 
distribution with log link function was used. Age, ethnicity and level of education were 
associated with the MoCA scores, in univariate analysis (Table 3.5). Comorbidities, 
dialysis vintage and laboratory parameters were not associated with MoCA scores.   
Table 3.5: Univariate effects from mixed model analysis - total MoCA score 
Predictors Coefficient 95% CI P value 
Age -0.005 -0.009 to -0.001 0.03 
Male Sex -0.045 -0.125 to 0.034 0.25 
Education for > 12 years 
0.058 0.007 to 0.109 0.03 
Ethnicity 
Caucasian 
Afro Caribbean 
Asian 
0.213 
0.063 
0.145 
0.007 to 0.419 
-0.152 to 0.278 
-0.060 to 0.350 
0.04 
0.54 
0.15 
Dialysis vs CKD -0.0001 -0.075 to 0.075 0.99 
Months on dialysis - 0.0001 -0.001 to 0.001 0.76 
Lab parameters 
Vitamin D (ng/ml) 
Na (mmol/l) 
Haemoglobin (g/dl) 
Albumin (g/dl) 
PTH (pg/ml) 
CRP (mg/ml) 
Bicarbonate (mmol/l) 
 
<0.001 
-0.004 
0.010 
-0.001 
< -0.001 
< 0.001 
-0.003 
 
-0.001 to 0.001 
-0.011 – 0.003 
-0.012 – 0.031 
-0.002 – 0.001 
-0.002 – 0.001 
-0.001 – 0.002 
-0.010 to 0.004 
 
0.94 
0.29 
0.38 
0.29 
0.45 
0.74 
0.41 
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Table 3.5 (continued) 
Predictors Coefficient 95% CI P value 
Stoke comorbidity score -0.028 -0.058 to 0.003 0.07 
Comorbidities 
Diabetes 
IHD 
PVD 
LV Dysfunction 
Malignancy 
 
-0.035 
0.020 
-0.015 
-0.132 
0.016 
 
-0.107 to 0.038 
-0.057 to 0.096 
-0.096 to 0.066 
0.019 to 0.245 
-0.152 to 0.184 
 
0.34 
0.61 
0.72 
0.02 
0.85 
PHQ- 9 -0.006 -0.013 to 0.001 0.10 
SGA scale 0.011 -0.023 to 0.045 0.52 
Clinic BP 
Systolic 
Diastolic 
 
0.001 
<0.001 
 
-0.001 to 0.003 
-0.003 to 0.003 
 
0.21 
0.90 
 
After adjusting for age, ethnicity and years of education, the MoCA scores deteriorated 
faster in the dialysis cohort compared to those with CKD (Coefficient = - 0.03, p = 0.03) 
(Table 3.6). Figure 3.2 depicts the trends in mean predicted MoCA scores over time. 
The downward trend in the dialysis cohort is consistent with results from Table 3.6. 
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Table 3.6: Multivariate Generalised Linear Mixed Model, Outcome variable - 
total MoCA score 
Predictors Coefficient 95% CI P value 
Age - 0.005 -0.008 to -0.001 0.01 
Ethnicity 
White European 
Afro Caribbean 
Asian 
 
0.168 
0.014 
0.098 
 
-0.061 to 0.397 
-0.226 to 0.255 
-0.132 to 0.328 
 
0.15 
0.91 
0.40 
<12 years of Education - 0.027 -0.102 to 0.048 0.50 
Time^ - 0.020 -0.001 to 0.042 0.06 
Dialysis vs CKD - 0.009 -0.080 to 0.063 0.81 
Dialysis * Time^ 
CKD* Time (ref) 
-0.030 
- 
-0.056 to -0.004           0.03 
- 
^ = every 4 months 
  
The same model was used to assess trends in executive function and memory 
between dialysis and CKD patients. There was no significant difference in the rate of 
change in short term memory (coefficient = - 0.104, p = 0.18) (Table 3.7; figure 3.3). 
There was a trend towards faster decline in executive function on dialysis compared 
to CKD (Figure 3.4) but it did not reach statistical significance (coefficient = - 0.065, p 
= 0.10) (Table 3.8). 
Table 3.7: Multivariate Generalised Linear Mixed Model, Outcome variable - 
MoCA memory score 
Predictors Coefficient 95% CI P value 
Age - 0.017 -0.031 to -0.003 0.02 
Ethnicity 
White European 
Afro Caribbean 
Asian 
 
0.666 
0.467 
0.564 
 
-0.123 to 1.455 
-0.376 to 1.309 
-0.229 to 1.356 
 
0.10 
0.27 
0.16 
<12 years of Education 0.143 -0.166 to 0.452 0.36 
Time^  0.146 0.011 to 0.282 0.04 
Dialysis vs CKD  0.120 -0.248 to 0.488 0.52 
Dialysis * Time^ 
CKD* Time (ref) 
-0.104 
- 
-0.257 to 0.049 0.18 
- 
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Table 3.8: Multivariate Generalised Linear Mixed Model, Outcome variable 
MoCA executive function 
Predictors Coefficient 95% CI P value 
Age - 0.013 -0.020 to -0.005 <0.01 
Ethnicity 
White European 
Afro Caribbean 
Asian 
 
0.523 
0.225 
0.425 
 
-0.027 to 1.073 
-0.347 to 0.796 
-0.125 to 0.974 
 
0.06 
0.43 
0.13 
Time^ - 0.006 -0.071 to 0.060 0.86 
<12 years of Education  0.146 - 0.420 to -0.068 <0.01 
Dialysis vs CKD  0.014 -0.136 to 0.165 0.85 
Dialysis * Time^ 
CKD* Time (ref) 
-0.065 
- 
-0.142 to 0.013 0.10 
- 
 
 
Figure 3.2: Longitudinal change in Total MoCA scores (Dialysis vs CKD) 
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Figure 3.3 Longitudinal change in MoCA memory scores (Dialysis vs CKD) 
 
Figure 3.4: Longitudinal change in MoCA Executive scores (Dialysis vs CKD) 
 
 To assess the influence of dialysis modality on cognitive trends, the mixed model 
analysis was repeated in the dialysis cohort (n = 66; HD = 41, PD =25), adjusting for 
age, ethnicity, years of education and dialysis vintage. There was no significant 
difference in the rate of change in total MoCA scores between PD and HD patients 
(Table 3.9, figure 3.5). Executive function did however decline more rapidly in the HD 
patients compared to PD patients (Table 3.10, figure 3.6). There was no difference in 
the trend of the memory scores between the cohorts (Table 3.11, figure 3.7).  
CKD 
DIALYSIS 
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Table 3.9: Generalised Linear Mixed Model (HD vs PD): total MoCA score 
Predictors Coefficient 95%CI p value 
Age -0.005 -0.010 to 0.000 0.06 
Ethnicity 
White European 
Afro Caribbean 
Asia 
 
0.118 
-0.011 
0.077 
 
-0.131 to 0.366 
-0.286 to 0.263 
-0.172 to 0.326 
 
0.34 
0.93 
0.53 
Months on Dialysis 0.001 -0.001 to 0.002 0.43 
<12 years of Education 0.003 -0.111 to 0.117 0.96 
HD vs PD -0.057 -0.177 to 0.064 0.35 
Time^ 0.015 -0.025 to 0.055 0.46 
HD*Time^ 
PD*Time^ (Reference) 
-0.016 
- 
-0.064 to 0.032 
- 
0.51 
- 
^ = every 4 months 
 
Table 3.10: Generalised Linear Mixed Model (HD vs PD):  MoCA Executive 
function 
Predictors Coefficient 95%CI p value 
Age -0.014 -0.025 to -0.004 0.01 
Ethnicity 
White European 
Afro Caribbean 
Asian 
 
-0.448 
-0.401 
-0.400 
 
-0.153 to 1.048 
-0.262 to 1.064 
-0.194 to 0.994 
 
0.14 
0.23 
0.18 
< 12 years of education -0.056 -0.326 to 0.214 0.68 
Months on dialysis -0.002 -0.004 to -0.001 <0.01 
HD vs PD 0.112 -0.104 to 0.329 0.30 
Time^ 0.013 -0.088 to 0.114 0.80 
HD* Time^ 
PD*Time^ (Reference) 
-0.120 
- 
-0.233 to -0.007 0.04 
- 
^ = every 4 months 
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Table 3.11: Generalised Linear Mixed Model (HD vs PD): Outcome MoCA 
Memory 
Predictors Coefficient 95%CI p value 
Age -0.015 -0.037 to 0.007 0.17 
Ethnicity 
White European 
Afro Caribbean 
Asian 
 
-0.580 
-0.525 
-0.577 
 
-0.381 to 1.542 
-0.557 to 1.064 
-0.380 to 1.533 
 
0.22 
0.33 
0.18 
< 12 years of education -0.161 -0.295 to 0.616 0.47 
Months on dialysis -0.000 -0.006 to 0.005 <0.01 
HD vs PD 0.217 -0.245 to 0.678 0.35 
Time^ 0.169 0.022 to 0.316 0.03 
HD* Time^ 
PD*Time^ (Reference) 
-0.177 
- 
-0.357 to 0.003 0.06 
- 
^ = every 4 months 
 
 
 
 
 
 
Figure 3.5: Longitudinal trends in MoCA total score (HD vs PD) 
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Figure 3.6: Longitudinal trends in executive function (HD vs PD) 
 
Figure 3.7: Longitudinal trends in MoCA Memory (HD vs PD) 
 
3.7.5 Dialysis and other study outcomes  
Generalised linear mixed model analysis was also used to analyse longitudinal trends 
in quality of life (EQ5D), symptom burden (POS-S renal) and physical function 
(TUAG). 
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3.7.5.1 Quality of Life (EQ5D) 
The EQ5D yields 2 measures. The EQ5D index (EQ5DI) was computed from patient 
responses using UK value sets published by EuroQol group. Scores range from -1 to 
+1, with higher scores indicating better QoL. There were therefore some negative 
EQ5DI values (n = 7) in the database. To allow appropriate regression analysis, all 
EQ5DI values were made positive by adding a fixed value (0.1) to each value. A visual 
analogue score (EQ5DVAS) based on a patient’s perception of health is also 
measured with scores ranging from 0 to 100. A Gaussian distribution with log link 
function was used for the EQ5D index and EQ5DVAS respectively, because of their 
negatively skewed distributions. In univariate analysis, poor nutritional status 
measured by the SGA as well as higher depression score (PHQ-9), symptom score 
(POS-S renal) and CRP levels were associated with lower EQ5DI (Table 3.12). 
However, there was a significant correlation (multicollinearity) between the PHQ-9 and 
POS-S renal scores (r = 0.79, p <0.001). The POS-S renal score was therefore 
removed from the final multivariate model. The model which included the PHQ-9 score 
provided a better fit.  After adjusting for CRP levels, PHQ-9 and nutritional status, 
EQ5DI was generally lower in dialysis patients but there was no significant difference 
in EQ5DI trends between the dialysis and CKD cohorts (Table 3.14, figure 3.8).  
 The EQ5D visual analogue score (EQ5DVAS) was associated with age, PHQ- 9 
score, POS-S renal and SGA scores in univariate analysis (Table 3.13). As the 
multicollinearity between PHQ-9 and symptom scores violated model assumptions, 
the POS-S renal score was again removed from the final model. After adjusting for 
these variables, the EQ5DVAS was preserved over time with no difference in trends 
between dialysis and CKD patients (Table 3.14, figure 3.9). 
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Table 3.12: Univariate fixed effects from mixed model: EQ5D index 
Predictor Coefficient 95% CI P value 
Age 0.001 -0.012 to 0.013 0.92 
Male Sex 0.040 -0.182 to 0.262 0.72 
Ethnicity 
Caucasian 
Afro Caribbean 
Asian 
 
- 0.237 
- 0.095 
- 0.340 
 
-1.028 to 0.555 
-0.933 to 0.743 
-1.132 to 0.452 
 
0.55 
0.82 
0.40 
Time 0.010 - 0.041 to 0.021 0.52 
Dialysis vs CKD 0.048 -0.184 to 0.281 0.68 
HD vs PD -0.283 -0.376 to 0.321 0.13 
Stoke comorbidity 
score 
-0.063 -0.171 to 0.045 0.25 
Comorbidities 
Malignancy 
Diabetes 
IHD 
PVD 
LV Dysfunction 
 
0.013 
0.010 
-0.057 
-0.189 
-0.021 
 
-0.481 to 0.506 
-0.210 to 0.230 
-0.278 to 0.164  
-0.456 to 0.079 
-0.348 to 0.306 
 
0.96 
0.93 
0.61 
0.16 
0.90 
PHQ-9 -0.059 -0.076 to -0.041 <0.01 
POS-R -0.042 -0.053 to -0.030 <0.01 
MoCA score 0.020 -0.014 to 0.053 0.24 
Lab Parameters 
Serum Haemoglobin 
Serum Bicarbonate 
Serum Sodium 
Serum Albumin 
Serum CRP 
 
0.027 
-0.017 
-0.007 
-0.005 
-0.004 
 
-0.027 to 0.082 
-0.040 to 0.006 
-0.030 to 0.016 
-0.011 to 0.002 
-0.008 to -0.000 
 
0.33 
0.15 
0.53 
0.14 
0.03 
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Table 3.13: Univariate fixed effects from mixed model: EQ5D VAS 
Predictor Coefficient 95% CI P value 
Age -0.644 -1.228 to -0.060 0.03 
Male gender 0.186 -0.011 to 0.382 0.06 
Ethnicity 
Caucasian 
Afro Caribbean 
South Asian 
 
-0.131 
0.132 
-0.236 
 
-0.643 to 0.381 
-0.447 to 0.710 
-0.751 to 0.278 
 
0.61 
0.65 
0.36 
<12 years of education -0.197 -0.466 to 0.071 0.15 
Stoke comorbidity score 0.003 -0.075 to 0.081 0.94 
SGA score 0.074 0.017 to 0.132 0.02 
PHQ-9 -2.110 -2.972 to -1.248 <0.01 
POS-S Renal score -0.026 -0.034 to -0.017 <0.01 
Comorbidities 
Malignancy 
LV dysfunction 
Diabetes 
IHD 
PVD 
 
0.034 
-0.049 
0.005 
0.009 
0.039 
 
-0.201 to 0.134 
-0.197 to 0.296 
-0.167 to 0.158 
0.057 to -0.075 
-0.039 to 0.118 
 
0.69 
0.69 
0.95 
0.79 
0.32 
Laboratory parameters 
Serum CRP 
Serum Haemoglobin 
Serum Sodium 
 
-0.001 
0.013 
-0.007 
 
-0.001 to 0.001 
-0.016 to 0.044 
-0.016 to 0.003 
 
0.93 
0.40 
0.17 
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Table 3.14: Generalised Linear Mixed Models (Dialysis vs CKD). Outcome 
variables- EQ5D Index and Visual Analogue scale (VAS) 
Outcome variable Predictor 
Variable   
Coefficient 95%CI p 
value 
EQ5D Index PHQ-9 -0.092 -0.123 to -0.061 <0.01 
SGA score -0.055 -0.174 to 0.045 0.24 
CRP -0.004 -0.009 to 0.000 0.08 
Time^ -0.141 -0.309 to 0.029 0.10 
Dialysis vs CKD -0.045 -0.227 to 0.317 0.74 
Dialysis* Time^ 
CKD*Time^ 
(reference) 
-0.028 
- 
-0.166 to 0.222 
- 
0.77 
- 
EQ5D VAS Age -0.360 0.862 to 0.143 0.157 
PHQ-9 -2.252 -3.337 to -1.168 <0.001 
SGA score 3.005 -0.693 to 6.704 0.109 
Time^ 0.718 -5.524 to 3.819 0.748 
Dialysis vs CKD 11.705 1.802 to 21.607 0.021 
Dialysis* Time^ 
CKD*Time^ 
(reference) 
0.425 
- 
-4.464 to 5.491 0.864 
- 
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Figure 3.8: longitudinal trends in EQ5D index 
 
Figure 3.9: Longitudinal trends in EQ5D VAS 
 
In the dialysis cohort, there was no significant change in the EQ5D measures over 
time. The HD patients did however have lower EQ5D index compared to the PD 
patients, irrespective of time (Table 3.15, figures 3.10 and 3.11). 
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Table 3.15: Generalised Linear Mixed Models (HD vs PD). Outcome variables- 
EQ5D Index and Visual Analogue scale 
Outcome 
variable 
Predictor Variable   Coefficient 95%CI p 
value 
EQ5D Index PHQ-9 -0.081 -0.125 to -0.037 <0.01 
SGA score -0.104 -0.265 to 0.058 0.20 
CRP -0.007 -0.012 to 0.002 0.01 
Time -0.10 -0.359 to 0.150 0.37 
HD vs PD -0.437 -0.785 to -0.088 0.02 
HD * Time^ 
PD * Time^(Reference) 
-0.011 -0.295 to 0.273 0.94 
EQ5D VAS Age -0.015 -0.028 to -0.001 0.04 
PHQ-9 -0.045 -0.046 to 0.105 0.001 
SGA score -0.030 -0.070 to -0.019 0.423 
Time^ 0.019 -0.044 to 0.082 0.518 
HD vs PD -0.106 -0.354 to 0.142 0.395 
HD * Time^ 
PD * Time^(Reference) 
-0.035 
- 
-0.110 to 0.039 0.307 
- 
^= every 4 months 
 
 
Figure 3.10: Longitudinal trends in EQ5D index by dialysis modality 
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Figure 3.11: Longitudinal trends in EQ5D VAS by dialysis modality 
 
3.7.5.2 Symptom burden 
 The POS-S renal score was used to evaluate symptom burden in patients with 
advanced kidney disease. As the data followed a positively skewed distribution, a 
generalised linear model with inverse Gaussian distribution was used. Longitudinal 
trends in the symptom score were compared between dialysis and CKD patients and 
subsequently between HD and PD patients. The POS-S renal score was associated 
with serum albumin levels, PHQ-9 scores and nutritional status (SGA scores) in 
univariate analysis (Table 3.16). 
After adjusting for these variables, the POS-S renal score increased more rapidly over 
time in CKD patients compared to patients on dialysis (effect estimate = -0.871, p = 
0.04) (Table 3.17). However, the plot of predicted trends did not clearly distinguish 
between the two groups (Fig 3.12).  
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Table 3.16: Univariate effects from mixed model - POS-S renal 
Predictor Variable Coefficient 95% CI p value 
Age -0.052 -0.231 to 0.127 0.57 
Male Sex -0.887 -4.501 to 2.727 0.63 
Ethnicity 
Caucasian 
Afro Caribbean 
Asian 
 
-2.232 
-2.993 
-1.470 
 
-12.657 to 8.192 
-13.912 to 7.926 
-11.994 to 9.054 
 
0.67 
0.59 
0.78 
Dialysis vintage 
No dialysis 
< 3 months 
3 months to 12 months 
12 months to 60 months 
>60 months 
 
-0.073 
-0.322 
0.053 
0.409 
- 
 
-0.487 to 0.342 
-0.738 to 0.093 
-0.359 to 0.464 
-0.442 to 1.261 
- 
 
0.73 
0.13 
0.80 
0.34 
- 
Stoke comorbidity score 0.320 -1.339 o 1.979 0.70 
Diabetes -0.058 -3.141 to 3.257 0.97 
IHD -0.249 -2.567 to 1.112 0.68 
LV Dysfunction -1.139  -6.207 to 3.929 0.65 
PVD 1.353 -3.124 to 5.830 0.54 
CRP -0.037 -0.096 to 0.021 0.21 
Serum Albumin -0.925 -1.193 to - 0.657 <0.01 
PHQ-9 0.144 0.115 to 0.173 <0.01 
Serum Haemoglobin -0.024 -0.104 to 0.057 0.56 
Serum Sodium 0.015 -0.013 to 0.044 0.30 
Bicarbonate 0.002 -0.028 to 0.032 0.88 
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Table 3.17: Generalised Linear Mixed Model (Dialysis vs CKD): Outcome 
variable- POS-S renal 
Predictor Variable Coefficient 95% CI p value 
Albumin 0.001 -0.052 to 0.054 0.98 
PHQ-9 1.430 1.108 to 1.752 <0.01 
SGA score -0.125 -1.020 to 0.770 0.78 
Time^ -0.077 -0.769 to 0.615 0.82 
Dialysis vs CKD 0.541 -1.696 to 2.778 0.63 
Dialysis* Time^ 
CKD *Time^ (reference) 
-0.871 -1.713 to -0.030 0.04 
^ = every 4 months 
 
 
Figure 3.12: Longitudinal trends in POS-S renal scores  
 
In the dialysis cohort, the symptom score declined over time. It declined more rapidly 
in the PD group compared to those on HD (Table 3.18, figure 3.13). 
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Table 3.18: Generalised Linear Mixed Model (HD vs PD): Outcome variable- 
POS-S renal 
 
Predictor variables 
Coefficient 95%CI p value 
Albumin -0.015 -0.078 to 0.047 0.61 
PHQ-9 1.387 0.952 to 1.822 <0.01 
SGA score -0.806 -2.137 to 0.526 0.21 
Time^ - 2.518 -3.915 to -1.121 <0.01 
HD vs PD 1.095 -2.642 to 4.833 0.55 
HD* Time^ 
PD *Time^ (reference) 
1.530 
- 
0.031 to 3.028 
0.05 
- 
^= every 4 months 
 
 
 
Figure 3.13: Longitudinal trends in POS-S renal scores (HD vs PD) 
 
3.7.5.3 Timed Up and Go test 
I used the same method to analyse TUAG scores as in the previous section. In 
univariate analysis, advancing age and higher comorbidity burden were associated 
with longer TUAG (3.19). In multivariate analysis, TUAG increased over time. It 
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increased at a slower rate in dialysis group compared to patients with CKD, suggesting 
that physical function was better preserved in the dialysis cohort compared to the CKD 
group (Table 3.20, figure 3.14). In the dialysis cohort, the trends in TUAG scores did 
not differ between the HD group and the PD group (Table 3.21, table 3.15).  
Table 3.19: Univariate fixed effects from mixed model analysis: Timed Up and 
Go 
Predictor variable Coefficient 95%CI p value 
Age 0.124 -0.003 to 0.311 0.05 
Male sex -3.433 -7.751 to 0.908 0.49 
Ethnicity 
Caucasian 
Afro Caribbean 
 
-3.082 
-3.336 
 
-6.744 to 0.580 
-8.082 to 1.356 
 
0.28 
0.53 
Comorbidities 
LV dysfunction 
Malignancy 
Diabetes 
IHD 
PVD 
 
3.025 
0.894 
1.833 
-1.220 
3.678 
 
-7.776 to 1.746 
-5.816 to 4.028 
-0.995 to 4.660 
-3.859 to 1.420 
-1.256 to 8.613 
 
0.99 
0.72 
0.20 
0.36 
0.14 
Stoke Comorbidity score 
Stoke Comorbidity grade 
Low risk vs High risk 
Moderate risk vs High risk 
0.083 
 
1.935 
3.639 
-0.061 to 0.227 
 
-1.774 to 5.645 
-0.779 to 8.057 
0.62 
 
0.30 
0.16 
SGA score 0.818 -1.515 to 3.190 0.49 
Time^ 3.832 0.831 to 4.614 <0.01 
 
However, the results from this analysis need to be interpreted with caution due to 
significant proportion of missing data. Only 30% of the cohort had valid TUAG times 
(figure 3.16). The reasons for missing data include study dropouts by withdrawal, 
death or transplantation. In addition, a significant number of patients were either 
wheelchair bound or did not feel well enough to complete the assessment. 
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Table 3.20 Generalised Linear Mixed Model (Dialysis vs CKD): Outcome 
variable- Timed Up and Go 
Predictor variable Coefficient 95%CI p value 
Age -0.014 -0.209 to 0.181 0.89 
Stoke Comorbidity Grade 
Low risk vs High risk 
Moderate risk vs High 
risk 
 
1.125 
3.479 
 
-3.153 to 5.404 
-1.410 to 8.369 
 
0.60 
0.16 
Time^ 2.808 1.259 to 4.398 <0.01 
Dialysis vs CKD 0.950 -3.321 to 5.220 0.66 
CKD* Time^ 
Dialysis *Time^ 
(reference) 
2.854 
- 
-5.283 to -0.425 0.02 
- 
^= every 4 months 
Table 3.21 Generalised Linear Mixed Model (HD vs PD): Outcome Variable-
Timed Up and Go 
Predictor variable Coefficient 95%CI p value 
Age 0.075 -0.394 to 0.545 0.64 
Stoke Comorbidity Grade 
Low risk vs High risk 
Moderate risk vs High 
risk 
 
2.342 
3.479 
 
-5.980 to 10.664 
-14.078 to 12.975 
 
0.55 
0.16 
Time^ 0.166 -0.860 to 0.191 0.71 
HD vs PD 1.900 -10.037 to 6.237 0.62 
HD* Time^ 
PD *Time^ (reference) 
0.680 
- 
-0.769 to 2.128 0.34 
^ = every 4 months 
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Figure 3.14: Longitudinal trends in TUAG scores  
 
 
Figure 3.15: Longitudinal trends in TUAG scores (HD vs PD) 
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Figure 3.16: Missing data profile for TUAG scores 
 
3.8 Conclusions 
One of the hypotheses of this study, is that dialysis is associated with a decline in 
cognitive function and patient reported outcome measures in comparison to CKD 
patients. Generalised linear mixed model analysis was used to compare trends in 
MoCA, EQ5D, POS-S renal and TUAG scores between dialysis and CKD patients. In 
multivariate analysis, the total MoCA scores declined at a faster rate in the dialysis 
cohort compared with the CKD cohort. The average MoCA memory scores during 
follow up were higher in the dialysis cohort compared with those on CKD. However, 
there were no differences in the longitudinal trends of the MoCA executive and 
MoCA memory scores between the groups. These findings suggest that global 
cognitive function is better preserved in patients with CKD compared with those on 
dialysis, while trends in executive function and memory do not differ over time.  
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In terms of the other outcome measures, the EQ5D measures did not change 
significantly during follow up, with no difference in trends (i.e. change over time) 
between the dialysis and CKD groups. Interestingly, the EQ5D VAS tended to be 
higher in the dialysis cohort compared to those with CKD (Coefficient =11.705, 1.802 
to 21.607, p = 0.021). It implies that dialysis patients perceived their state of health to 
be better than that of the CKD patients during follow up. The plot of predicted values 
however suggests that the trajectories of EQ5D VAS are not consistently different. 
The effect estimates from the mixed model may therefore not be of clinical 
significance. Similarly, the effect estimates from mixed model analysis suggest that 
the POS-S renal scores reduced over time in the dialysis group compared to CKD 
patients. The plot of predicted values (figure 3.12) however does not clearly 
distinguish the trajectories of the symptom score between the cohorts. The effect 
estimate is again small (coefficient = -0.871, -1.713 to -0.030; p=0.04) and may also 
not be clinically relevant. 
 The study also hypothesized that cognitive function and patient reported outcome 
measures would decline faster in patients on HD compared to PD. To test this 
hypothesis, the mixed model analysis was repeated in dialysis cohort, comparing 
trends in MoCA, EQ5D, POS-S renal and TUAG scores between HD and PD.  In this 
analysis, trends in the total MoCA and MoCA memory scores did not differ between 
the HD and PD cohorts. However, the MoCA executive scores were better preserved 
in the PD group compared to those on HD (figure 3.6). The symptom score (POS-S 
renal) reduced during follow up in the PD group compared to those on HD. While the 
EQ5D measures did not change significantly over time as a group or according to 
dialysis modality. However, the EQ5D index was consistently lower during follow up, 
in the HD group compared with those on PD (figure 3.10).   
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Trends in TUAG scores were also compared between dialysis and CKD as well as 
between HD and PD patients. After mixed model analysis, the TUAG scores 
increased over time in the CKD cohort compared with those on dialysis. There was 
no difference in TUAG trends between HD and PD. In other words, physical function 
deteriorated during follow up in the CKD cohort when compared to the dialysis cohort 
but did not differ significantly when the HD and PD cohorts were considered. The 
validity of these models is however in doubt due to the high proportion of missing 
data. As shown in figure 3.16., only about a third of patients had valid times. 
The findings from this analysis need to be interpreted with caution due to the 
following limitations. Firstly, this was a single centre observational study in which 
participants were selected by convenience sampling. The study findings will 
therefore need to be corroborated in larger studies. In contrast to the FEPOD study 
discussed in chapter 2, participants were recruited throughout the study. The follow 
up duration was therefore not fixed and the mean follow up period was consequently 
shorter. As I have already mentioned in the results section, the effect estimates from 
the mixed models were small, even when they reached statistical significance. 
Therefore, the differences reported between the groups may not be clinically relevant 
without longer follow up. 
This study suggests that cognitive function declined on dialysis and possibly more so 
on HD compared to PD. While dialysis patients perceived their health status to be 
better than patients with CKD, there were no differences in the trends of patient 
reported outcome measures between the groups during follow up. Accepting the 
limitations in the analysis, physical function declined more rapidly in the CKD cohort 
compared the dialysis cohort. The relevance of these findings will be discussed 
subsequently. 
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4. COGNITIVE IMPAIRMENT AND DECISION MAKING IN  
ADVANCED KIDNEY DISEASE- A PILOT STUDY 
4.1 Introduction 
 In section 1.4.2, cognitive impairment was shown to influence decision making (DMC) 
in medical patients. Memory, executive function and language domains are most 
commonly associated with impaired DMC. The presence of cognitive impairment is 
however not synonymous with impaired DMC. 
To make an informed choice, patients with advanced kidney disease receive a 
significant amount of information about RRT. Research has focused on factors that 
influence the choices made by such patients. But little is known about their capacity to 
make them. It is well established that cognitive impairment is common but under 
recognised in renal patients. It is therefore possible that impairments in DMC are also 
underestimated in renal patients. Terawaki et al [277]  found that the capacity to give 
consent to treatment in predialysis patients was impaired due to deficits in attention 
and concentration. Executive function, which is commonly affected in renal patients, 
was however not assessed. 
Using assessment tools that also evaluate executive function, this pilot study 
evaluated the relationship between cognitive function and DMC in advanced kidney 
disease. The findings will form the basis for a larger, adequately powered study.  
4.2 Study design  
  This is a single centre cross sectional pilot study. This study was approved by the 
London- Fulham research ethics committee (REC approval number 14/LO/2223). 
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4.3 Location of the sample 
Patients were recruited from 3 outpatient clinics at Imperial College Healthcare NHS 
trust. The HD clinic was located at Charing Cross hospital, while the PD and low 
clearance clinics took place at Hammersmith hospital. 
4.4 Patient selection 
Eligible patients were over 40 years of age. These patients were either on dialysis or 
had CKD with an estimated GFR ≤ 30ml/min. Patients deemed by their managing 
clinician to have a life expectancy of less than 6 months were excluded from the study. 
Those with known dementia as well as those unable to understand English, were 
excluded from the study.  
I approached eligible participants during their routine clinic visits with a patient 
information sheet. Those willing to take part were consented at their subsequent clinic 
visit. Patients were recruited between January and October 2015. 
4.5 Study assessment 
4.5.1 Setting 
 I assessed all participants in this study, having received some training on how to 
conduct capacity interviews. The study interview was conducted after their usual clinic 
visit in the outpatient department or at a time of their choosing. For the HD patient, 
these clinic visits coincided with their mid-week dialysis sessions. For convenience, 
their interviews were conducted in a private room on the dialysis unit, prior to starting 
dialysis.  
4.5.2 The study interview 
The interview included assessments for depression, cognitive performance and 
capacity to consent to treatment (study outcome), performed in a standard order 
(Table 4.1). The study interview took 45 to 60 minutes to complete. 
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Table 4.1: Study assessments 
Domains Study Assessments 
Demographic and clinical 
information 
Designed proforma 
Depression Patient Health Questionnaire – 9 (PHQ-9) 
Cognitive Function Montreal Cognitive Assessment (MoCA) 
Capacity to consent to 
treatment 
Macarthur competency assessment tool (MACCAT T) 
 
Demographic and Clinical information were collected using a designed proforma. 
These included 
- Age 
- Gender 
- Ethnicity 
- Dialysis modality,  
- Time on dialysis (in months) 
- Level of education 
- Cause of ESRD 
- Comorbidities - Stoke –Davies comorbidity score, past psychiatric history 
 
The Patient Health Questionnaire -9 (PHQ-9) was used to assess depressive 
symptoms and has been described in section 3.5. It was important to assess for 
depression as it has been known to influence cognitive performance as well as DMC. 
The Montreal Cognitive Assessment (MoCA) was used to assess cognitive 
function. This is because executive function is assessed as one of its domains.  
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The Macarthur Competency Assessment tool (MACCAT-T) was used to evaluate 
capacity to consent to treatment as a measure of DMC. This semi structured interview 
is considered to be the gold standard for assessing capacity to consent. It evaluates 
the 4 recognised domains of DMC (Understanding, appreciation, reasoning and 
expression of choice). The choice of the capacity assessment tool was based on 
discussions with experts in the field as well 2 peer reviews of the study proposal. I 
received some clinical training from Dr Okai, a neuropsychiatrist and a collaborator on 
this study. I also acquired further skills through personal study, including a review of 
the published manual on the use of the MacCAT –T.  In this pilot study, the capacity 
to consent was assessed based on changes to treatment made during the clinic visit. 
For the predialysis patients, the interview was based on RRT options. 
4.6 Statistical methods 
All analyses were carried out using the SPSS program (version 22). Continuous 
variables were expressed as mean and standard error or median and interquartile 
ranges, for parametric or non- parametric data respectively. Categorical variables 
were expressed as percentages. Patients were deemed to have cognitive impairment 
if the MoCA score was less than 26. The MACCAT-T scores were compared between 
patients with cognitive impairment and those without, using the Mann Whitney test. 
Spearman’s correlation was used to evaluate to relationship between the cognitive 
domains assessed by MoCA and the 4 MACCAT-T domains. 
4.7 Results 
4.7.1 Participant characteristics 
10 patients were recruited into the pilot study. This cohort consisted of 5 PD, 3 CKD 
and 2 HD patients. All patients were of male gender with a mean age of 54.3 years 
(Table 4.2). 7 patients had some degree of cognitive impairment based on a MoCA < 
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26. 2 patients had a prior history of depression, one of whom had a PHQ-9 score of > 
10. 
Table 4.2: Participant characteristics 
Variable N = 10 
Mean Age (years) 54.3± 1.8 
Ethnicity 
White European 
Asian 
Afro Caribbean 
 
30% 
40% 
30% 
Stoke Grade  
Low risk 
Medium risk 
High risk 
 
50% 
40% 
10% 
Diabetes  
Ischaemic Heart Disease 
Peripheral Vascular Disease 
Depression 
40% 
40% 
40% 
20% 
< 12 Years education 60% 
PHQ-9 < 10 10% 
Cognition 
MoCA score, median (IQR) 
%Cognitive Impairment (MoCA < 26) 
 
25 (24 – 26) 
70% 
 
4.7.2 Relationship between cognitive function and MACCAT-T scores 
Spearman’s correlation was used to evaluate the relationship between global cognitive 
function, specific cognitive domains and the 4 domains of decision making capacity. 
As shown in figure 4.1 and table 4.3, there was a positive correlation between the total 
MoCA scores and the total MACCAT-T scores (r = 0.59). This however did not reach 
statistical significance (p - 0.09). There was also no significant correlation between the 
MACCAT-T domains and individual cognitive domains. Patients with a MoCA score 
less than 26 (i.e. potentially cognitively impaired) had lower total MacCAT-T scores 
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compared with those with higher MoCA scores [17.4 (16.3 – 18.4) vs 19 (17.9 – 19.6), 
p = 0.05]. 
 
 
Figure 4.1: Correlation between MacCAT-T and MoCA score 
 
4.8 Conclusions 
The relationship between cognitive function and capacity to give consent was 
evaluated in this pilot of study of 10 participants. While there may have been a trend 
towards a positive correlation between total MoCA and MacCAT-T scores, there was 
no demonstrable relationship between individual domains of cognition and DMC. 
Some of the correlations were unexpectedly negative, suggesting better 
performance in certain domains of DMC with poorer cognitive scores. The results are 
unreliable because of the sample size was too small.  The p values presented have 
not been adjusted for multiple comparisons. Such an adjustment would not alter the 
outcomes reported. More importantly, as the purpose of multiple adjustment is to 
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protect against false positive errors, there seems to be little to gain in a study where 
the number of positive associations is negligible. 
 
Table 4.3: Correlation between MACCAT and MoCA domains 
Cognitive 
domains 
MACCAT – T 
domains 
Spearman’s r P value 
Global function 
(MoCA Total) 
Understanding 
Appreciation 
Reasoning 
Expression 
Total 
0.33 
0.06 
0.50 
-0.30 
0.59 
0.35 
0.87 
0.17 
0.40 
0.09 
Executive 
function 
Understanding 
Appreciation 
Reasoning 
Expression 
Total 
- 0.13 
0.32 
0.36 
-0.19 
0.40 
0.71 
0.37 
0.34 
0.60 
0.30 
Memory  
(Delayed Recall) 
Understanding 
Appreciation 
Reasoning 
Expression 
Total 
0.57 
-0.36 
0.36 
0.36 
0.02 
0.11 
0.34 
0.34 
0.34 
0.95 
Attention Understanding 
Appreciation 
Reasoning 
Expression 
Total 
0.07 
0.23 
0.35 
-0.38 
0.33 
0.86 
0.56 
0.36 
0.32 
0.39 
Language Understanding 
Appreciation 
Reasoning 
Expression 
Total 
-0.23 
0.40 
0.27 
-0.32 
0.26 
0.56 
0.29 
0.48 
0.41 
0.50 
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The choice of a cut off age of 40 years is not consistent with the other studies in this 
thesis. Although most commonly seen in older people, cognitive deficits are also seen 
in younger renal patients. Moreover, it was anticipated that recruitment into this pilot 
study would be challenging.  The requirement to conduct the study interview after a 
clinic visit was a potential drawback. In addition, there were competing interests with 
the study discussed in chapter 3, as I was recruiting from the same clinics. 
There was a trend towards a higher capacity assessment score in the patients with a 
MoCA score of 26 or more. The cut off score of 26 is recommended by the original 
authors based on validation studies in the general population. While this cut off is 
therefore not arbitrary, it is recognised a MoCA score below 26 may not represent 
cognitive impairment in renal patients. One study suggests a cut off score of 24 but 
this is based on sample of 43 HD patients only.[229]  
It is unclear whether the results would be similar if standard scenario was used for all 
participants. It is possible that capacity assessment scores vary within and between 
individuals depending on the complexity of the proposed treatment. In order to 
introduce such standardisation, one would have to consider using clinical vignettes. 
However, in contrast to some of the other capacity assessment tools, the MacCAT- T 
is designed to help assess capacity for intended treatment. It has also been suggested 
that assessments based on such vignettes, may not reflect true capacity. [318] 
Ultimately, the pilot demonstrates that it is feasible to conduct a larger study in this 
research domain for patients with advanced kidney disease. It is not without 
challenges. I will discuss potential strategies to overcome them, in the next chapter. 
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5. DISCUSSION AND FUTURE WORK 
This thesis set out to evaluate cognitive function and patient reported outcomes in 
patients with advanced kidney disease, focusing on older people. Specifically, it 
compared QoL outcomes between older patients on assisted PD and similar patients 
on HD. The relationship between cognitive trends and dialysis modality was also 
evaluated. Finally, a pilot study provided some insight into the relationship between 
cognitive function and decision making in patients with advanced kidney disease. This 
chapter will put these findings in the context of existing research evidence and 
highlight their relevance for future research. 
It has been shown that the principal determinants of QoL in older people are being 
independent and being in control of one’s own life. [319]  Assisted PD in comparison 
to HD enables the older person to dialyse at home, and is thus more likely to promote 
independence. Therefore, it was hypothesized in the first study that QoL would be 
better preserved in patients on assisted PD compared with matched patients receiving 
in centre HD. At baseline, there were no differences in QoL measures between 
modalities, except treatment satisfaction. The treatment satisfaction (RTSQ) scores 
were higher in assisted PD patients, even after considering demographic and clinical 
characteristics. In the longitudinal analysis, there were no consistent differences in 
QoL trends between older patients on HD and those on assisted PD. 
The higher baseline treatment satisfaction score reported in the assisted PD group is 
unsurprising, due to the control and flexibility afforded by dialysis at home.  Treatment 
satisfaction has also been shown to be higher in patients receiving conventional PD in 
comparison to HD. [320, 321]  In the study by Juergensen et al [321], the PD patients 
were younger and less comorbid  compared to their HD counterparts. The authors 
commented on the risk of modality selection bias in that study. In contrast, the patients 
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on assisted PD in the FEPOD study were matched for age and comorbidity to those 
on HD. Treatment satisfaction did not differ significantly between assisted PD and HD 
during follow up. This may be explained by other unmeasured determinants. For 
example, in a study of 736 incident dialysis patients, the domains in which patient 
ratings differed between HD and PD included staff availability and information provided 
by dialysis staff.[322] These domains were rated poorly in an international survey of 
2748 HD patients from Europe and South America [323] .They were not assessed in 
this study. 
 There were no consistent differences in QoL outcomes between the assisted PD and 
HD cohorts, either at baseline or during follow up. These findings are consistent with 
prior studies that have evaluated QoL in older patients on self-care PD. [140, 172] The 
BOLDE study, which had a similar study design to FEPOD at baseline, did find that 
illness intrusion was lower in PD patients. Otherwise, there were no differences in QoL 
measures.  In comparison to BOLDE, the SF12 scores were lower in the FEPOD 
study, with higher illness intrusion scores. Possible depression (HADS depression 
score >7) was also more prevalent in the FEPOD study compared to the BOLDE study 
(32% vs 18%). These differences are possibly explained by the degree of frailty within 
the FEPOD cohort, as it is often an indication for assistance with PD. 
  The frailty score was predominantly associated with adverse QoL outcomes at 
baseline, highlighting it as an important confounder of outcomes in dialysis patients. It 
performed better than the comorbidity score as a predictor of outcomes. This is 
consistent with findings in other studies evaluating frailty in the dialysis population.[72]  
It was also a better predictor of outcomes compared to age. Thus, frailty is a concept 
that is distinct of age, despite their recognised link. Indeed, chronological age may be 
a poor predictor of outcomes, as is often a composite of other relevant risk factors. 
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Although the clinical frailty scale assesses frailty in a continuum, 48% of our 
participants were characterised as frail (frailty score ≥ 5), suggesting that there were 
other indications for assistance in the other participants (e.g. visual impairment, 
stroke). There are no standardised criteria for assisted PD, other than a requirement 
for assistance to enable PD at home. The indications for assisted PD were not 
assessed at individual centres. Unfortunately, it was also not feasible to consistently 
assess frailty during follow up. The baseline frailty score was used in the longitudinal 
analysis. But frailty scores may have changed during follow up. This may explain why 
the baseline results (in terms of the consistent association of frailty with outcome 
measures) were not replicated in the longitudinal study. 
Some of the limitations of the FEPOD study have been previously highlighted. These 
include its observational nature, sample size and potential risk of selection bias. 
Although it is the largest study to compare QoL between older patients on assisted PD 
and HD, the findings may not be generalizable. This is because the frailest patients 
with short life expectancy and significant cognitive impairment were excluded. The 
study outcomes may also differ in a population with a different model of assisted PD 
compared to the UK. It would be of interest to evaluate illness intrusion for example, 
in patients on assisted CAPD. A healthcare professional may visit such patients as 
many as 4 times a day. These visits may be valued but could equally be considered 
to be intrusive. As the FEPOD cohort consisted of UK patients only, they would most 
likely have been on assisted APD. 
If frailty was one of the emerging themes from the first study, the second study 
highlighted cognitive decline, as another under recognised problem faced by older 
people with CKD. The risk of cognitive impairment increases as renal function 
declines.[251, 324] In addition, several studies have shown that cognitive 
 
174 
 
performance is poorer in dialysis patients compared to matched healthy 
controls.[224] Dialysis potentially exerts an additive effect on cognitive dysfunction in 
patients with advanced CKD. This is supported by the improvement in cognitive 
function in dialysis patients following transplantation.[236] By demonstrating faster 
cognitive decline in dialysis patients compared to patients with CKD patients, this 
study lends support to this theory. To my knowledge, this is first study to directly 
compare cognitive decline in dialysis patients and predialysis patients. More recently, 
the findings have been corroborated by another study. Kurella Tamura et al, recently 
found that dialysis initiation in patients with advanced CKD, is associated with a 
decline in executive function.[325]  The mechanisms by which dialysis influences 
cognitive function is the subject of ongoing investigation. Recently, certain uraemic 
toxins have been linked to cognitive decline, by metabolic profiling.[326] Yet 
observational studies, have so far failed to show an association with small solute 
clearance [246] or dialysis frequency[247]. Data on the influence of intradialytic 
hypotension on cognition are conflicting. Observational studies have previously 
shown no relationship between intradialytic hypotension and cognitive impairment. 
More recently though, it has been linked directly with cerebral white matter changes 
which in turn has been associated with cognitive deficits. [227, 327]  
 The reported faster decline in executive function in HD patients compared to those 
on PD, is noteworthy despite the lack of significant differences in global cognitive 
trends. It is consistent with studies reporting a lower cumulative incidence of 
dementia (predominantly vascular in origin) in PD compared to HD patients.[250] 
Kurella Tamura et al reported a 19% prevalence of isolated executive dysfunction 
(executive dysfunction despite normal global cognitive function) in a cross sectional 
study of 383 HD patients.[227] It is therefore plausible that a decline in executive 
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function predates global cognitive decline. But this will need to be investigated in a 
prospective study.  HD has been shown to exert injurious ischaemic effects on the 
brain. These include silent cerebral infarcts, white matter changes, micro-
haemorrhages and altered cerebral blood flow. These features have also been 
reported in PD patients, but to lesser degree. This may explain the differences noted 
in this study.  
PROMs were also evaluated during this study. The EQ5D index did not differ 
between the dialysis and CKD cohorts. In contrast, the dialysis patients had a higher 
average perception (EQ5D VAS) of their state of health. Abdel- Kader et al[328] in a 
cross sectional study of 177 patients (HD-90, CKD -87), found that HRQoL, 
measured using the SF-36, did not differ between HD and CKD patients. This lack of 
difference in outcomes has also been reported in other studies. In terms of health 
perception, Jansen et al found that dialysis patient tended to have a higher 
perception of illness and treatment consequences compared to their predialysis 
counterparts. However, these perceptions did vary over time.[329]  The reasons for 
these differences may include unmeasured confounders such frailty. There is also 
the potential influence of unknown clinical interventions. The EQ5D 3L version was 
used in this study rather than the EQ5D 5L version. It has been shown to be less 
discriminatory in patients with chronic conditions [330] and thus may not have been 
sensitive to subtle changes in QoL over time. 
 The EQ5D measures were relatively preserved in the dialysis cohort regardless of 
modality, although the EQ5D index was lower on average in the HD cohort 
compared to PD (Coefficient = -0.421, p = 0.021). Cross sectional studies have 
predominantly shown no difference in QoL measures between dialysis modalities. 
However, a recent systematic review of 26 studies reported lower self-rated QoL in 
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HD patients compared to those in PD.[171] Few longitudinal studies have evaluated 
QoL and dialysis modality. The NECOSAD study of 230 dialysis patients found that 
QoL declined more quickly in the PD cohort over a follow up period of 18 
months.[331] However, the North Thames Dialysis study reported no differences in 
QoL at 6 and 12 months in older patients on HD and PD.[140] These findings were 
also reported in a more recent study of 350 dialysis patients.[332]  QoL may 
therefore be influenced by factors other than dialysis modality. 
 Patients with advanced kidney disease are known to have a high symptom burden. 
In this study, the symptom score decreased over time in dialysis patients, but less so 
in the HD cohort. As highlighted earlier, the clinical significance of these findings is 
doubtful, when the absolute values are considered. Nonetheless ,the reported 
decline in symptom burden on dialysis is consistent with outcomes from Novak et 
al’s study of 45 PD patients.[333] Comparative studies between modalities are 
limited. Abdel Kader et al reported that the symptom burden between dialysis and 
CKD patients were similar, in a cross sectional study of 177 patients. There are 
several confounding issues to consider here. Certain symptoms (such as fatigue) are 
potentially aggravated by dialysis, especially in older people. This may well be offset 
by improvement in other uraemic symptoms. This is relevant because the symptom 
score is a measure of symptom count as well as severity.  In addition, dialysis 
patients, by the very nature of the treatment, have frequent contact with health 
professionals. It is possible that symptoms are more likely to be reported by this 
cohort and therefore treated, compared with CKD patients. There are no longitudinal 
studies comparing trends in symptom burden between dialysis modalities.  
  Physical function declined over time in this study (as suggested by increasing 
TUAG times). In contrast to prior studies,[185] physical function declined more 
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rapidly in the CKD group compared to those on dialysis. There was no difference in 
functional trends between those on HD compared to PD, as was the case with the 
FEPOD study discussed earlier. These results however need to be interpreted with 
caution as only about 30% of the study cohort had valid TUAG times. In addition, 
frailty was not measured, and thus not considered in this study. 
This study does have other noteworthy limitations. It was a single centre 
observational study and as such causality cannot be established. The findings are 
also unlikely to be generalizable. The sample is relatively small and may thus not be 
adequately powered to detect differences. Due to convenience sampling, one cannot 
exclude the possibility of selection bias. In addition, longer follow up may have been 
required to detect clinically important differences in the outcome measures. 
 In the final pilot study, there was a trend towards an association between cognitive 
function and capacity assessment scores.  In Terawaki et al’s study of 26 predialysis 
patients, [277] attentional deficits in MMSE correlated significantly with poor 
understanding and reasoning evaluated by MACCAT-T. I found no correlation 
between specific cognitive domains and the 4 domains assessed by MACCAT-T. The 
mean scores were also lower in Terawaki et al’s study compared to this pilot 
(Understanding – 3.72 ± 1.11 vs 5.76 ± 0.08, Appreciation – 2.88 ± 0.88 vs 3.88 ± 
0.11, Reasoning – 4.30 ± 2.11 vs 6.44± 0.41). The exclusion of patients with significant 
cognitive impairment may contribute to these noted differences. In addition, sample 
size was too small to detect significant associations. 
The MacCAT –T is considered to be the gold standard for assessing DMC. Although 
the 4 domains of understanding, appreciation, reasoning and expression of choice are 
assessed, it is unclear what the total score signifies. There is also no cut off value that 
indicates the presence or lack of capacity. Patients with very low scores in all four 
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domains would possibly lack sufficient decision making capacity, but the original 
authors suggest that these scores must be put in clinical context.[334]  None of the 
patients in the pilot study were deemed to lack capacity to consent, after assessment. 
Recruitment into this pilot study was evidently low. There were initial difficulties with 
obtaining research ethical approval. This was due to concerns about obtaining consent 
to a study that evaluates the capacity to consent to treatment. Having consulted known 
researchers in the field, it was felt that consenting to this form of research was 
associated with a lower clinical risk when compared to consenting to treatment. In 
addition, capacity is often time and situation specific. Secondly, the study assessment 
was performed just after a routine clinic visit. As the study was not funded, it was not 
possible to arrange transport for a separate visit. Thirdly, the study assessment lasted 
between 45 and 60 minutes in duration. Refusal rates were therefore high due to a 
lack of perceived benefit by eligible participants. 
Regardless of its shortcomings, the pilot study demonstrates that it is feasible to 
conduct an adequately powered study in this domain. Recruitment could be increased 
by prolonging the study duration and recruiting from more than one centre. 
Consideration also should be given to conducting the interview at home or at study 
visits that are not tied to clinic appointments. An appropriately funded study would 
need to cover transport costs, a potential disincentive to study participation. As 
mentioned earlier, it would be preferable to use real scenarios instead of clinical 
vignettes. It is recognised though, that standard scenarios are required. This ensures 
that the treatment proposals have a consistent level of complexity.  Patients could be 
recruited solely from low clearance clinics. A standard scenario that is themed around 
dialysis choices, could then be used. This is because RRT options are necessarily 
discussed with predialysis patients, at these clinics. It would also be necessary to 
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establish the reliability of the study findings, by assessing inter-rater agreement. The 
MacCAT –T assessment is delivered in standard manner. Therefore, inter-rater 
agreement would pertain to the allocation of scores within each domain. To assist with 
this, ethical approval and consent would be required, so that interviews can be 
recorded. Another trained investigator could provide a second assessment for 
comparison, based on the recorded interviews. 
Finally, conclusions can be drawn from this research thesis that are relevant to clinical 
practice, whilst informing further research. It is reasonable to surmise that HD does 
not confer an advantage, at least in terms of QoL, over PD in older patients with ESRD. 
Despite the availability of assisted PD, the majority of older UK patients are on centre 
based HD. Given the choice, a higher proportion of older patients are likely to opt for 
PD than current registry data suggests. Therefore, there are likely to be other 
explanatory factors for the discrepancy between clinical practice and patient choice. A 
cost benefit analysis of assisted peritoneal dialysis compared to the more prevalent 
centre based HD, would be helpful. The cost of hospital transport provided for the HD 
patients will need to be factored into such analysis. Conversely, the inevitable increase 
in staff workload associated with assisted PD programme needs to be considered. 
Dialysis is of course not the only option available to older patients with ESRD. 
Conservative kidney management (CKM) i.e. active non- dialysis therapy, may be 
more appropriate for frail older patients. QoL is reportedly similar between older 
patients receiving CKM and those on dialysis. The FEPOD study will provide some 
insights here, after it was extended to recruit frail older patients receiving CKM. The 
aim is to compare outcomes between patients on assisted PD, HD and CKM. 
 Dialysis modality seems to have little influence on QoL, especially in older people. 
Rather, geriatric syndromes such as frailty have been shown to be associated with 
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poor QoL outcomes. Frailty is now known to be common in patients with CKD. But 
there remain many unanswered questions in this domain. It is not clear whether it is 
preventable or reversible in renal patients. The comprehensive geriatric assessment 
is one evidence based intervention that has been used in the general population. The 
role and feasibility of this intervention needs to be explored in older patients with 
advanced kidney disease. Exercise has gained traction as a means of maintaining 
physical function in patients with renal disease. The specific impact of exercise on 
frailty status in older renal patients warrants investigation.   
Cognitive decline, another geriatric syndrome, is potentially accelerated by dialysis 
depending on modality. As we improve our understanding of dialytic effects on 
cognition, new targets for intervention may be identified. Dialysate cooling can easily 
be implemented on HD, with negligible cost implications. It may have a role in 
preserving cognitive function via protective mechanisms against intra dialytic 
hypotension. Future research should evaluate the influence of other HD techniques, 
such as haemodiafiltration and high flux HD, on cognitive function. Residual renal 
function has been linked with the clearance of protein uraemic toxins. Some of these 
toxins have been recently implicated in cognitive impairment. Techniques that 
preserve residual renal function, such as incremental dialysis, may therefore be 
protective against cognitive decline. This will require corroboration in an adequately 
powered study. 
Frailty and cognitive impairment have been highlighted as important syndromes in 
patients with renal disease. Yet, they are rarely recognised in routine renal practice. 
There is an argument for screening to identify and intervene on these issues, 
especially in older people with advanced CKD. However, most assessment tools for 
frailty and cognitive function have not been extensively validated in the renal 
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population. For cognitive function in particular, cut off values that signify impairment 
may differ from those of the general population. In the older CKD population, tools that 
are reliable and responsive with minimal completion burden are required, as is the 
case with PROMS. 
There is the potential to evaluate the association between cognitive impairment and 
DMC in a well-designed study of CKD patients. Demonstrating such an association 
has implications for how dialysis education is delivered and evaluated. It will also 
emphasize the need to screen regularly for cognitive impairment, which in turn could 
be a prompt for advance care planning.  
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7. APPENDICES 
7.1 –  Detailed tables from mixed model analysis in the FEPOD study 
Table 2.12(full): Effect Estimates of from Mixed Model (Barthel index) 
Parameter Estimate 
Upper 
Bound 
Lower 
Bound 
P value 
Intercept 9.43 21.71 -2.85 0.13 
PD  
HD (reference) 
4.18 
- 
11.99 
- 
-3.64 
- 
0.29 
- 
Follow up status 
DD 
SW 
CS (reference) 
 
-30.22 
6.73 
- 
 
-16.19 
35.26 
- 
 
-44.25 
-21.80 
- 
 
<0.01 
0.64 
- 
Time point 
6 months  
12 months  
18 months 
24 months (reference) 
 
4.65 
5.84 
5.54 
- 
 
11.02 
12.31 
12.35 
- 
 
-1.71 
-0.62 
-1.26 
- 
 
0.15 
0.08 
0.11 
- 
Barthel score at baseline 0.83 0.96 0.70 <0.01 
Dialysis modality* Follow up status 
PD vs HD* DD 
PD vs HD*SW 
PD vs HD*CS (reference) 
 
28.81 
-11.02 
- 
 
46.93 
8.84 
- 
 
10.69 
-30.88 
- 
 
<0.01 
0.28 
- 
Dialysis Modality* Time point 
PD vs HD* 6 months  
PD vs HD* 12 months  
PD vs HD* 18 months  
PD vs HD* 24 months (reference) 
 
-5.57 
-3.80 
-4.03 
- 
 
3.80 
5.63 
5.69 
- 
 
-14.93 
-13.24 
-13.75 
- 
 
0.24 
0.43 
0.41 
- 
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Follow up status* Time point 
DD vs CS * 6 months 
DD vs CS * 12 months 
SW vs CS * 6 months  
SW vs CS * 12 months  
SW vs CS * 18 months  
DD vs CS * 24 months 
SW vs CS * 24 months  
 
28.31 
25.78 
-3.47 
-12.10 
-11.80 
- 
- 
 
43.82 
41.89 
25.67 
17.02 
13.16 
- 
- 
 
12.79 
9.68 
-32.62 
-41.22 
-36.76 
- 
- 
 
<0.01 
<0.01 
0.81 
0.41 
0.35 
- 
- 
Dialysis modality* Follow up 
status*Time point 
 PD* DD* 6 months 
PD* DD* 12 months 
PD* SW* 6 months  
PD* SW* 12 months 
 
 
-28.91 
-25.62 
10.14 
12.60 
 
 
-8.74 
-4.37 
32.12 
34.66 
 
 
-49.07 
-46.87 
-11.84 
-9.47 
 
 
0.01 
0.02 
0.36 
0.26 
DD- died during follow up, SW- withdrew from study, CS – completed study 
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Table 2.14 (full): Estimate of Fixed Effects from Mixed Model (RTSQ) 
Parameter Estimate 
95%CI 
Lower 
95% CI 
Upper 
 
p value 
Intercept -9.37 -28.46 9.73 0.33 
 PD vs HD -1.24 -3.53 1.04 0.28 
Follow up status 
DD  
SW  
CS (reference) 
 
0.37 
0.78 
- 
 
-4.79 
-3.75 
- 
 
5.53 
5.30 
- 
 
0.89 
0.74 
- 
Time point (months) 
6 
12 
18  
24 (reference) 
 
0.63 
3.96 
1.40 
- 
 
-2.76 
0.37 
-2.38 
- 
 
4.01 
7.54 
5.17 
- 
 
0.72 
0.03 
0.47 
- 
Ethnicity 
Asian vs  
White European  
Afro Caribbean (reference) 
 
24.94 
23.10 
- 
 
13.26 
12.16 
- 
 
36.62 
34.04 
- 
 
<0.01 
<0.01 
- 
Time to dialysis recovery 
< 2 hours  
2 to 6 hours  
6 to 12 hours 
>12 hours (reference) 
 
15.09 
15.75 
12.60 
- 
 
3.39 
3.82 
0.47 
- 
 
26.79 
27.68 
24.72 
- 
 
0.01 
0.01 
0.04 
- 
RTSQ at baseline 0.68 0.54 0.82 <0.01 
Age at baseline (years) -0.17 -0.33 -0.017 0.03 
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Follow up status* Time point 
DD vs CS * 6 months  
DD vs CS * 12 months 
DD vs CS * 18 months 
SW vs CS * 6 months 
SW vs CS * 12 months  
SW vs CS * 18 months 
DD vs CS * 24 months 
SW vs CS * 24 months 
 
- 0.87 
-2.92 
1.47 
0.17 
-2.02 
1.39 
- 
- 
 
- 6.51 
-8.81 
-4.86 
-5.19 
-7.46 
-4.34 
- 
- 
 
4.76 
2.97 
7.80 
5.53 
3.42 
7.13 
- 
- 
 
0.76 
0.33 
0.65 
0.95 
0.47 
0.63 
- 
- 
DD- died during follow up, SW- withdrew from study, CS – completed study 
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Table 2.15: Effect estimates of Fixed Effects (HADS depression score) 
Parameter Estimate 
95% CI  
Lower 
95%CI 
Upper 
 
P value 
Intercept 1.67 -0.20 3.53 0.08 
PD 
HD (reference) 
- 0.09 
- 
-1.83 
- 
1.65 
- 
0.92 
- 
HADS Depression score at 
baseline 
0.55 0.41 0.68 <0.01 
Frailty Score at baseline 0.43 0.02 0.84 0.04 
Follow up status 
DD  
 SW  
 CS (reference) 
 
8.28 
2.10 
- 
 
3.54 
-4.55 
- 
 
13.03 
8.74 
- 
 
<0.01 
0.54 
- 
Time point 
3 months 
6 months 
9 months  
 12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
      -0.40 
0.21 
-0.60 
-0.06 
-0.20 
0.22 
0.11 
- 
 
-1.59 
-1.02 
-1.85 
-1.27 
-1.40 
-0.97 
-1.03 
- 
 
0.79 
1.44 
0.65 
1.16 
1.00 
1.41 
1.24 
- 
 
0.51 
0.74 
0.35 
0.93 
0.75 
0.72 
0.85 
- 
Dialysis * Timepoint 
PD vs HD * 3 months 
PD vs HD * 6 months  
PD vs HD * 9 months 
PD vs HD * 12 months 
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months 
PD vs HD * 24 months 
(reference) 
 
0.51 
- 0.09 
0.72 
-0.02 
0.93 
- 0.63 
0.03 
- 
 
-1.24 
-1.87 
-1.13 
-1.81 
-0.88 
-2.40 
-1.67 
- 
 
2.27 
1.70 
2.57 
1.77 
2.74 
1.14 
1.73 
- 
 
0.57 
0.92 
0.45 
0.98 
0.31 
0.49 
0.97 
- 
Dialysis modality * Follow up 
PD vs HD * DD  
PD vs HD * SW  
PD vs HD * SC 
 
-3.83 
-2.73 
- 
 
-10.49 
-8.17 
- 
 
2.83 
2.71 
- 
 
0.26 
0.33 
- 
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Time point * Follow up status 
3 months * DD vs CS 
3 months * SW vs CS 
6 months * DD vs CS 
6 months * SW vs CS 
9 months * DD vs CS 
9 months * SW vs CS 
12 months * DD vs CS 
12 months * SW vs CS 
15 months * DD vs CS 
15 months * SW vs CS 
18 months * DD vs CS 
18 months * SW vs CS 
24 months * DD vs CS 
24 months * SW vs CS 
 
-7.13 
-1.03 
- 8.25 
1.37 
-6.90 
0.25 
-6.67 
0.36 
-9.36 
2.55 
- 6.00 
-0.11 
- 
- 
 
-11.85 
-7.75 
-13.08 
-5.30 
-11.76 
- 6.56 
-11.51 
-6.37 
-14.65 
-2.98 
-11.27 
-7.44 
- 
- 
 
-2.41 
5.69 
-3.41 
8.04 
-2.02 
7.07 
-1.84 
7.08 
-4.08 
8.09 
-0.65 
7.22 
- 
- 
 
<0.01 
0.76 
<0.01 
0.69 
<0.01 
0.94 
0.01 
0.92 
<0.01 
0.37 
0.03 
0.98 
- 
- 
Dialysis modality * Time point 
* Follow up status 
PD * 3 months * DD vs CS 
PD * 3 months * SW vs CS 
PD * 6 months * DD vs CS 
PD * 6 months * SW vs CS 
PD * 9 months * DD vs CS 
PD * 9 months * SW vs CS 
PD * 12 months * DD vs CS 
PD * 12 months * SW vs CS 
PD * 15 months * DD vs CS 
PD * 18 months * DD vs CS 
 
 
3.01 
2.29 
5.67 
- 0.09 
4.59 
3.61 
2.89 
0.86 
8.06 
9.31 
 
 
-3.64 
-3.29 
-1.07 
-5.70 
-2.20 
-2.28 
-3.88 
-5.88 
0.86 
2.03 
 
 
9.65 
7.88 
12.40 
5.52 
11.39 
9.49 
9.65 
7.59 
15.25 
16.58 
 
 
0.38 
0.42 
0.10 
0.98 
0.19 
0.23 
0.40 
0.80 
0.03 
0.01 
DD- died during follow up, SW- withdrew from study, CS – completed study 
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Table 2.19 (full): Effect estimates for fixed effects – symptom score 
Parameter Estimate 
95% CI 
Lower 
95%CI 
Upper P value 
Intercept 5.03 -2.36 12.41 0.18 
 PD  
 HD (reference) 
-7.83 
- 
-15.07 
- 
-0.58 
- 
0.03 
- 
Follow up status 
DD  
SW  
CS (reference) 
 
5.94 
2.99 
- 
 
-5.04 
-15.01 
- 
 
16.91 
20.99 
- 
 
0.29 
0.74 
- 
Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
-4.12 
-3.51 
-5.08 
-2.53 
-3.90 
-4.07 
-2.05 
- 
 
-7.72 
-7.04 
-8.56 
-6.11 
-8.16 
-8.40 
-5.68 
- 
 
-0.52 
0.03 
-1.59 
1.04 
0.37 
0.26 
1.59 
- 
 
0.03 
0.05 
<0.01 
0.16 
0.07 
0.07 
0.27 
- 
Symptom score at baseline 0.74 0.51 0.97 <0.01 
Frailty Score at baseline 1.67 -0.06 3.40 0.06 
Dialysis modality * Follow up 
status 
PD vs HD * DD  
PD vs HD * SW 
PD vs HD * SC  
 
 
8.63 
-1.42 
- 
 
 
-7.77 
-18.91 
- 
 
 
25.04 
16.08 
- 
 
 
0.30 
0.87 
- 
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Dialysis modality * Time point 
PD vs HD * 3 months  
PD vs HD * 6 months  
PD vs HD * 9 months  
PD vs HD * 12 months  
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months  
PD vs HD * 24 months  
 
5.14 
1.42 
4.49 
1.83 
5.66 
3.57 
2.03 
- 
 
-1.72 
-5.51 
-2.41 
-4.86 
-2.46 
-3.39 
-4.46 
- 
 
11.99 
8.34 
11.40 
8.52 
13.77 
10.53 
8.52 
- 
 
0.14 
0.69 
0.20 
0.59 
0.17 
0.31 
0.54 
- 
Follow up status * Time point 
DD vs CS * 3 months  
DD vs CS * 6 months  
DD vs CS * 9 months  
DD vs CS * 12 months  
DD vs CS * 15 months  
DD vs CS * 18 months  
SW vs CS * 3 months  
SW vs CS * 6 months  
SW vs CS * 9 months  
SW vs CS * 12 months  
SW vs CS * 15 months  
SW vs CS * 18 months  
DD vs CS * 24 months  
SW vs CS * 24 months  
 
-2.77 
-10.00 
-1.84 
-4.31 
-3.15 
11.95 
-1.14 
-0.89 
-6.19 
-1.86 
-1.78 
7.39 
- 
- 
 
-13.15 
-20.61 
-12.43 
-15.07 
-15.69 
-3.27 
-18.88 
-18.56 
-24.07 
-19.52 
-15.06 
-10.98 
- 
- 
 
7.60 
.61 
8.74 
6.44 
9.39 
27.18 
16.59 
16.78 
11.70 
15.80 
11.50 
25.77 
- 
- 
 
0.60 
0.06 
0.73 
0.43 
0.62 
0.12 
0.90 
0.92 
0.49 
0.84 
0.79 
0.43 
- 
- 
Table 2.19 - continued 
 
221 
 
Dialysis modality * Follow up 
status* Time point 
PD vs HD * DD* 3 months  
PD vs HD * DD* 6 months  
PD vs HD * DD* 9 months  
PD vs HD * DD* 12 months  
PD vs HD * SW * 3 months  
PD vs HD * SW* 6 months  
PD vs HD * SW * 9 months  
PD vs HD * SW* 12 months  
 
 
-10.62 
2.68 
5.02 
-6.52 
0.93 
10.51 
11.46 
-1.45 
 
 
-27.08 
-14.53 
-11.81 
-23.38 
-16.21 
-6.47 
-6.71 
-19.21 
 
 
5.83 
19.89 
21.85 
10.33 
18.07 
27.49 
29.63 
16.30 
 
 
0.20 
0.76 
0.56 
0.45 
0.91 
0.22 
0.21 
0.87 
DD- died during follow up, SW- withdrew from study, CS – completed study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.19 - continued 
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Table 2.21(full): Effect estimates of fixed effects from mixed model -SF12 PCS 
Parameter Estimate 
95% CI 
Lower 
95% CI 
Upper 
 
P value 
Intercept 23.58 10.26 36.89 <0.01 
PD vs HD -1.27 -4.82 2.28 0.48 
 Follow up status  
 DD  
 SW  
 CS (reference) 
 
-7.17 
-4.40 
- 
 
-17.05 
-18.12 
- 
 
2.71 
9.33 
- 
 
0.15 
0.53 
- 
 Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months  
24 months (reference) 
 
1.06 
0.33 
1.85 
1.85 
1.52 
-0.25 
0.78 
- 
 
-1.53 
-2.33 
-0.81 
-0.85 
-1.14 
-2.83 
-1.71 
- 
 
3.65 
2.99 
4.51 
4.55 
4.19 
2.33 
3.26 
- 
 
0.42 
0.81 
0.17 
0.18 
0.26 
0.85 
0.54 
- 
Female Gender 28.92 7.99 49.85 0.01 
SF12PCS at baseline 0.37 0.25 0.49 <0.01 
Age at baseline 0.13 -0.04 0.30 0.13 
Female * Age at baseline -0.37 -0.65 -0.10 0.01 
Dialysis modality * Follow up 
status 
PD vs HD * DD   
PD vs HD * SW   
PD vs HD * CS 
 
-10.99 
6.75 
- 
 
-24.78 
-4.44 
- 
 
2.81 
17.93 
- 
 
0.12 
0.24 
- 
Dialysis modality * Time point 
PD vs HD * 3 months  
PD vs HD * 6 months  
PD vs HD * 9 months  
PD vs HD * 12 months  
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months  
PD vs HD * 24 months  
 
1.20 
-.062 
-0.60 
-0.66 
-1.12 
1.52 
0.32 
- 
 
-2.58 
-4.47 
-4.56 
-4.56 
-5.02 
-2.30 
-3.33 
- 
 
4.98 
3.22 
3.35 
3.25 
2.78 
5.35 
3.98 
- 
 
0.53 
0.75 
0.76 
0.74 
0.57 
0.43 
0.86 
- 
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Follow up status * Time point 
DD vs SC * 3 months  
DD vs SC * 6 months  
DD vs SC * 9 months  
DD vs SC * 12 months  
DD vs SC * 15 months  
DD vs SC* 18 months  
SW vs SC* 3 months  
SW vs SC * 6 months  
SW vs SC * 9 months  
SW vs SC * 12 months  
SW vs SC * 15 months  
SW vs SC * 18 months  
DD vs SC * 21 months 
SW vs SC * 21 months 
 
3.39 
10.99 
4.25 
5.66 
6.93 
4.16 
1.66 
-.45 
-.12 
-5.19 
-2.29 
-1.88 
- 
- 
 
- 6.52 
0.91 
-5.87 
-4.93 
-6.66 
-6.46 
-12.30 
-14.28 
-14.30 
-19.23 
-13.72 
-16.99 
- 
- 
 
13.31 
21.06 
14.38 
16.25 
20.53 
14.78 
15.62 
13.39 
14.06 
8.86 
9.15 
13.23 
- 
- 
 
0.50 
0.03 
0.41 
0.29 
0.32 
0.44 
0.82 
0.95 
0.99 
0.47 
0.69 
0.81 
- 
- 
PD * Follow up status * Time 
point 
PD * DD * 3 months  
PD * DD * 6 months  
PD * DD * 9 months  
PD * DD * 12 months  
PD * DD * 15 months  
PD * DD * 18 months  
PD * SW * 3 months  
PD * SW * 6 months  
PD * SW * 9 months  
PD * SW * 12months  
 
 
13.53 
6.27 
11.04 
12.75 
11.46 
10.76 
-5.55 
-0.95 
-6.78 
2.69 
 
 
- 0.35 
-7.76 
-3.10 
-1.71 
-5.50 
-4.24 
-17.20 
-12.61 
-19.31 
-11.36 
 
 
27.42 
20.30 
25.17 
27.21 
28.42 
25.75 
6.10 
10.72 
5.74 
16.75 
 
 
0.06 
0.38 
0.13 
0.08 
0.18 
0.16 
0.35 
0.87 
0.29 
0.71 
DD- died during follow up, SW- withdrew from study, CS – completed study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.21 - continued 
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Table 2.23: Effect estimates of Fixed Effects (full) (SF12 MCS) 
Parameter Estimate 
95% CI 
Lower  
95% CI 
Upper  
p 
value 
Intercept 27.91 21.75 34.07 <0.01 
PD vs HD 8.44 0.76 16.11 0.03 
Follow up status 
DD  
SW  
CS (reference) 
 
-7.65 
-17.88 
- 
 
-20.22 
-35.36 
- 
 
4.92 
-0.39 
- 
 
0.23 
0.05 
- 
Time point 
3 months  
6 months  
9 months  
12 months  
15 months  
18 months  
21 months   
24 months (reference) 
 
-1.66 
-1.38 
-0.86 
-1.10 
-1.76 
-0.13 
-0.39 
- 
 
-5.05 
-4.86 
-4.35 
-4.56 
-5.24 
-3.51 
-3.66 
- 
 
1.73 
2.11 
2.62 
2.36 
1.73 
3.25 
2.88 
- 
 
0.34 
0.44 
0.63 
0.53 
0.32 
0.94 
0.81 
- 
SF12MCS at baseline 0.19 0.06 0.32 <0.01 
Frailty Score at baseline -0.05 -1.10 1.00 0.92 
PD * Frailty Score at baseline -1.74 -3.32 -0.15 0.03 
Dialysis modality * Follow up 
status 
PD vs HD * DD  
PD vs HD * SW  
PD vs HD * CS 
 
 
11.23 
17.83 
- 
 
 
- 6.40 
4.25 
- 
 
 
28.86 
31.41 
- 
 
 
0.21 
0.01 
- 
Dialysis modality * Time point 
PD vs HD * 3 months  
PD vs HD * 6 months  
PD vs HD * 9 months  
PD vs HD * 12 months  
PD vs HD * 15 months  
PD vs HD * 18 months  
PD vs HD * 21 months  
PD vs HD * 24 months 
 
-1.01 
-0.22 
1.15 
0.83 
0.05 
-0.10 
-0.58 
- 
 
-5.95 
-5.23 
-4.03 
-4.22 
-5.04 
-5.11 
-5.39 
- 
 
3.93 
4.80 
6.32 
5.89 
5.15 
4.92 
4.24 
- 
 
0.69 
0.93 
0.66 
0.75 
0.98 
0.97 
0.81 
- 
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Follow up status * Time point 
DD vs SC * 3 months  
DD vs SC * 6 months  
DD vs SC * 9 months  
DD vs SC * 12 months  
DD vs SC * 15 months  
DD vs SC * 18 months 
SW vs SC * 3 months  
SW vs SC * 6 months  
SW vs SC * 9 months  
SW vs SC * 12 months  
SW vs SC * 15months  
SW vs SC * 18 months  
DD vs SC * 21 months 
SW vs SC * 21 months 
 
8.87 
8.41 
5.47 
2.51 
18.09 
3.84 
18.02 
14.33 
11.06 
16.35 
10.90 
19.91 
- 
- 
 
-4.01 
-4.75 
-7.80 
-11.23 
0.52 
-10.03 
-.10 
-3.55 
-7.22 
-1.82 
-3.87 
0.55 
- 
- 
 
21.75 
21.58 
18.73 
16.24 
35.67 
17.71 
35.95 
32.20 
29.33 
34.53 
25.66 
39.28 
- 
- 
 
0.18 
0.21 
0.42 
0.72 
0.04 
0.59 
0.05 
0.12 
0.23 
0.08 
0.15 
0.04 
- 
- 
PD * Follow up status * Time point 
PD * DD * 3 months  
PD * DD * 6 months  
PD * DD * 9 months  
PD * DD * 12 months  
PD * DD * 15 months  
PD * DD * 18 months  
PD * SW * 3 months  
PD * SW* 6 months  
PD * SW * 9 months 
PD * SW * 12 months  
 
-10.19 
-12.16 
-11.35 
-6.97 
-25.46 
-14.60 
-19.98 
-15.77 
-8.83 
-11.27 
 
-28.28 
-30.47 
-29.87 
-25.80 
-47.49 
-34.22 
-34.48 
-30.37 
-24.48 
-29.46 
 
7.90 
6.16 
7.16 
11.86 
-3.43 
5.01 
-5.48 
-1.17 
6.83 
6.92 
 
0.27 
0.19 
0.23 
0.47 
0.02 
0.14 
0.01 
0.03 
0.27 
0.22 
DD- died during follow up, SW- withdrew from study, CS – completed 
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7.2 FEPOD Questionnaires 
ILLNESS INTRUSIVENESS RATINGS SCALE 
 
The following items ask about how much your illness and/or its treatment interfere 
with different aspects of your life.  PLEASE CIRCLE THE ONE NUMBER THAT 
BEST DESCRIBES YOUR CURRENT LIFE SITUATION.  If an item is not 
applicable, please circle the number one (1) to indicate that this aspect of your life is 
not affected very much. Please do not leave any item unanswered.  Thank you. 
How much does your illness and/or its treatment interfere with your: 
1. HEALTH 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
2. DIET (i.e. the things you eat and drink) 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
3. WORK 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
4. ACTIVE RECREATION (e.g. sports) 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
5. PASSIVE RECREATION (e.g. reading, listening to music) 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
6. FINANCIAL SITUATION 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
7. RELATIONSHIP WITH YOUR SPOUSE OR PARTNER 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
8. SEX LIFE 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
9. FAMILY RELATIONS 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
10. OTHER SOCIAL RELATIONS 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
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11. SELF-EXPRESSION/SELF – IMPROVEMENT 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
12. RELIGIOUS EXPRESSION 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
 
13. COMMUNITY AND CIVIC INVOLVEMENT 
Not very 
much 
1 2 3 4 5 6 7 Very 
much 
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Short Form – 12 
 
This survey asks for your views about your health. This information will help you keep 
track of how you feel and how well you are able to do your usual activities.  
 
Answer every question by selecting the answer as indicated. If you are unsure 
about how to answer a question, please give the best answer you can.  
 
1. In general, would you say your health is: [Tick the box that best describes 
your answer]  
Excellent Very good Good Fair Poor 
     
 
 
2. The following questions are about activities you might do during a typical 
day. Does your health now limit you in these activities? If so, how much? 
[Tick the box that best describes your answer] 
  Yes, 
limited 
a lot 
Yes, 
limited 
a little 
Not 
limited 
at all 
a Moderate Activities, such as moving a table,  
pushing a vacuum cleaner, bowling, or playing golf 
   
b Climbing several flights of stairs 
 
   
 
3.  During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a 
result of your physical health?  
  All of 
the 
time 
Most of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
a Accomplished less than you would like 
 
     
b Were limited in the kind of work or other 
activities 
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4. During the past 4 weeks, how much of the time have you had any of the 
following problems with your work or other regular daily activities as a result 
of any emotional problems (such as feeling depressed or anxious)?  
  All of 
the 
time 
Most of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
a Accomplished less than you would like 
 
     
b Were limited in the kind of work or other 
activities 
     
 
 
 
5.  During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)?  
 
Not at all A little bit Moderately Quite a bit Extremely 
     
 
 
6. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that 
comes closest to the way you have been feeling. How much of the time 
during the past 4 weeks...  
  All of 
the 
time 
Most of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
a Have you felt calm and peaceful? 
 
     
b Did you have a lot of energy? 
 
     
c Have you felt downhearted and depressed? 
 
     
 
 
7.  During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, 
relatives, etc.)?  
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
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MOOD QUESTIONNAIRE 
 
This questionnaire is designed to help your doctor to know how you feel.  
Read each item and place a firm tick in the box opposite the reply, which 
comes closest to how you have been feeling in the past week. 
 
Don’t take too long over your replies; your immediate reaction to each 
item will probably be more accurate than a long thought-out response. 
 
 
Tick only one box in each section 
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1. I feel tense or ‘wound up’:  8.  I feel as if I am slowed down:  
Most of the time  Nearly all the time  
A lot of the time  Very often  
Time to time, occasionally  Sometimes  
Not at all  Not at all  
2.  I still enjoy the things I used to enjoy:  9.  I get a sort of frightened feeling 
like “butterflies” in the stomach: 
 
Definitely as much  Not at all  
Not quite so much  Occasionally  
Only a little   Quite often  
Hardly at all  Very often  
3.  I get a sort of frightened feeling as if 
something awful is about to happen: 
 10.  I have lost interest in my 
appearance: 
 
Very definitely and quite badly  Definitely 
 
 
Yes, but not too badly  I don’t take so much care as I should  
A little, but it doesn’t worry me  I may not take quite as much care   
Not at all  I take just as much care as ever  
4.  I can laugh and see the funny side of 
things: 
 11. I feel restless as if I have to be on 
the move: 
 
As much as I always could  Very much indeed  
Not quite so much now  Quite a lot  
Definitely not so much now  Not very much   
Not at all  Not at all  
5.  Worrying thoughts go through my mind:  12. I look forward with enjoyment to 
things: 
 
A great deal of the time  As much as I ever did  
A lot of the time  Rather less than I used to  
From time to time but not too often  Definitely less than I used to  
Only occasionally  Hardly at all  
6.  I feel cheerful  13. I get sudden feelings of panic:  
Not at all  Very often indeed  
Not often  Quite often  
Sometimes  Not very often  
Most of the time  Not at all  
7.  I can sit at ease and feel relaxed:  14. I can enjoy a good book or radio 
or TV programme: 
 
Definitely  Often  
Usually  Sometimes  
Not often  Not often  
Not at all  Very seldom  
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SYMPTOM SCALE 
 
Below is a list of symptoms, which you may or may not have 
experienced.  Please put a tick in the box to show how you feel 
each of these symptoms has affected you and how you have been 
feeling over the past week.   
 Not at 
all 
No 
effect 
Slightly 
But not 
bothered 
to be rid 
of it 
Moderately 
Limits some 
activity or 
concentration 
Severely 
Activities or 
concentration 
markedly 
affected 
Overwhelmingly 
Unable to think of 
anything else 
Pain 0 1 2 3 4 
Shortness of 
breath 
 
0 
 
1 
 
2 
 
3 
 
4 
Weakness or 
lack of energy 
 
0 
 
1 
 
2 
 
3 
 
4 
Nausea 
(feeling like 
you are going 
to be sick) 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
Vomiting 
(being sick) 
 
0 
 
1 
 
2 
 
3 
 
4 
Poor appetite 0 1 2 3 4 
Constipation 0 1 2 3 4 
Mouth 
problems 
0 1 2 3 4 
Drowsiness 0 1 2 3 4 
Poor mobility 0 1 2 3 4 
Itching 0 1 2 3 4 
Difficulty 
sleeping 
0 1 2 3 4 
Restless legs 
or difficulty 
keeping legs 
still 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
Feeling 
anxious 
0 1 2 3 4 
Feeling 
depressed 
0 1 2 3 4 
Changes in 
skin 
0 1 2 3 4 
Diarrhoea 0 1 2 3 4 
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Which symptom has affected you the 
most?____________________________ 
Which symptom has improved the 
most?______________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Any other symptoms (please state what they are) 
1) 0 1 2 3 4 
2) 0 1 2 3 4 
3) 0 1 2 3 4 
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DIALYSIS RECOVERY TIME 
 
How long does it take you to recover from a dialysis session 
(haemodialysis or overnight peritoneal dialysis): Please circle one of the 
options below. 
 
Less than 2 hours 
2 – 6 hours 
6 – 11 hours 
12 hours or more  
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RENAL TREATMENT SATISFACTION QUESTIONNAIRE 
 
The following questions are concerned with the treatment for your 
renal condition (which may include some form of dialysis, tablets, 
dietary and/or fluid restrictions) and your experience over the past 
few weeks.  Please answer each question by circling a number on 
each of the scales. 
1 How satisfied are you with your current treatment? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
2 How well controlled do you feel your renal condition is now? 
 Very well 
controlled 
 
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very poorly 
controlled 
3 How convenient have you been finding your treatment to be 
recently? 
 Very convenient  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
inconvenient 
4 How flexible have you been finding your treatment to be recently? 
 Very flexible  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very inflexible 
5 How satisfied are you with the amount of freedom you have with 
your present treatment? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
6 How satisfied are you with your understanding of your renal 
condition? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
7 How satisfied are you with the time taken by your present form of 
treatment? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
8 How satisfied are you with the amount of discomfort or pain 
involved with your present form of treatment? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
9 How satisfied are you with the extent to which your treatment fits 
in with your lifestyle? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
10 Would you recommend this form of treatment to someone else 
with your kind of renal condition?  
 Yes I would definitely 
recommend the treatment 
No, I would definitely not 
recommend the treatment 
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11 How satisfied would you be to continue with your present form of 
treatment? 
 Very satisfied  
6 
 
5 
 
4 
 
3 
 
2 
 
1 
 
0 
Very 
dissatisfied 
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SOCIAL SUPPORT:  How much support do you have at home? 
Where do you live?  
(Please circle one of the 
answers) 
Own or family home 
Warden-controlled accommodation 
Residential care 
Nursing home 
Who lives with you?  
(Please circle more than one 
answer if appropriate)  
Husband / Wife / Partner 
Son / Daughter/ Daughter in law 
Grandchildren: number____ 
Brother/sister 
Friend 
Paid carer 
No-one: I live on my own 
Not applicable (in residential care or 
nursing-home) 
Do you have family or 
friends who regularly (at 
least once a week) help 
you, e.g., with shopping or 
other activities, e.g., 
cooking, cleaning, other 
chores.   
(Please circle more than one 
answer if appropriate) 
Son 
Daughter 
Son-in-law 
Daughter-in-law 
Brother/sister 
Friend/neighbour 
How often do you have 
assistance from a paid or 
un-paid carer (not related 
to dialysis)?  
(Please circle one answer) 
Never 
Once a week 
Two to three times a week 
Daily 
2 or more visits per day 
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If on assisted peritoneal 
dialysis, who connects 
and disconnects you from 
the machine? 
(Circle more than one 
answer if appropriate) 
Myself 
Family member (state who) 
Paid carer 
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BARTHEL INDEX:  To be completed by the Nurse 
 Score 
FEEDING  
0 Unable 
5 Needs help cutting, spreading butter, etc., or requires 
modified diet 
10 Independent  
BATHING  
0 Dependent  
5 Independent (or in shower) 
GROOMING  
0 Needs help with personal care 
5 Independent face/hair/teeth/shaving (implements 
provided) 
DRESSING  
0 Dependent 
5 Needs help but can do about half unaided 
10 Independent (including buttons, zips, laces, etc.) 
BOWELS  
0 Incontinent (or needs to be given enemas) 
5 Occasional accident 
10 Continent 
BLADDER  
0 Incontinent, or catheterised and unable to manage alone 
5 Occasional accident 
10 Continent 
TOILET USE  
0 Dependent 
5 Needs some help, but can do something alone 
10 Independent (on and off, dressing, wiping) 
TRANSFERS (BED TO CHAIR AND BACK)  
0 Unable, no sitting balance 
5 Major help (one or two people, physical), can sit 
10 Minor help (verbal or physical) 
15 Independent 
MOBILITY (ON LEVEL SURFACES)  
0 Immobile or < 50 yards 
5 Wheelchair independent, including corners, > 50 yards 
10 Walks with help of one person (verbal or physical), > 50 
yards 
15 Independent (but may use any aid; for example, stick) > 
50 yards 
STAIRS   
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THE FRAILTY SCALE:  To be completed by the Nurse 
 
  
0 Unable 
5  Needs help (verbal, physical, carrying aid) 
10 Independent 
TOTAL SCORE 0-100  
Category Description Characteristics 
1 Very Fit Robust, active, energetic, 
well-motivated and fit, 
these people commonly 
exercise regularly and 
are in the most fit group 
for their age 
2 Well Without active disease, 
but less fit than people in 
category 1 
3 Well, with treated comorbid 
disease 
Disease symptoms are 
well controlled compared 
with those in category 4 
4 Apparently vulnerable Although not frankly 
dependent, these people 
commonly complain of 
being “slowed up” or 
have disease symptoms 
5 Mildly frail With limited dependence 
on others for instrumental 
activities of daily living 
6 Moderately frail Help is needed with both 
instrumental and non-
instrumental activities of 
daily living  
7 Severely frail Completely dependent on 
others for the activities of 
daily living, or terminally 
ill 
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DEMOGRAPHICS: To be completed by the Nurse 
Dialysis modality:  
Screening Male  Female   
Age:  _________years (ensure 60 years 
or above) 
On dialysis for 90 days or 
more 
Yes                 No  
Free form hospital 
admission for 30 days 
Yes                 No  
Does the patient perceive 
having had a choice of 
dialysis modality? 
Yes                 No  
Length of time attended renal 
clinic (pre dialysis) 
 
Years_____   
Months______ 
Length of time on dialysis 
(excluding periods of 
transplantation or off dialysis) 
 
Years_____   
Months______ 
Ethnic 
background 
 Postcode  
Cause of kidney 
disease                                                       
 
Comorbidity Malignancy  
IHD  
PVD  
LV dysfunction  
DM  
Systemic collagen 
vascular disease 
 
Other  
Hospital 
admissions in 
previous 6 months 
Dialysis 
related 
 
 
Other  
Dialysis adequacy(latest result)  
Blood 
results 
(latest 
results) 
Hb  
CaAdj  
Phosphate  
Alk. phos  
Albumin  
Bicarbonate  
CRP  
Erythropoietin dose  
Medications 
and dosage 
  
  
 
242 
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7.3 - Questionnaires for Cognitive function and PROM in advanced kidney 
disease study 
 
 
IMPACT OF PATIENT OUTCOMES AND COGNITIVE IMPAIRMENT IN 
ADVANCED KIDNEY DISEASE: A PROSPECTIVE STUDY 
 
DEMOGRAPHICS DATA (1ST VISIT) 
Date completed:  
Age: Months on Dialysis: 
Sex: Months seen in renal clinic: 
Renal Modality:  HD/PD/CKD Ethnic background: 
Cause of Renal Disease:  
Comorbidities: 
Malignancy Yes    □ No    □ 
IHD Yes    □ No    □ 
PVD Yes    □ No    □ 
DM Yes    □ No    □ 
LV Dysfunction Yes    □ No    □ 
Systemic Collagen vascular disorder Yes    □ No    □ 
Other diagnoses (especially 
CVA/stroke like symptoms) 
 
 
Stoke co morbidity score  
 
 
RRT Time Line: 
 
 
 
 
 
 
 
DIALYSIS PARAMETERS 
Haemodialysis Peritoneal Dialysis 
Modality: High flux □ Low Flux□ HDF 
□                 
CAPD □ APD □ 
KT/v □ URR □ Weekly Kt/v □ Weekly Creatinine □ 
Average Interdialytic weight gain: 
______ Kg 
Residual urine volume :_______ mls 
Recurrent Intradialytic hypotension   
YES/NO 
Average Predialysis Blood 
Pressure:____ mmhg 
Vascular Access: AVF/AVG/ Tesio 
Average Post dialysis BP: 
____mmHg 
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MEDICATIONS 
 
EPO TYPE DOSE:_________ units/ 
micrograms/mg 
FREQUENCY_______ 
weekly/fortnightly/ monthly 
 
PATIENT EVENTS 
Dialysis 
related 
Admissions 
in last 3 
months 
List the cause for each admission 
please 
 
 
 
 
Number of days in hospital 
Other 
admissions 
in last 3 
months 
List the cause for each admission 
please 
 
 
 
 
Number of days in hospital 
Line related 
bacteraemia 
(treated as 
outpatient) in 
last 3 
months 
How many?  
PD 
Peritonitis  in 
last 3 
months 
(treated as 
outpatient) in 
last3 months 
How many?  
Stroke like 
events? 
How many?  
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Clinic Blood Pressure: __________ mm/Hg: 
INVESTIGATIONS (as available) 
Hb : ALP: Beta2 Microglobulin: 
Sodium: Bicarbonate: *Urea: 
Adj. Calcium: Albumin: *Creatinine: 
Phosphate: CRP: *eGFR: 
PTH: Ferritin: *Urine PCR: 
Vitamin D: TSH:  
*For predialysis patients only 
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IMPACT OF PATIENT OUTCOMES AND COGNITIVE IMPAIRMENT IN 
ADVANCED KIDNEY DISEASE: A PROSPECTIVE STUDY 
 
DEMOGRAPHICS DATA (FOLLOWUP VISIT) 
CHANGE IN MODALITY?  YES/ NO.  IF YES TO     HD□            PD □          TX□         
NON DIALYSIS CARE□   
Reasons for change if any: 
 
 
 
 
 
 
 
DIALYSIS PARAMETERS 
Haemodialysis Peritoneal Dialysis 
Modality : High flux □ Low Flux□ HDF 
□                 
CAPD □ APD □ 
KT/v _____  URR  _________ Weekly Kt/v _____ Weekly Creatinine 
______ 
Average Interdialytic weight gain: 
______ Kg 
Residual urine volume :_______ mls 
Recurrent Intradialytic hypotension   
YES/NO 
Average Predialysis Blood 
Pressure:____ mmhg 
 
 
PATIENT EVENTS SINCE THE LAST STUDY VISIT 
Dialysis 
related 
Admissions  
List the cause for each admission 
please 
 
 
 
 
Number of days in hospital 
Other 
admissions  
List the cause for each admission 
please 
 
 
 
 
Number of days in hospital 
Line related 
bacteraemia 
(treated as 
outpatient)  
How many? 
PD 
Peritonitis  in 
last 3 
months 
How many? 
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(treated as 
outpatient)  
Stroke like 
events? 
How many? 
 
Clinic Blood Pressure: __________ mm/Hg: 
INVESTIGATIONS (as available) 
Hb : ALP: Beta2 Microglobulin: 
Sodium: Bicarbonate: *Urea: 
Adj. Calcium: Albumin: *Creatinine: 
Phosphate: CRP: *eGFR: 
PTH: Ferritin: *Urine PCR: 
Vitamin D: TSH:  
*For predialysis patients only 
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Timed Up and Go (TUG) Test 1, 2 
1. Equipment: arm chair, tape measure, tape, stop watch. 
 
2. Begin the test with the subject sitting correctly in a chair with arms, the subject’s 
    back should resting on the back of the chair. The chair should be stable and   
    positioned such that it will not move when the subject moves from sitting to   
    standing. 
 
3. Place a piece of tape or other marker on the floor 3 meters away from the chair so 
    that it is easily seen by the subject. 
 
4. Instructions: “On the word GO you will stand up, walk to the line on the floor, turn 
    around and walk back to the chair and sit down. Walk at your regular pace. 
 
5. Start timing on the word “GO” and stop timing when the subject is seated again 
    correctly in the chair with their back resting on the back of the chair. 
 
6. The subject wears their regular footwear, may use any gait aid that they normally 
    use during ambulation, but may not be assisted by another person. There is no    
    time limit. They may stop and rest (but not sit down) if they need to. 
 
7. Normal healthy elderly usually complete the task in ten seconds or less. Very 
    frail or weak elderly with poor mobility may take 2 minutes or more. 
 
8. The subject should be given a practice trial that is not timed before testing. 
 
9. Results correlate with gait speed, balance, functional level, the ability to go out,    
    and can follow change over time. 
 
 
 
 
 
 
Score:     
 
 
 
 
 
 
 
 
 
10. Interpretation  
             < 10 seconds = normal 
 
             < 20 seconds = good mobility, can go out alone, mobile without a 
                                       gait aid. 
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             < 30 seconds = problems, cannot go outside alone, requires a gait 
                                       aid. 
 
A score of more than or equal to fourteen seconds has been shown to indicate high 
risk of falls 
 
1. Podsiadlo D, Richardson S. The Time “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly Persons. Journal of the     
    American Geriatrics Society 1991; 39(2): 142148 
 
2. Shumway- Cook A, Brauer S, Woollacott M. Predicting the Probability for Falls in Community Dwelling 
    Older Adults Using the Timed Up & Go Test. Physical Therapy 2000 Vol 80(9): 896903. 
   Saskatoon Falls Prevention Consortium, Falls Screening and Referral Algorithm, TUG, Saskatoon Falls Prevention                           
consortium, June, 2005 
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SUBJECTIVE GLOBAL ASSESSMENT RATING FORM 
 
 
Patient Name: ________________________________ID #:________________ 
Date: _______________         
 
WEIGHT 
Baseline Weight: ________________   (Dry weight from 6 months ago) 
Current Weight: _________________ (Dry weight today) 
Actual Wt loss/past 6 mo.__________ % wt loss________ (actual loss from 
baseline/last SGA) 
Wt change over past two weeks      ______No change   ______Increase   
______Decrease 
RATING:  1  2  3  4  5  6  7  
DIETARY INTAKE 
______No change (Adequate)  ______No change (Inadequate) 
Change:   
Sub optimal Intake________ Protein__________ Kcal________ Duration________ 
Full Liquid______________ Hypocaloric Liquid_____________Starvation ________ 
RATING:  1  2  3  4  5  6  7   
GASTROINTESTINAL SYMPTOMS 
(*Frequency: Never, daily, 2-3 times/wk, 1-2 times/wk, > 2 weeks, < 2 weeks)  
Symptom:    Frequency   : * Duration: 
________None    ________    ________ 
________Anorexia   ________    ________  
________Nausea    ________    ________ 
________Vomiting   ________    ________ 
________Diarrhea   ________    ________ 
RATING:  1  2  3  4  5  6  7  
FUNCTIONAL CAPACITY 
Description:         Duration: 
________No Dysfunction        ________ 
________Change in Function       ________ 
________Difficulty with ambulation      ________ 
________Difficulty with activity (patient specific “normal”)   
 ________ 
________Light activity        ________ 
________Bed/chair ridden with little or no activity    
 ________ 
________Improvement in function      
 ________ 
RATING:  1  2  3  4  5  6  7   
DIAGNOSIS/CO-MORBIDITIES RELATED TO NUTRITIONAL NEEDS 
Primary 
diagnosis_______________________Comorbidities_______________________ 
________Normal requirements         ________Increased 
requirements 
________Decreased requirements 
Acute Metabolic Stress:  ________None    ________Low    ________Moderate     
________High  
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RATING:  1  2  3  4  5  6  7   
PHYSICAL EXAM 
________Loss of subcutaneous fat                                         ________Some areas 
________All areas       
             (below eye, triceps, biceps, chest)   
 ________Muscle wasting                                                       ________Some areas 
________All areas 
                (temple, clavicle, scapula, ribs, quadriceps, calf, knee, interosseous) 
________Edema (related to undernutrition/use to evaluate weight change) 
RATING:  1  2  3  4  5  6  7   
OVERALL RATING 
________6-7=Very Mild risk to well nourished; most categories or 
significant/continued improvement 
________3-4-5=Mild/Moderate; No clear sign of normal status or severe malnutrition 
________1-2=Severely Malnourished; most categories/significant physical signs of 
malnutrition  
Fat and Muscle Store Assessment 
 
Muscle (orange) stores 
Fat (blue) stores 
Edema (green) should be assessed at the ankle. In mobility-restricted 
patients the edema may be visible around the eye or at the sacrum. 
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*Remember to assess fat and muscle stores in relation to recent weight 
changes. 
 
Date: 
________________________________________________________ 
 
SGA Score: 
___________________________________________________ 
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7.4 – Cognition and DMC in Advanced kidney disease Questionnaires 
COGNITIVE IMPAIRMENT AND DECISION MAKING CAPACITY IN 
ADVANCED KIDNEY DISEASE 
 
DEMOGRAPHICS DATA  
Date completed:  
Age: Months on Dialysis: 
Sex: Months seen in renal clinic: 
Level of Education: 
Renal Modality:  HD/PD/CKD Ethnic background: 
Cause of  Renal Disease:  
Comorbidities: 
Malignancy Yes    □ No    □ 
IHD Yes    □ No    □ 
PVD Yes    □ No    □ 
DM Yes    □ No    □ 
LV Dysfunction Yes    □ No    □ 
Systemic Collagen vascular disorder Yes    □ No    □ 
Other  Medical diagnoses  
 
 
 
Stoke co morbidity score  
 
Dementia:     Yes / No                                                    Type: 
 
 
Psychiatric history           
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7.6 – Permissions 
For Figure 1.1 
 
 
Back to The National Archives 
You are encouraged to use and re-use the Information that is available under this licence freely and flexibly, with 
only a few conditions. 
Using Information under this licence 
Use of copyright and database right material expressly made available under this licence (the 'Information') 
indicates your acceptance of the terms and conditions below. 
The Licensor grants you a worldwide, royalty-free, perpetual, non-exclusive licence to use the Information subject 
to the conditions below. 
This licence does not affect your freedom under fair dealing or fair use or any other copyright or database right 
exceptions and limitations. 
You are free to: 
• copy, publish, distribute and transmit the Information; 
• adapt the Information; 
• exploit the Information commercially and non-commercially for example, by combining it with other 
Information, or by including it in your own product or application. 
You must (where you do any of the above): 
• acknowledge the source of the Information in your product or application by including or linking to any 
attribution statement specified by the Information Provider(s) and, where possible, provide a link to this 
licence; 
 If the Information Provider does not provide a specific attribution statement, you must use the following: 
 Contains public sector information licensed under the Open Government Licence v3.0. 
If you are using Information from several Information Providers and listing multiple attributions is not practical in 
your product or application, you may include a URI or hyperlink to a resource that contains the required 
attribution statements. 
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These are important conditions of this licence and if you fail to comply with them the rights granted to you under 
this licence, or any similar licence granted by the Licensor, will end automatically. 
 Exemptions 
This licence does not cover: 
• personal data in the Information; 
• Information that has not been accessed by way of publication or disclosure under information access 
legislation (including the Freedom of Information Acts for the UK and Scotland) by or with the consent of 
the Information Provider; 
• departmental or public sector organisation logos, crests and the Royal Arms except where they form an 
integral part of a document or dataset; 
• military insignia; 
• third party rights the Information Provider is not authorised to license; 
• other intellectual property rights, including patents, trademarks, and design rights; and 
• identity documents such as the British Passport 
Non-endorsement 
This licence does not grant you any right to use the Information in a way that suggests any official status or that 
the Information Provider and/or Licensor endorse you or your use of the Information. 
No warranty 
The Information is licensed 'as is' and the Information Provider and/or Licensor excludes all representations, 
warranties, obligations and liabilities in relation to the Information to the maximum extent permitted by law. 
The Information Provider and/or Licensor are not liable for any errors or omissions in the Information and shall 
not be liable for any loss, injury or damage of any kind caused by its use. The Information Provider does not 
guarantee the continued supply of the Information. 
Governing Law 
This licence is governed by the laws of the jurisdiction in which the Information Provider has its principal place of 
business, unless otherwise specified by the Information Provider. 
Definitions 
In this licence, the terms below have the following meanings: 
'Information' means information protected by copyright or by database right (for example, literary and artistic 
works, content, data and source code) offered for use under the terms of this licence. 
'Information Provider' means the person or organisation providing the Information under this licence. 
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'Licensor' means any Information Provider which has the authority to offer Information under the terms of this 
licence or the Controller of Her Majesty's Stationery Office, who has the authority to offer Information subject to 
Crown copyright and Crown database rights and Information subject to copyright and database right that has 
been assigned to or acquired by the Crown, under the terms of this licence. 
'Use' means doing any act which is restricted by copyright or database right, whether in the original medium or in 
any other medium, and includes without limitation distributing, copying, adapting, modifying as may be technically 
necessary to use it in a different mode or format. 
'You', 'you' and 'your' means the natural or legal person, or body of persons corporate or incorporate, acquiring 
rights in the Information (whether the Information is obtained directly from the Licensor or otherwise) under this 
licence. 
About the Open Government Licence 
The Controller of Her Majesty's Stationery Office (HMSO) has developed this licence as a tool to enable 
Information Providers in the public sector to license the use and re-use of their Information under a common open 
licence. The Controller invites public sector bodies owning their own copyright and database rights to permit the 
use of their Information under this licence. 
The Controller of HMSO has authority to license Information subject to copyright and database right owned by 
the Crown. The extent of the Controller's offer to license this Information under the terms of this licence is set out 
in the UK Government Licensing Framework. 
This is version 3.0 of the Open Government Licence. The Controller of HMSO may, from time to time, issue new 
versions of the Open Government Licence. If you are already using Information under a previous version of the 
Open Government Licence, the terms of that licence will continue to apply. 
These terms are compatible with the Creative Commons Attribution License 4.0 and the Open Data Commons 
Attribution License, both of which license copyright and database rights. This means that when the Information is 
adapted and licensed under either of those licences, you automatically satisfy the conditions of the OGL when 
you comply with the other licence. The OGLv3.0 is Open Definition compliant. 
Further context, best practice and guidance can be found in the UK Government Licensing Framework section on 
The National Archives website. 
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Figure 1.8 – Pathogenesis of cognitive impairment in CKD 
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